Clinical and Economic Outcomes of Virtual vs. In-Person Transplant Pharmacotherapy Clinics: A Cross-Sectional Study in Iran

Clinical and Economic Outcomes of Virtual vs. In-Person Transplant Pharmacotherapy Clinics: A Cross-Sectional Study in Iran | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Clinical and Economic Outcomes of Virtual vs. In-Person Transplant Pharmacotherapy Clinics: A Cross-Sectional Study in Iran Mahnaz Sadat Hosseini, Seyed Hossein Hajimiri, Simin Dashti-Khavidaki, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8712266/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background Pharmacist-led pharmacotherapy clinics play an essential role in optimizing medication use and preventing adverse drug events (ADEs) among solid organ transplant (SOT) recipients. Evidence comparing the clinical and economic value of virtual versus in-person transplant pharmacotherapy clinics remains limited, particularly in resource-constrained settings. Methods This cross-sectional study evaluated SOT candidates and recipients who received pharmacist-led virtual consultations (October–December 2024) or in-person consultations (September 2024–May 2025) at a tertiary transplant center in Iran. Pharmacist interventions included medication reconciliation, identification and resolution of drug-related problems (DRPs), adherence monitoring, and vaccination review. ADE risk was estimated using a validated risk-matrix approach, and a partial cost–benefit analysis was conducted from a societal perspective, incorporating direct medical and nonmedical costs. Cost savings from medication optimization and cost avoidance from estimated preventable ADEs were calculated, and benefit-to-cost ratios (BCRs) were derived. Results A total of 232 patients (63.1% male; mean age 50.3 ± 12.4 years) were evaluated. Pharmacists identified 1,607 DRPs and issued 2,268 recommendations, with preventive therapy needs being the most common DRP category. An expert panel estimated 428 preventable ADEs across both clinic models. The virtual clinic generated direct cost savings of $ 1,882.93 and cost avoidance of $ 30,552.43, while the in-person clinic achieved $ 768.07 in direct savings and $ 75,666.94 in cost avoidance. The resulting BCRs were 11.1:1 for the virtual clinic and 12.3:1 for the in-person clinic. Conclusions Pharmacist-led virtual and in-person transplant pharmacotherapy clinics were associated with improved medication safety and substantial economic benefits. These findings support the integration of Telepharmacy services into transplant care, particularly in low- and middle-income healthcare systems. Drug-related problems Economic analysis Telemedicine Transplant pharmacist Pharmacotherapy Virtual clinic Figures Figure 1 Introduction Telemedicine involves exchanging medical information through electronic communication to enhance patient outcomes [ 1 ]. Using real-time audio and video, it connects patients and healthcare providers across distances [ 2 ]. Pharmacist involvement in telemedicine model of outpatient services began in the early 2000s [ 3 ] and has since expanded to managing hypertension [ 4 ], diabetes [ 5 ], and anticoagulation therapy [ 6 ]. A virtual clinic, a specific form of telemedicine, enables clinician–patient interactions without in-person visits. In transplant care, pharmacists conduct virtual consultations to assess medication regimens, identify drug-related problems (DRPs), review vaccinations, monitor patient’s adherence, educate patients, manage drug interactions, recommend dose adjustments, and address long-term adverse effects [ 7 ]. Advances in digital technology have made virtual clinics integral to telemedicine, improving access, reducing costs, and enhancing convenience. The objective of this study is to examine the clinical and economic impacts of the transplant clinical pharmacist’s interventions on solid organ transplant (SOT) candidates and recipients, utilizing both in-person and virtual pharmacotherapy clinics. Materials and methods Study design and participants This cross-sectional study was conducted at the virtual and in-person drug therapy clinics affiliated with Tehran University of Medical Sciences (TUMS). It assessed the real-world outcomes of pharmacist interventions during in-person as well as remote consultations with organ transplant candidates and recipients, utilizing the TUMS video and audio communication system. Data for the virtual pharmacotherapy clinic were collected over three months (October–December 2024), while data from the in-person pharmacotherapy clinic were collected over eight months (September 2024–May 2025). Both clinics operate one day per week. Under the leadership of a clinical pharmacist with 20 years of experience in transplantation, the clinic followed a three-step approach: reviewing medical records and conducting remote interviews to perform medication reconciliation, evaluate adherence, identify DRPs [8], and verify vaccination status; providing recommendations to optimize treatment and monitoring; and delivering individualized education and guidance regarding medication and vaccine use (see Form 1). Clinical outcome analysis Transplant clinical pharmacists systematically detected and resolved DRPs during virtual consultations. DRPs were independently scored by a transplant pharmacist and a pharmacoeconomic specialist, with discrepancies resolved by consensus. To evaluate the adverse drug event (ADE) risk was assessed using a validated risk matrix method [9] that includes: Probability assessment (1-5 scale) via literature evidence and followed a Delphi process with three rounds among a panel of five experts to reduce subjectivity to reach consensus from the transplant team (specialist with 15 years of experience in the field of SOT, two clinical pharmacists, and a pharmacoeconomic observer) (Table 1) Table 1. Probability score of adverse drug events Score Domains Probability Description 1 Rare 0% This will probably never happen/recur 2 Unlikely 1% Do not expect it to happen/recur but it is possible 3 Possible 10% Might happen or recur occasionally 4 Likely 40% Will probably happen/recur, but it is not a persisting issue/circumstances 5 Almost certain 60% Will undoubtedly happen/recur, possibly frequently Severity scoring (1-5 scale) emphasizing ADEs with allograft rejection or damage potential (e.g., immunosuppressant toxicity/therapeutic failure) (Table 2) Table 2. Severity score of adverse drug events Score Domains Impact on the safety of patients 1 Negligible Minimal injury requiring no/minimal intervention or treatment 2 Minor Minor injury or illness requiring minor intervention Increase in length of hospital stay by 1−3 days 3 Moderate Moderate injury requiring professional intervention Increase in length of hospital stay by 4−15 days 4 Major Major injury leading to long-term incapacity/disability Increase in length of hospital stay by >15 days 5 Catastrophic Incident leading to death Multiple permanent injuries or irreversible health effects Each DRP's risk score (probability × severity) was categorized as follows (9): Low (1-3): minor laboratory abnormalities Moderate (4-6): requiring drug dose adjustments High (8-12): ADEs with hospitalization risk Extreme (15-25): allograft or other organ damage/potential death events (Table 3) This approach prioritizes DRPs that can be achieved through infection-related complications, cardiovascular events, and hospitalization probabilities. Economic Analysis A partial cost-benefit analysis was conducted from a societal perspective, including both direct medical and nonmedical costs during the three-month virtual and eight-month in-person interventions. The benefit components were associated primarily with cost savings and cost avoidance. The cost savings derived from medication optimization were calculated as follows: (daily cost of discontinued/reduced medications) × (remaining days of the original prescription period). Cost avoidance was estimated as follows: a) Preventable ADEs = Σ (Number of DRPs × ADE probability tier [1%, 10%, 40%, 60%]) b) Applied only to DRPs with ≥10% ADE probability and ≥moderate severity (excluding "rare/negligible" cases per Table 3) c) Hospitalization cost parameters sourced from institutional data [9]. Direct nonmedical costs included transportation (based on round-trip distance), accommodation for necessary overnight stays, and meals calculated at the standard per diem rate, offering a comprehensive view of related expenses. To clarify the overall financial impact, key analytical parameters were computed. The benefit-to-cost ratio (BCR) was calculated by dividing total cost savings and avoidance by intervention costs. All values in Iranian Rials (IRR) were converted to U.S. Dollars (USD) using the 2024 Central Bank rate of 285,000 IRR per USD [10]. The cost per tele-pharmacotherapy clinic encounter was $6.9, and in-person pharmacotherapy clinic $3.7. Data collection and analysis Prospective clinical and economic data from in-person or virtual consultations were collected via standardized forms, verified by two researchers, and analyzed in Microsoft Excel 2013 using descriptive statistics and cost-benefit calculations, including savings and cost-avoidance estimates. Robustness of the base-case BCR was assessed via multi-method sensitivity analysis: deterministic one-way (±20% variations per component, visualized in a tornado diagram to identify drivers); probabilistic Monte Carlo simulation (10,000 iterations with normal distributions for costs and lognormal for cost avoidance); and two-way deterministic analysis of the two key parameters' interactions. Analyses were performed in Python (v3.9; NumPy, Pandas, Matplotlib). Ethical Approval The study was approved by the TUMS Ethics Committee (IR.TUMS.TIPS.REC.1403.024) and conducted in accordance with the Declaration of Helsinki for human studies. All participants provided informed consent, and data analyses were performed using coded identifiers to ensure confidentiality. Results Demographic and clinical characteristics of the patients During the study, a total of 232 patients (147 males and 85 females) were consulted. The mean age of the participants was 50.28±12.4 years. Most patients were liver transplant candidates or recipients who were referred from the liver transplant clinic to the pharmacotherapy clinic. Clinical outcomes During this study, 22 tele-pharmacotherapy clinics and 32 in-person pharmacotherapy sessions were held, with each consultation lasting about 45 minutes. Table 4 presents a comprehensive summary of all DRPs and the corresponding recommendations identified in both clinic settings. Post-intervention follow-up revealed marked improvement in vaccination coverage, with significant increases in influenza, pneumococcal, tetanus, and hepatitis B vaccine uptake compared with the pre-visit period (Table 4). However, overall, 11 patients received no vaccinations prior to transplantation owing to non-adherence to treatment; 35 patients did not receive the pneumococcal vaccine, and 41 did not receive the influenza vaccine due to vaccine shortages; 11 patients with hepatitis B infection were ineligible; and an additional 5 patients exhibited non-adherence solely to the hepatitis B vaccine. Table 4. Clinical - economic assessment related to DRPs by the transplant clinical pharmacists Virtual clinic In-person clinic Total No. of patients 82 150 No. of post-transplant patients 11 65 No. of pretransplant patients 71 85 Target organ Liver 82 140 Others 0 10 No. of DRPs 504 1103 No. of Recommendations 674 1594 DRP/Patient encounters 6.15 13.5 Types of DRPs Preventive therapy required 258 (51.1%) 291 (26.4%) Request for drug information 86 (17.1%) 156 (14.2%) Request for disease management advice 85 (16.8%) 156 (14.2%) High daily dose 5 (2%) 70 (6.4%) Drug allergy 26 (5.2%) 20 (1.8%) Inadequate drug safety 15 (3%) 25 (2%) Others 29 (5.7%) 385 (35%) Types of recommendations Initiate medication 262 (39%) 415 (26%) Drug regimen education 79 (11.7%) 165 (10.4%) Patient knowledge education 79 (11.7%) 155 (9.7%) Adherence education 75 (11.1%) 102 (6.4%) Pharmaconutrition advice 74 (11%) 154 (9.7%) Discontinue medication 17 (2.5%) 125 (7.8%) Others 88 (13%) 478 (30%) Associated medications Vaccines 126 (72%) 319 (55%) Dietary supplements 15 (8.5%) 85 (14.8%) Hypoglycemia agents 8 (4.5%) 86 (15%) Antiplatelets and anticoagulants 6 (3.5%) 13 (2.2%) Others 20 (11.5%) 71 (13%) Physicians’ acceptance rate 82% 84% Patients’ acceptance rate 74% 77% Vaccination rate (Pre vs post-transplant) Influenza 2 vs 23 (P < 0.001) 3 vs 17 (P < 0.001) Pneumococcal 1 vs 26 (P < 0.001) 0 vs 23 (P < 0.001) Tetanus 1 vs 26 (P < 0.001) 5 vs 48 (P < 0.001) Hepatitis B 0 vs 18 (P < 0.001) 6 vs 46 (P < 0.001) Of the 140 DRPs with potential to cause ADEs identified in the tele-pharmacotherapy clinic, 106 (75.7%) exhibited an estimated progression probability exceeding 10%. Among these, 40 (28.6%) were classified as extreme-risk ADEs, with the remainder categorized as high (63%), moderate (5.4%), or low (3%) risk (Table 5). The data represent the number of drug-related problems (%).ADE, adverse drug event. * Drug-related problems belonging to the green and yellow categories were not used in the calculation of preventable ADEs. In the in-person pharmacotherapy clinic, 281 (68.9%) of 408 DRPs with potential to cause ADEs had an estimated progression probability exceeding 10%. Among these, 128 (31.4%) were classified as extreme-risk ADEs, with the remainder categorized as high (42.1%), moderate (11.5%), or low (15%) risk (Table 6). The data represent the number of drug-related problems (%).ADE, adverse drug event. * Drug-related problems belonging to the green and yellow categories were not used in the calculation of preventable ADEs. Cost outcomes The analysis used hospital reference data to quantify clinical costs associated with transplant rejection. The mean hospitalization duration for rejection episodes was 4.6 days, with an average daily cost of $167.83. These values formed the basis for evaluating direct medical cost outcomes in the study population. In the virtual pharmacotherapy clinic, 17 medication order adjustments yielded $142.84 in savings from treatment optimization. In the in-person pharmacotherapy clinic, 125 interventions generated $768.07 in savings. The number of preventable ADEs was 128 in the virtual pharmacotherapy clinic and 300 in the in-person pharmacotherapy clinic. The estimated 39.36 ADEs in the virtual pharmacotherapy clinic corresponded to a cost avoidance of $30,552.43, while the 97.48 events in the in-person pharmacotherapy clinic corresponded to $756,666.94. Implementation costs for the virtual clinic included $353 for setup, $2,652.46 for vaccines and medications, and $265.20 for miscellaneous expenses (10% of the total). Costs for the in-person clinic totaled $6192.73. The resulting marginal cost-benefit ratios were 11.1 for the virtual clinic and 12.3 for the in-person clinic, indicating strong economic feasibility for both programs. Nonmedical cost savings for the virtual clinic were also notable. Among 82 participants, 52 residents of Tehran saved $8.40 each in transport costs. The 17 patients living nearby saved $29.52 each through combined travel and meal reductions, while 13 patients from more distant regions achieved $61.65 in savings from transportation, meals, and lodging. Additionally, it eliminates approximately 196 miles of patient commuting and saves roughly 6 hours of travel time per visit. Sensitivity Analysis In the virtual clinic, one-way sensitivity analysis showed that BCR was most sensitive to cost avoidance variations, with a 20% reduction causing a substantial decline, while pharmacist and miscellaneous costs had minor effects due to their smaller scale. The Tornado diagram confirmed cost avoidance, vaccine/medication costs, and savings as primary BCR influencers, underscoring the intervention's value in preventing adverse drug events and complications. Monte Carlo simulation (10,000 iterations) affirmed robustness, with BCR ranging 8.32–14.91 (mean 11.19, median 11.13; 95% CI: 9.34–13.41), supporting the virtual pharmacotherapy clinic's economic viability under uncertainty (Figure 1, A and B). The BCR of 12.34 for the in-person transplant pharmacotherapy clinic proves most sensitive to variations in total cost avoided and personnel costs; a 20% personnel cost increase reduces the BCR to 10.59, while a decrease elevates it to 14.75. Monte Carlo simulation across 10,000 scenarios reinforces this robustness, yielding a mean BCR of 12.42 with all values exceeding 1.0 and a 90% probability interval of 9.21–16.12 (Figure 1, C and D). Discussion This study provides the first comprehensive evaluation in Iran of the clinical and economic outcomes associated with pharmacist-led virtual and in-person pharmacotherapy clinics in solid organ transplantation. Across both models, transplant pharmacists identified a high burden of clinically significant DRPs, many of which carried moderate to extreme risk for progression to ADEs. Interventions targeting medication optimization, vaccination gaps, supplement use, and glycemic control contributed to meaningful improvements in medication safety and generated substantial cost savings and cost avoidance. The virtual pharmacotherapy model provided notable clinical, economic, and operational benefits. It reduced travel and time burdens, improved access for remote patients, and prevented ADEs that could lead to hospitalization or graft compromise. Sensitivity analysis conducted at both clinics confirmed the model's robustness, with the CBR primarily driven by avoided costs associated with ADEs. Even with variations in pharmacist service costs, drug costs, and administrative expenses, the program consistently demonstrated high clinical and economic efficiency. Overall, these findings support pharmacotherapy clinics as a sustainable and cost-effective strategy in organ transplant pharmacotherapy. The heightened vulnerability of SOT recipients to infections necessitates diligent vaccination planning. Due to chronic immunosuppression, these patients face elevated risks of infections caused by influenza, pneumococcus, hepatitis B, and tetanus. Vaccination can markedly reduce both the incidence and severity of such infections. Influenza remains the most prevalent viral infection among organ transplant recipients. In a study by Yeo et al., conducted over one year in 308 transplant patients, pretransplant influenza vaccination significantly reduced infection incidence (odds ratio 0.19, 95% CI 0.04–0.99) [10]. Similarly, Harboe et al. evaluated data covering over 11,000 person-years from 5,745 solid organ transplant recipients and found that influenza vaccination correlated with reduced all-cause pneumonia admissions (P = 0.035) and mortality (P = 0.001) [11]. Consistent with these findings, the American Society of Transplantation recommends annual influenza vaccination for all transplant recipients aged ≥6 months who are at least one month posttransplant, with high-dose or booster formulations considered when clinically indicated [12-14]. Transplant recipients are also at significantly increased risk—up to 41 times higher—of developing invasive pneumococcal disease compared with the general population [15]. However, pneumococcal vaccination remains underutilized. Long-term surveillance data from Canada demonstrated a substantial decline in the incidence of pneumococcal disease among immunocompromised adults following the widespread adoption of the PPV23 and PCV7 vaccine programs, with incidence rate ratios falling by 43–90% [16]. Such evidence reinforces international guidelines advocating pneumococcal vaccination to prevent both sinopulmonary and invasive infections among SOT recipients [17,18]. Similarly, hepatitis B virus (HBV) infection continues to pose a major threat to patient and graft survival, as it can lead to liver cirrhosis, hepatocellular carcinoma, and posttransplant complications [19]. Vaccination before transplantation significantly lowers infection risk and improves posttransplant outcomes, including reduced HBV reactivation and enhanced graft survival [20-22]. Current clinical guidelines accordingly recommend routine hepatitis B vaccination for all transplant candidates with chronic liver disease to improve posttransplant safety and long-term prognosis [23]. Tetanus vaccination is another crucial preventive measure, especially given its potentially severe impact on immunocompromised individuals [24]. Patients with chronic liver disease or those undergoing surgical interventions, such as transplantation, are more susceptible to tetanus infection due to immune dysregulation and perioperative exposure [24]. The American Society of Transplantation thus advocates updating tetanus immunization before major procedures to minimize postoperative infection risk [25,26]. Beyond vaccination management, the pharmacotherapy clinics addressed a growing issue among transplant populations: the use of dietary supplements. While many patients seek to improve health outcomes through supplements, these products can pose serious risks due to potential drug–herb interactions [27], immunomodulatory effects [28], and unregulated contents [29]. In transplant recipients, such interactions may alter immunosuppressant metabolism, increasing the risk of rejection or toxicity [27]. Our team systematically reviewed patient-reported supplements that use identified high-risk ingredients, and discontinued several products linked to potential graft rejection, immune activation, or uncertain efficacy. This pharmacist's oversight highlights the importance of medication reconciliation and education in minimizing preventable harm within vulnerable populations. Blood glucose management represented another critical focus of virtual and in-person clinical interventions. Hyperglycemia, commonly triggered by surgical stress, corticosteroids, and immunosuppressive therapy, markedly increases the risk of infection, delayed graft function, and mortality [30,31]. The multidisciplinary approach adopted in our clinic—integrating telemonitoring, patient education, and individualized pharmacotherapy—proved effective in sustaining glycemic control. Pharmacists adjusted or discontinued metformin, when necessary, due to renal or hepatic compromise and initiated newer agents such as sodium–glucose co-transporter 2 inhibitors in appropriate candidates with chronic kidney disease or cardiovascular comorbidities [32,33]. These interventions underscore the capacity of Telepharmacy to manage complex metabolic conditions safely in the transplant population. Pharmacist-led interventions substantially advanced DRP resolution, particularly through vaccination management. SOT recipients face an increased risk of infection due to chronic immunosuppression. Our clinics markedly improved post-intervention vaccination coverage for influenza, pneumococcal, tetanus, and hepatitis B vaccines. Despite short-term cost increases, this approach promises reduced morbidity, hospitalizations, and graft compromise [34]. Systematic dietary supplement reviews and tailored glycemic management further mitigated underappreciated risks in this population. Virtual clinics offer distinct advantages over traditional face-to-face consultations, including enhanced accessibility, reduced travel and indirect costs, lower air pollution, and location-independent personalized follow-up care [35]. Prior research has substantiated the economic advantages of telemedicine interventions; for instance, Evers et al. reported mean patient savings of $131.34 ± $82.27 per virtual visit, primarily attributable to decreased transportation and lodging expenses [36]. Similarly, Chi et al. observed that telemedicine consultations improved clinical outcomes while mitigating productivity losses from absenteeism and care disruptions [37]. These efficiencies hold relevance for transplant recipients, who require frequent monitoring yet often contend with mobility limitations or geographic distance from healthcare facilities [35]. Virtual care further promotes treatment adherence, care continuity, and patient satisfaction. Real-time access to clinical pharmacists enables patients to address treatment side effects, optimize dosages, and receive prompt adjustments to immunosuppressive regimens [38]. Hesser et al. documented enhanced self-management and patient engagement via telehealth platforms, underscoring the value of such interventions [39]. Moreover, for immunocompromised transplant recipients, minimized exposure to hospital environments lowers the risk of opportunistic infections, reinforcing the safety profile of virtual follow-up [40]. Our findings are consistent with international evidence demonstrating the value of clinical pharmacists in transplant care. Previous studies have reported benefit-to-cost ratios ranging from 2.4 to 4.2 for pharmacist services in transplant settings; the higher BCRs observed in the present study likely reflect the high baseline risk of ADEs in SOT recipients and the inclusion of cost avoidance related to hospitalization, graft-related complications, and cardiovascular events. The observed economic benefits of virtual clinics align with prior telemedicine studies showing reduced travel burden, indirect costs, and improved access to specialized care [41]. From a societal perspective, both virtual and in-person pharmacotherapy clinics demonstrated strong economic value. The virtual clinic reduced nonmedical costs related to transportation, lodging, and time lost, highlighting its relevance for patients residing far from transplant centers. These findings support the expansion of Telepharmacy services as a cost-effective strategy to enhance equity of access to transplant-related pharmaceutical care, especially in low- and middle-income countries. Several limitations should be acknowledged. First, the cross-sectional design precludes causal inference between pharmacist interventions and clinical or economic outcomes. Second, the virtual and in-person clinics differ in observation periods, which may limit the direct comparability of outcomes. Third, the pharmacist's fee of $2.35 per 45-minute session reflected local rates but diverges substantially from international benchmarks (e.g., $42 per 15 minutes in California) [42], potentially underestimating service costs elsewhere. Fourth, the study was conducted at a single center, limiting generalizability. Finally, infrastructure and personnel costs were not fully captured, which may underestimate the true cost of implementation in other settings. Future studies should adopt longitudinal or controlled designs to directly measure clinical outcomes such as hospitalization, rejection episodes, and mortality. Multicenter studies and international comparisons would further clarify the generalizability of economic findings. Incorporating patient-reported outcomes and productivity losses would enable a more comprehensive societal evaluation. Conclusion Pharmacist-led virtual and in-person pharmacotherapy clinics play a critical role in identifying and resolving drug-related problems among solid organ transplant recipients. By preventing adverse drug events and optimizing preventive care, these services generate substantial clinical and economic benefits. Integration of Telepharmacy into transplant care pathways represents a sustainable and cost-effective strategy, particularly for healthcare systems facing resource constraints. Abbreviations Solid organ transplant SOT Drug-related problems DRPs Adverse drug events ADEs Tehran University of Medical Sciences TUMS Benefit-to-cost ratio BCR U.S. Dollars USD Iranian Rials IRR Hepatitis B virus HBV Declarations Ethics approval and consent to participate: This study was approved by the local ethics committee of Tehran University of Medical Sciences (number IR.TUMS.TIPS.REC.1403.024). The study was performed in accordance with the Helsinki Declaration for human studies. Patients whose data were used for data analysis signed informed consent forms. All analyses were conducted without disclosing patient identities and instead used identification codes. Consent for publication: No personal information or images of patients have been published. Availability of data and materials: The data have been entered into an Excel spreadsheet, which can be obtained by contacting the corresponding author. Competing Interests: All the authors declare that they have no conflicts of interest. Funding: This study is a part of a Clinical Pharmacy residency thesis and is supported by Tehran University of Medical Sciences (grant number 1402-4-246-69201). Authors' contributions: Mahnaz Sadat Hosseini: Data curation, clinical and economic data analysis, writing original draft, editing and finalizing the manuscript. Seyed Hossein Hajimiri: Economic analysis of the results, manuscript editing and finalization. Simin Dashti-Khavidaki: research idea, data curation, clinical data analysis, supervision, validation and manuscript review, editing and finalization. Mohsen Nasiri-Toosi: Clinical data analysis, manuscript editing and finalization. MarjanMoghadamnia: Clinical data analysis, manuscript editing and finalization. Monavar Talebian: Clinical data analysis, manuscript editing and finalization. Abbas Kebriaeezadeh: Economic analysis of the results, manuscript editing and finalization. Acknowledgements: We extend our gratitude to Dr. Maede Salahshour and Dr. Soroush Kohansal for their assistance in the collection of patient data for this study. References Su Z, Li C, Fu H, Wang L, Wu M, Feng X. Development and prospect of telemedicine. Intell Med. 2024. 10.1016/j.imed.2022.10.004 . Metzger GA, Cooper J, Lutz C, Jatana KR, Nishimura L, Deans KJ, Minneci PC, Halaweish I. The value of telemedicine for the pediatric surgery patient in the time of COVID-19 and beyond. J Pediatr Surg. 2021. 10.1016/j.jpedsurg.2021.02.018 . Littauer SL, Dixon DL, Mishra VK, Sisson EM, Salgado TM. Pharmacists providing care in the outpatient setting through telemedicine models: a narrative review. Pharm Pract (Granada). 2017. 10.18549/PharmPract.2017.04.1134 . Green BB, Cook AJ, Ralston JD, Fishman PA, Catz SL, Carlson J, Carrell D, Tyll L, Larson EB, Thompson RS. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA. 2008. 10.1001/jama.299.24.2857 . Maxwell LG, McFarland MS, Baker JW, Cassidy RF. Evaluation of the impact of a pharmacist-led telehealth clinic on diabetes‐related goals of therapy in a veteran population. Pharmacotherapy. 2016. 10.1002/phar1719 . Singh LG, Accursi M, Black KK. (2015). Implementation and outcomes of a pharmacist-managed clinical video telehealth anticoagulation clinic. Am J Health Syst Pharm. 2015; 10.2146/ajhp130750 Maldonado AQ, Hall RC, Pilch NA, Ensor CR, Anders S, Gilarde JA, Tichy EM. (2020). ASHP guidelines on pharmacy services in solid organ transplantation. Am J Health Syst Pharm. 2020; 10.1093/ajhp/zxz291 Pharmaceutical Care Network Europe Association. PCNE Classif V 9.1. Pascarella G, Rossi M, Montella E, Capasso A, De Feo G, Botti G, Nardone A, Montuori P, Triassi M, D’Auria S, Morabito A. Risk analysis in healthcare organizations: methodological framework and critical variables. Risk Manag Healthc Policy. 2021. 10.2147/RMHP.S309098 . Yeo YT, Song J, Ng EG, Lee NL, Kee TY, Tan CK, Fan PY, Lee PH. Increasing influenza vaccination rates in solid organ transplant recipients in an outpatient transplant center. Proc. Singap. Healthc.2020; 10.1177/2010105820960159 Harboe ZB, Modin D, Gustafsson F, Perch M, Gislason G, Sørensen SS, Rasmussen A, Biering-Sørensen T, Nielsen SD. (2022). Effect of influenza vaccination in solid organ transplant recipients: a nationwide population-based cohort study. Am J Transplant. 2022; 10.1111/ajt.17055 Danziger-Isakov L, Kumar D. AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transpl. 2020. 10.1111/ctr.13563 . Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein S, Hayden FG, Harper SA, Hirshon JM, Ison MG. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019. 10.1093/cid/ciy874 . Grohskopf LA. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2022–23 influenza season. MMWR Recomm Rep. 2022. 10.15585/mmwr.rr7101a1 . Kumar D, Humar A, Plevneshi A, Green K, Prasad GV, Siegal D. Toronto Invasive Bacterial Diseases Network, McGeer A. Invasive Pneumococcal Disease in Solid Organ Transplant Recipients—10-Year Prospective Population Surveillance. Am J Transpl. 2007. 10.1111/j.1600-6143.2006.01705.x . Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL, Johnstone J, Kitai I, Krajden S, Lovinsky R, Muller M. Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs. Clin Infect Dis. 2016. 10.1093/cid/civ803 . Danzinger-Isakov L, Kumar DA, AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transpl. 2009. 10.1111/ctr.13563 . Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014. 10.1093/cid/cit816 . Park JS, Gayam V, Pan CQ. Preventing hepatitis B graft infection in hepatitis B patients after liver transplantation: immunoglobulin vs anti-virals. Aliment Pharmacol Ther. 2020. 10.1111/apt.15999 . Lee Y, Seong J, Ahn S, Han M, Lee JA, Kim JH, Ahn JY, Ku NS, Choi JY, Yeom JS, Kim BK. Hepatitis B reactivation and vaccination effectiveness after solid organ transplantation: a matched case-control study. Vaccines. 2024. 10.3390/vaccines12070804 . Reiss G, Keeffe EB. Hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther. 2004. 10.1111/j.1365-2036.2004.01906.x . Poland GA, Poterucha JJ. Hepatitis B immunization after liver transplantation: what is the answer? Liver Transpl. 2005. 10.1002/lt.20538 . Danzinger-Isakov L, Kumar DA, AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transpl. 2009. 10.1111/j.1600-6143.2009.02917.x . Balloni A, Assael BM, Ghio L, Pedrazzi C, Nebbia G, Gridelli B, Melada E, Panuccio A, Foti M, Barbi M, Luraschi C. Immunity to poliomyelitis, diphtheria and tetanus in pediatric patients before and after renal or liver transplantation. Vaccine. 1999. 10.1016/s0264-410x(99)00064-x . Pedrazzi C, Ghio L, Balloni A, Panuccio A, Foti M, Edefonti A, Assael BM. Duration of immunity to diphtheria and tetanus in young kidney transplant patients. Pediatr Transpl. 1999. 10.1034/j.1399-3046.1999.00013.x . Danziger-Isakov L, Kumar D. AST ID Community of practice. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transpl. 2019. 10.1111/ctr.13563 . Hosseini MS, Dashti-Khavidaki S, Talebian M, Nasiri‐Toosi M, Safaei M. Allograft Injury Following Nandrolone and High‐Dose Dietary Supplements Use in a Liver Transplant Recipient: A Case Report. Clin case Rep. 2025. 10.1002/ccr3.70721 . Polak E, Stępień AE, Gol O, Tabarkiewicz J. Potential immunomodulatory effects from consumption of nutrients in whole foods and supplements on the frequency and course of infection: Preliminary results. Nutrients. 2021. 10.3390/nu13041157 . Pelvan E, Karaoğlu Ö, Fırat EÖ, Kalyon KB, Ros E, Alasalvar C. Immunomodulatory effects of selected medicinal herbs and their essential oils: A comprehensive review. J Funct Foods. 2022. 10.1016/j.jff.2022.105108 . Shivaswamy V, Boerner B, Larsen J. (2016). Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev.2016; 10.1210/er.2015-1084 Chakkera HA, Mandarino LJ. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation. 2013. 10.1097/TP.0b013e31826e592e . Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P. (2022). Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022; 10.1007/s00125-022-05787-2 Arvanitakis K, Koufakis T, Kalopitas G, Papadakos SP, Kotsa K, Germanidis G. (2024). Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2024; 10.1016/j.dsx.2023.102935 Viganò M, Beretta M, Lepore M, Abete R, Benatti SV, Grassini MV, Camagni S, Chiodini G, Vargiu S, Vittori C, Iachini M. Vaccination recommendations in solid organ transplant adult candidates and recipients. Vaccines. 2023. 10.3390/vaccines11101611 . Arvanitakis K, Koufakis T, Kalopitas G, Papadakos SP, Kotsa K, Germanidis G. Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential. Diabetes Metabolic Syndrome: Clin Res Reviews. 2024. 10.1016/j.dsx.2023.102935 . Evers EC, Fritz SA, Colditz GA, Burnham JP. Perceptions of telemedicine and costs incurred by a visit to a general infectious diseases clinic: a survey. OFID. 2022. 10.1093/ofid/ofab661 . Chi NC, Demiris G. A systematic review of telehealth tools and interventions to support family caregivers. J Telemed Telecare. 2015. 10.1177/1357633X14562734 . Tolu-Akinnawo O, Ezekwueme F, Awoyemi T. Telemedicine in cardiology: enhancing access to care and improving patient outcomes. Cureus. 2024. 10.7759/cureus.62852 . Hezer B, Massey EK, Reinders ME, Tielen M, Van De Wetering J, Hesselink DA, Van Den Hoogen MW. Telemedicine for kidney transplant recipients: current state, advantages, and barriers. Transplantation. 2024. 10.1097/TP.0000000000004660 . Shokri F, Bahrainian S, Tajik F, Rezvani E, Shariati A, Nourigheimasi S, Shahrebabaki ES, Ebrahimi M, Shamoon F, Heidary M. The potential role of telemedicine in the infectious disease pandemic with an emphasis on COVID-19: A narrative review. Health Sci Rep. 2023. 10.1002/hsr2.1024 . Hosseini MS, Hajimiri SH, Dashti-Khavidaki S, Nasiri-Toosi M, Kebriaeezadeh A. Economic Evaluation of Clinical Pharmacists’ Services Provided for Solid Organ Transplant Patients: A Systematic Review. Int J Organ Transpl Med (IJOTM). 2024. 10.61186/ijotm.2024.15.1139 . California Pharmacists Association. (2024). Medi-Cal Medication Therapy Management Guide. [online]. https://cpha.com/wp-content/uploads/2022/05/Medi-Cal-Medication-Therapy-Management-Guide-v2.pdf . Accessed 15 December 2024. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8712266","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":588733729,"identity":"466576d9-5840-43c6-a22b-ad7528c09d7d","order_by":0,"name":"Mahnaz Sadat Hosseini","email":"","orcid":"","institution":"1Department of Clinical Pharmacy, Faculty of Pharmacy","correspondingAuthor":false,"prefix":"","firstName":"Mahnaz","middleName":"Sadat","lastName":"Hosseini","suffix":""},{"id":588733730,"identity":"0b1c7cc2-b529-4dd2-8e15-7a5044bf29da","order_by":1,"name":"Seyed Hossein Hajimiri","email":"","orcid":"","institution":"2Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy","correspondingAuthor":false,"prefix":"","firstName":"Seyed","middleName":"Hossein","lastName":"Hajimiri","suffix":""},{"id":588733731,"identity":"2e9a7fed-2cc8-44b6-957d-40b5f895b039","order_by":2,"name":"Simin Dashti-Khavidaki","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA8klEQVRIiWNgGAWjYDCCAwxsDAwGDHIMzCjCBgS0HDBgMIZoSSBaCwNDYgMDihY8gO/48WePPxTUpc9v5z34gfHH4Wj5BuaHHxgK7uHUInkmx9zggMHh3A2H+ZIlGBKAjANsxhIMBsU4tRgcyGGTOGBwIHcDM48BRAsDgxlQHLcTDc4/fwbUUpcu38xj/AOkZX4D+zf8Wm4kmAG1MCcwHOYxA9vScIAHvy2SN96YSZwxOGy4AajFIiEtHegpnmKJBDxa+M6nP5Oo+FMnL99/xvjGBxvr3Pnt7Rs/fPiDWwsqAKtjZiAufkbBKBgFo2AU4AYAMS5SmIHAjyUAAAAASUVORK5CYII=","orcid":"","institution":"1Department of Clinical Pharmacy, Faculty of Pharmacy","correspondingAuthor":true,"prefix":"","firstName":"Simin","middleName":"","lastName":"Dashti-Khavidaki","suffix":""},{"id":588733732,"identity":"a583cc10-7ddd-4c98-adf3-b6daf520f1ce","order_by":3,"name":"Mohsen Nasiri-Toosi","email":"","orcid":"","institution":"5Liver Transplantation Research center","correspondingAuthor":false,"prefix":"","firstName":"Mohsen","middleName":"","lastName":"Nasiri-Toosi","suffix":""},{"id":588733737,"identity":"99776205-dbdf-4bef-bd1d-720271367a8d","order_by":4,"name":"Marjan Moghadamnia","email":"","orcid":"","institution":"6Department of Clinical Pharmacy, Faculty of Pharmacy","correspondingAuthor":false,"prefix":"","firstName":"Marjan","middleName":"","lastName":"Moghadamnia","suffix":""},{"id":588733738,"identity":"cd4ad0ff-20fa-4dce-ba3d-72587fda772a","order_by":5,"name":"Monavar Talebian","email":"","orcid":"","institution":"5Liver Transplantation Research center","correspondingAuthor":false,"prefix":"","firstName":"Monavar","middleName":"","lastName":"Talebian","suffix":""},{"id":588733739,"identity":"2f5d0269-246a-496c-be67-e7182ee1b410","order_by":6,"name":"Abbas Kebriaeezadeh","email":"","orcid":"","institution":"8Professor of Pharmacology and Toxicology, Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy","correspondingAuthor":false,"prefix":"","firstName":"Abbas","middleName":"","lastName":"Kebriaeezadeh","suffix":""}],"badges":[],"createdAt":"2026-01-27 15:38:14","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8712266/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8712266/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":102441456,"identity":"a78705d9-09db-457d-992b-f2948023be87","added_by":"auto","created_at":"2026-02-11 16:55:34","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":4257076,"visible":true,"origin":"","legend":"\u003cp\u003eTornado diagram and Monte Carlo simulation sensitivity analysis\u003c/p\u003e","description":"","filename":"Fig1.TornadodiagramandMonteCarlosimulationsensitivityanalysis.png","url":"https://assets-eu.researchsquare.com/files/rs-8712266/v1/8c939b46f67248914f715f8d.png"},{"id":102962446,"identity":"3ea85102-1a07-4b93-a2c5-124eb5d3f7ee","added_by":"auto","created_at":"2026-02-19 04:08:44","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":5310004,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8712266/v1/bf78acdf-9f0f-411e-9f44-0c6acd711966.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Clinical and Economic Outcomes of Virtual vs. In-Person Transplant Pharmacotherapy Clinics: A Cross-Sectional Study in Iran","fulltext":[{"header":"Introduction","content":"\u003cp\u003eTelemedicine involves exchanging medical information through electronic communication to enhance patient outcomes [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Using real-time audio and video, it connects patients and healthcare providers across distances [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. Pharmacist involvement in telemedicine model of outpatient services began in the early 2000s [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e] and has since expanded to managing hypertension [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e], diabetes [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e], and anticoagulation therapy [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eA virtual clinic, a specific form of telemedicine, enables clinician\u0026ndash;patient interactions without in-person visits. In transplant care, pharmacists conduct virtual consultations to assess medication regimens, identify drug-related problems (DRPs), review vaccinations, monitor patient\u0026rsquo;s adherence, educate patients, manage drug interactions, recommend dose adjustments, and address long-term adverse effects [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eAdvances in digital technology have made virtual clinics integral to telemedicine, improving access, reducing costs, and enhancing convenience. The objective of this study is to examine the clinical and economic impacts of the transplant clinical pharmacist\u0026rsquo;s interventions on solid organ transplant (SOT) candidates and recipients, utilizing both in-person and virtual pharmacotherapy clinics.\u003c/p\u003e"},{"header":"Materials and methods","content":"\u003cp\u003e\u003cstrong\u003e\u003cem\u003eStudy design and participants\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis cross-sectional study was conducted at the virtual and in-person drug therapy clinics affiliated with Tehran University of Medical Sciences (TUMS). It assessed the real-world outcomes of pharmacist interventions during in-person as well as remote consultations with organ transplant candidates and recipients, utilizing the TUMS video and audio communication system. Data for the virtual pharmacotherapy clinic were collected over three months (October\u0026ndash;December 2024), while data from the in-person pharmacotherapy clinic were collected over eight months (September 2024\u0026ndash;May 2025). Both clinics operate one day per week. Under the leadership of a clinical pharmacist with 20 years of experience in transplantation, the clinic followed a three-step approach: reviewing medical records and conducting remote interviews to perform medication reconciliation, evaluate adherence, identify DRPs [8], and verify vaccination status; providing recommendations to optimize treatment and monitoring; and delivering individualized education and guidance regarding medication and vaccine use (see Form 1).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eClinical\u0026nbsp;\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u003cem\u003eoutcome\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u003cem\u003e\u0026nbsp;analysis\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTransplant clinical pharmacists systematically detected and resolved DRPs during virtual consultations. DRPs were independently scored by a transplant pharmacist and a pharmacoeconomic specialist, with discrepancies resolved by consensus. To evaluate the adverse drug event (ADE) risk was assessed using a validated risk matrix method [9] that includes:\u003c/p\u003e\n\u003col start=\"1\" type=\"1\"\u003e\n \u003cli\u003eProbability assessment (1-5 scale)\u0026nbsp;via\u0026nbsp;literature evidence and followed a Delphi process with three rounds among a panel of five experts to reduce subjectivity to reach consensus from the transplant team (specialist with 15 years of experience\u003cspan dir=\"RTL\"\u003e\u0026nbsp;\u003c/span\u003ein the field of SOT, two clinical pharmacists, and a pharmacoeconomic observer) (Table 1)\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003eTable 1. Probability score of adverse drug events\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eScore\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eDomains\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eProbability\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eDescription\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eRare\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eThis will probably never happen/recur\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eUnlikely\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eDo not expect it to happen/recur but it is possible\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003ePossible\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e10%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eMight happen or recur occasionally\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eLikely\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e40%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eWill probably happen/recur, but it is not a persisting issue/circumstances\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eAlmost certain\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e60%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eWill undoubtedly happen/recur, possibly frequently\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003col start=\"2\" type=\"1\"\u003e\n \u003cli\u003eSeverity scoring (1-5 scale) emphasizing ADEs with allograft rejection or damage potential (e.g., immunosuppressant toxicity/therapeutic failure) (Table 2)\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003eTable 2. Severity score of adverse drug events\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eScore\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eDomains\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eImpact on the safety of patients\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eNegligible\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eMinimal injury requiring no/minimal intervention or treatment\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eMinor\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eMinor injury or illness requiring minor intervention\u003c/p\u003e\n \u003cp\u003eIncrease in length of hospital stay by 1\u0026minus;3 days\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eModerate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eModerate injury requiring professional intervention\u003c/p\u003e\n \u003cp\u003eIncrease in length of hospital stay by 4\u0026minus;15 days\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eMajor\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eMajor injury leading to long-term incapacity/disability\u003c/p\u003e\n \u003cp\u003eIncrease in length of hospital stay by \u0026gt;15 days\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eCatastrophic\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eIncident leading to death\u003c/p\u003e\n \u003cp\u003eMultiple permanent injuries or irreversible health effects\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\n\u003col start=\"3\"\u003e\n \u003cli\u003eEach DRP\u0026apos;s risk score (probability \u0026times; severity) was categorized as follows (9):\u003c/li\u003e\n\u003c/ol\u003e\n\u003cul type=\"disc\"\u003e\n \u003cli\u003eLow (1-3): minor laboratory abnormalities\u003c/li\u003e\n \u003cli\u003eModerate (4-6): requiring drug dose adjustments\u003c/li\u003e\n \u003cli\u003eHigh (8-12): ADEs with hospitalization risk\u003c/li\u003e\n \u003cli\u003eExtreme (15-25): allograft or other organ damage/potential death events (Table 3)\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cimg src=\"data:image/png;base64,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\" width=\"609\" height=\"475\"\u003e\u003c/p\u003e\n\u003cp\u003eThis approach prioritizes DRPs that can be achieved through infection-related complications, cardiovascular events, and hospitalization probabilities.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eEconomic Analysis\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA partial cost-benefit analysis was conducted from a societal perspective, including both direct medical and nonmedical costs during the three-month virtual and eight-month in-person interventions.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe benefit components were associated primarily with cost savings and cost avoidance.\u003c/p\u003e\n\u003cp\u003eThe cost savings derived from medication optimization were calculated as follows: (daily cost of discontinued/reduced medications) \u0026times; (remaining days of the original prescription period).\u003c/p\u003e\n\u003cp\u003eCost avoidance was estimated as follows:\u003c/p\u003e\n\u003cp\u003ea) Preventable ADEs = \u0026Sigma; (Number of DRPs \u0026times; ADE probability tier [1%, 10%, 40%, 60%])\u003c/p\u003e\n\u003cp\u003eb) Applied only to DRPs with \u0026ge;10% ADE probability and \u0026ge;moderate severity (excluding \u0026quot;rare/negligible\u0026quot; cases per Table 3)\u003c/p\u003e\n\u003cp\u003ec) Hospitalization cost parameters sourced from institutional data [9].\u003c/p\u003e\n\u003cp\u003eDirect nonmedical costs included transportation (based on round-trip distance), accommodation for necessary overnight stays, and meals calculated at the standard per diem rate, offering a comprehensive view of related expenses.\u003c/p\u003e\n\u003cp\u003eTo clarify the overall financial impact, key analytical parameters were computed. The benefit-to-cost ratio (BCR) was calculated by dividing total cost savings and avoidance by intervention costs. All values in Iranian Rials (IRR) were converted to U.S. Dollars (USD) using the 2024 Central Bank rate of 285,000 IRR per USD [10]. The cost per tele-pharmacotherapy clinic encounter was $6.9, and in-person pharmacotherapy clinic $3.7.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eData collection and analysis\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eProspective clinical and economic data from in-person or virtual consultations were collected via standardized forms, verified by two researchers, and analyzed in Microsoft Excel 2013 using descriptive statistics and cost-benefit calculations, including savings and cost-avoidance estimates. Robustness of the base-case BCR was assessed via multi-method sensitivity analysis: deterministic one-way (\u0026plusmn;20% variations per component, visualized in a tornado diagram to identify drivers); probabilistic Monte Carlo simulation (10,000 iterations with normal distributions for costs and lognormal for cost avoidance); and two-way deterministic analysis of the two key parameters\u0026apos; interactions. Analyses were performed in Python (v3.9; NumPy, Pandas, Matplotlib).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eEthical Approval\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe study was approved by the TUMS Ethics Committee (IR.TUMS.TIPS.REC.1403.024) and conducted in accordance with the Declaration of Helsinki for human studies. All participants provided informed consent, and data analyses were performed using coded identifiers to ensure confidentiality.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003e\u003cstrong\u003e\u003cem\u003eDemographic and clinical characteristics of the patients\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eDuring the study, a total of 232 patients (147 males and 85 females) were consulted. The mean age of the participants was 50.28\u0026plusmn;12.4 years. Most patients were liver transplant candidates or recipients who were referred from the liver transplant clinic to\u0026nbsp;the pharmacotherapy clinic.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eClinical outcomes\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eDuring this study, 22 tele-pharmacotherapy clinics and 32 in-person pharmacotherapy sessions were held, with each consultation lasting about 45 minutes. Table 4 presents a comprehensive summary of all DRPs and the corresponding recommendations identified in both clinic settings. Post-intervention follow-up revealed marked improvement in vaccination coverage, with significant increases in influenza, pneumococcal, tetanus, and hepatitis B vaccine uptake compared with the pre-visit period (Table 4). However, overall, 11 patients received no vaccinations prior to transplantation owing to non-adherence to treatment; 35 patients did not receive the pneumococcal vaccine, and 41 did not receive the influenza vaccine due to vaccine shortages; 11 patients with hepatitis B infection were ineligible; and an additional 5 patients exhibited non-adherence solely to the hepatitis B vaccine.\u003c/p\u003e\n\u003cp\u003eTable 4. Clinical\u003cspan dir=\"RTL\"\u003e-\u003c/span\u003eeconomic assessment related to DRPs by the transplant clinical pharmacists\u003c/p\u003e\n\u003cdiv\u003e\n \u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"620\" class=\"fr-table-selection-hover\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003eVirtual clinic\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003eIn-person clinic\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTotal No. of patients\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e82\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e150\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNo. of post-transplant patients\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e65\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNo. of pretransplant patients\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e71\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e85\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTarget organ\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eLiver\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e82\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e140\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eOthers\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNo. of DRPs\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e504\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e1103\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNo. of Recommendations\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e674\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e1594\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDRP/Patient encounters\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e6.15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e13.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTypes of DRPs\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003ePreventive therapy required\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e258 (51.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e291 (26.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eRequest for drug information\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e86 (17.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e156 (14.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eRequest for disease management advice\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e85 (16.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e156 (14.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eHigh daily dose\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e5 (2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e70 (6.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eDrug allergy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e26 (5.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e20 (1.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eInadequate drug safety\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e15 (3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e25 (2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eOthers\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e29 (5.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e385 (35%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTypes of recommendations\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eInitiate medication\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e262 (39%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e415 (26%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eDrug regimen education\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e79 (11.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e165 (10.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003ePatient knowledge education\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e79 (11.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e155 (9.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eAdherence education\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e75 (11.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e102 (6.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003ePharmaconutrition advice\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e74 (11%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e154 (9.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eDiscontinue medication\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e17 (2.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e125 (7.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eOthers\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e88 (13%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e478 (30%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAssociated medications\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eVaccines\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e126 (72%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e319 (55%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eDietary supplements\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e15 (8.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e85 (14.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eHypoglycemia agents\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e8 (4.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e86 (15%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eAntiplatelets and anticoagulants\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e6 (3.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e13 (2.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eOthers\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e20 (11.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e71 (13%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePhysicians\u0026rsquo; acceptance rate\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e82%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e84%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePatients\u0026rsquo; acceptance rate\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e74%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e77%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eVaccination rate (Pre vs post-transplant)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eInfluenza\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e2 vs 23 (P \u0026lt; 0.001)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e3 vs 17 (P \u0026lt; 0.001)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003ePneumococcal\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e1 vs 26 (P \u0026lt; 0.001)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e0 vs 23 (P \u0026lt; 0.001)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eTetanus\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e1 vs 26 (P \u0026lt; 0.001)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e5 vs 48 (P \u0026lt; 0.001)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 306px;\"\u003e\n \u003cp\u003eHepatitis B\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 162px;\"\u003e\n \u003cp\u003e0 vs 18 (P \u0026lt; 0.001)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 152px;\"\u003e\n \u003cp\u003e6 vs 46 (P \u0026lt; 0.001)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n\u003c/div\u003e\u003c/br\u003e\n\u003cp\u003eOf the 140 DRPs with potential to cause ADEs identified in the tele-pharmacotherapy clinic, 106 (75.7%) exhibited an estimated progression probability exceeding 10%. Among these, 40 (28.6%) were classified as extreme-risk ADEs, with the remainder categorized as high (63%), moderate (5.4%), or low (3%) risk (Table 5).\u003c/p\u003e\n\u003cp\u003e\u003cimg src=\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAoYAAAGWCAYAAADltEJ/AAAQAElEQVR4AezdBbxlVdkG8HdTEoIISMfQKV0iMSBKIyECItKgiICKiiApoIRIIyId+klLh4QISAnSzdAhSknXt/972MOZy70z987cOOeed36z7j579XpWPetd71p7nI/yXyKQCCQCiUAikAgkAolAIlAiME7kv0QgEUgEEoFBjEAWLRFIBBKB7iOQxLD7WKXPRCARSAQSgUQgEUgEBjUCSQxbsHozy4lAIpAIJAKJQCKQCPQFAkkM+wLVjDMRSAQSgUQgERhzBDJkIjBgCCQxHDDoM+FEIBFIBBKBRCARSASaC4Ekhs1VH5mbwYpAlisRSAQSgUQgEWgBBJIYtkAlZRYTgUQgEUgEEoFEoLkRGCy5S2I4WGoyy5EIJAKJQCKQCCQCicBYIpDEcCwBzOCJQCIwWBHIciUCiUAi0H4IJDFsvzrPEicCiUAikAgkAolAItApAm1FDDtFIC0TgUQgEUgEEoFEIBFIBCoE+pUYvvXWW/Hss8/GK6+8UiXe2Z/3338//v3vf1d+Pvroo868NKXdm2++GY8++mi8/fbbo8yfMvEDB2FG6bmJHD/88MN48skn48UXX+yVXMHgqaeeikceeSSefvrpeOedd3ol3o6RwPt///tflXdpdnRv5nd511f0hw8++KBfsqqeX3/99XjiiSdG25b7IkPGiGeeeSbUWVfxv/fee/Gf//wnXnjhha68DIj9c889V/UPGPZWBtT7yy+/HOLurTi7G480tb3eLE9309ZXjTWvvfZad4PU/kY833jjjaqN1GNL3Z+MO36P8DiaH8rfm2PfaJJL50RgwBHoFjE0WF922WXxhz/8YZTm4osv7rJABvLTTjstVl999TjllFO69Pe3v/0tttxyy/jd734XJoAuPXbD4ZZbbhkpv//4xz+6ESqqSfGMM84YKWxd9r/+9a9hYDFYNEZ2/fXXxxe/+MW47bbbGq0/9RuWZ599dqy55ppxww03fMq9WS1M1F/96ldj9913H+ssmuhOPPHE+P3vfx+77rprbLTRRnH++edHX/xDMo4++uj48pe/HLfffntfJNFncT7++OOxxx57xE9+8pN46aWX+iydOmKTpbZ92GGHxdJLLx3/+te/aqd+eSKkp59+enzta1+LrsYSk7x+bIz48Y9/3C/56m4i2223XfzsZz+L3lrwWSSrA/W/+eabdzcbveZv6623jr322iuMWb0WaTci0g4uvPDCalz4v//7v26E+LSX//73v9X4vckmm8Tdd99deUCyTzrppFhrrbV6NLcY+7TJ3XbbrYon/yQCgx2BbhFDqzZE7d57742JJpoo3n333TjyyCPj0EMPrd7HH3/8uOmmmyq7rgAbZ5xxYpJJJqkkRF35Yf/Zz362khaYALyPqXn11Vdjn332qfIkr8zzzz/frejGHXfcyt/+++9fTcqPPfZYVU4kw0S9ww47xB133BEm0spj+WfBBRcMg87cc89dvnX9X9zwQo4aw3cdom9d5OOBBx4YbSLq/ZBDDgmTxWg9j8aDSf+6666LX/ziF9Xgve+++8acc87ZeaixtJ1wwglD2zO4j2VU/R58vPHGi6IoKulYdxNHJvTTMS2vetYuxzR8d/PZmT99Q12NSkpVFEVMP/30Vf/rLI6BtENUt91229DmxiYf//znPysJelEUMcUUU1QSdWPu2MQ5JmER0i222CI+85nPjDb45ZdfPlo/3fVQFEUYR8dmIacdTTnllGHsrtPVvlZbbbU44IADQt+q7Uf31CcOPvjgXhn7RpdWuicCzYBAt4ihjJLqIEVWYOuvv35MN910MfXUU4f373znO3HEEUdUEjN+OzOf//znuzX5zzHHHNVg2FkcPbGz4txqq63i6quvHmHWWGONbkUx44wzxre+9a0gATAofOUrX6nK+fOf/7ySmJEakmw0SjThseGGG8YXvvCFUaZhkJ1tttkqojlKj/3keNddd8Vf/vKX0aaGzFppL7XUUqP1OyoPpCk333xzfO5zn6smnMknnzxWWmmlWHTRRUcVbIzdpppqqlhiiSVisskmG+M4BirgDDPMEExP0rfldcUVV4yRlKcoiqpPq2OLuJ6k2xt+J5544tA39JGu4ptgggli9tlnr9pOV34Gyn6FFVaIL33pSz0iHR3zavvUjoJ+gsgMGTIkjJ0d/fXH+9ChQ6u+MzoS9fDDD4cdgN7KE+GAhfbYxGdc6bjYLIoi5plnnmrXCnHsbvz12EeK3t0w6a9nCKTv5kKgW8TQALXYYotVk3ln2S+KopIGLrfccpWInm4K3TE6dyRSHbddvbPnx9ZVd7Yq6IuY9IQRfyMp65gnEgdSKQODAcAgYfWog3f029V7URRhomp0NynNO++8MdNMM4Ut7zoPJCzyRy+rUdJJ0goDq9ZR6RTCwuDK2D7sDA86N+IQp0kDFuIlGZX+K6+8Uklj2TfmwfYJXSz5EL8tSXYkS7apkGdpcpNunY7ftv+5KRuJBVyFhwnpqTDMsGHDKgmHuvHOTfz8NRpxPvjgg0Fyqxz80i+s/UgHhuLpWMfKLF7h5EvZG8tZx+EJD5jywwjDnuFGGiYd7/KijDU+2qO8i1v+GHHxy2i7MKj9c68N985MY5rKoWzqST2IT93Jp3LbAmPXWTzsuNX+pQsTeeWmnkm5L7rookpSIh32wohXnqXjNztujN/suMPCVp48c+vMSA9u8sGvMIyy8S8+9srITrv1mz13dt6VV/61C/YdDdzlV51olx3dO76Lh1+4SFM98uOpzuCjHcNF2kiYPGl32rDyaxvCMNz44Vd+/a77PPdGIw39g6nt9U1pyrv063x1FQc/Bx54YKg/eanbaB2f9gJ3+WlMp3av+wXM1E1t3/hUd8oiL0wdjzx6Z2Agj8orT3V45WFX15/83XffffHd7363kmoKC0fp+82vsNqWPGsj6ogdw772q05gyL4npq5P6Ulbu+uq7apPZZAWP4xy121QO1Am+YRTnQ9pwKkRC27KYvxSNu1OXOzTJAKtjkC3iCGpC5KFII6qwGuvvXb8+c9/jp122il+9atfxaabbho77rhj6Gh1OJ3TYHLQQQfFN77xjVh++eXj2GOPjcbJu/ZbPw2GdPxIJem4iZdEsLOBRGen53frrbcGCaGtnbPOOisMGHV8Y/M0OBh0reSRTnEZAI877rhKj03Z2PG39957V9sWti7k+cYbb+T0KXPNNddUYUkpDz/88OqgRKMneb/ggguqlS4clGefcpt85ZVXDlJMupQnn3xyhTWpHomDgV0c1157bfzoRz8KhOF73/tepb9JSmgQPOeccypc6GzZKjG4sqMHSsfSJEV6dOqpp4Z4SETVq3hJTNdZZ52Ya665KskqDHbZZZdYdtll4/jjj++0Pg3AykfnBymV5p/+9CfRBcK4d4mXdvHLX/6y2rax/a9dGMz5W3XVVSvdU2WWL3qdVeCGP9qXrTh+9ttvv9hzzz0rdQKTEG8manlYZpllqu1IbZWUx7bZiiuuWLVJ7c1EAOOFF1441K2w2has6RrBc+edd47555+/qhd55qczo9yHHXZYhY262WabbcIiij0sjjrqqLBN//3vf78qt/xLq7O4TEL6gG14eG2wwQaVxFdfIIkVH1IhTm0GHvqCMjPawPbbbx8PPfRQFT13ZVJ+ZRKv/qjNVR46/FEXZ555Zqy77rrx29/+NpTLjgEM4a1vPPXUU/Gb3/ymkgRrq5tvvnlVXhOyiVQ4df/rX/+6arP86i+NSelH/Gy00UZBYi9M42Td6Ndv6SqzMULdr7feeqGNIjnKbwFkLCLtpwKj7X77298OffLcc8+t2onxQj0oY5T/bMlrP/KpLWy22WYxbNiw0mXk//qaPqSP08njiphqy+pa/KecckoYi6RrfOqsfql03HnnnaFdaPv6urhqI6/0ZcVhp6YRM3Wov8JSWdUz0lWHrZ/av3rSbpdccsm49NJLKyf51X+NH9RkpCUNZedBnvR9JJB00FigXrTnJ554osJFfVE5gtV8881XqfIIS5da2bV5OLHT/tSHNmx8+vrXvx493Y5Wt3QQ1bm0paH9amfS6GjUnbFYPaozY6Dw6p0Ovd/6lh0MakHCI3/GPu1QWHaM8UQdSRsudMb9rtsOP2kSgVZFoFvEsCeFM5AS15tcDLK2KUnX6jiseg3wOqOBD7kxmP39738fSWev9m+1hqwIYxARLzIina4mL4OSicRkZ0Az+Qsnrjrenj51eBOvgYfk0CRQb3l5FkVRnaau4zXgGrgNHiYiE2dNJGs/niZmkkmTtQHXAEe/hlttiqKopJcmDhOm8tHLEwYRt11OORqetk3/+Mc/VqcjhTdY2bY1oYgfcTAIshPHrLPOWhEbB0GkO+mkk1YHHZQVcYe59GaZZZZKSipOxmBusqPvRaXA9s9CCy0UDpPQtaIbxV+joSaAnDgIYkEgTZMRSYf6hAVycswxx1QHEEzwBmu42U675557qgMkVBmQsyHlNltj/H6b4LQ7243KLj1SXu2HO/0vbRDhRBJMJtLmT3n5YagTmOQa00C+TA7KBk8E2PYhPyYH4Toz0kQEEE7k2+SqTbJHuuVP+toogm1S6qxty/dVV10V999/f5jc5Q+m5513XkXEEXqETT3oU9KRpvZgUpaG/JvItUt5NVkiMAgwvPQb5TFxcu9oiqIIknfkE7lH0IXRn8VvwaY9q0t9T1o/+MEPKgIonDwjhyZgv2HuUJp23JiWNoGkIHsIDNKjvhr9NP5WF7DTLvQDB8EQFFhpn8i2BSrVEIRE+Y1L2rDxBAY//OEPA+lFCMWtbmxpyqe+Ms0007D+lCmK4Vvw2l49xlhE60v6KwKCwMPXWGFBoy11jMii6pvf/GZoezBtXGzAEUlRp+oewZJ/cUj3pz/9aXWowlijLMafxvD8MTPPPHMoi35P/UVfYm8LX9zGTLtD0047bXUSum4HyqNeEUaSMf2UrjUCCmttWH9GJOUdzuJl1KNDOX7XBv7ajzZzwgknVAd22NXu3XkibHaGED1pb14uQCxEtM3OwlOPMA4gddxtkRvLSaaNi4svvnjIv74CI36KooiOYx97Y4wFtnJpH8Z3i3Ntm3uaRKCVEegWMexJAQ0IBlMdjk6GAdAkXMehM5qEkAMd0UBOL8+qsh5Ua7+eJggHW3Q85MOkbOAywSIv/DSaohjekQ1GiJMVrcHWQGaSaPTbnd9W2FbH88wzT1BcNmgjqiZChEUctqpNpvU7O6tZE4CJmX4bIgkTbo2GtNAAKa8GWJNno7vfyo3oFEURJmK40T2DCXLh3cCMpPltIjIA1mERPvViUjBJdkY6+DVpIRomANJfEzI9SwOlOIqi4K0y8iktuF555ZWBDJowlMOEWHnq5h9K5upYHLA0gJukTFwmbvHKV1EUQWqIBJuU2HVMgrQDAZB/uFEhGDp06Ai9VfHDQTuUBumAMqpX2DTGBw+41XaIkVm+2AAAEABJREFUmTan/bI3eZKamAxgXvvr+CRxN7lIk7RH20FObOnJr74ATyoK2oAJ36KiYzzeEUxtUbnkwW9tTT/j3tGY8Ex88lwURaWfp62ajMUFd9JREht4wQAmXdWhtqwNqiNExkl17QAJQVxsg/KjvNqmeiBNQYT1D8SRZBbJgoc+ZbxAdhrzrm0z2iDiLj8IX6Of+jdiRKpLwmUBoY4Rdn0XkdF39D3kR1uGM/eiKCqdRospdWmRapu0rkvhtU346m/aS51m41M5kEvp1vbKh3yxg5c2p42xVyd1/6z9j+6pb6sX+dDXtRdtUTiLb+1BO9Jm1YcxVTtCKPlpNMpqgUvKqny1m7FI29T/9XeLx9pNGHXKqDN5IeGWTu2nfhqj1XX97tkYl3fupJbqS5vTl7tq8/x3ZowN+gvsuSO5+hO8vXc0sFeO2l77VEee2oB2qI4YdY/Uc4NFUXwy9sEUod14440D7uoCUURU67zUaeQzEWhFBHqdGFpFGXyt5BCqjqAURRFWn0UxvKMZMAzcJvN6dRoN/wzUJGKIlQ7KWBGb3AxsDV4/9VM6BlSTsMGUUv6nPI3GwmBCamVVaCI1AZOgGQxGFRQxRWxgQUpjYjJwN4YxEJNSmKSQh0a3rn4b+ItiOHZFUVQnbuWlKIbbGXCj4R9pjAkThiY29dPg3OVPAyJHGHaMk31tTCSIF4mP1bP81W7dfZLm2P5RV3UY8cAFsbYIqO2RoaIYLrWq7eqn+rHAMBkjLrW9yUu4+r1+IkJFUYzUHmM0/9S/xYq0eIUP0qIO2JlQbJPVhtSMv9rIR1EU1QEF24Ymd9JT7XqBBRaoDkqZmJHQOkz9lBbirf0jlaRoJsfaveNTHLaebSkjWdIwacLbBK/P2YI0uclXHV6bh3/93vFZtwdtpCiGtzt1px2Y3GuJDH/iLYpPykuqV+MuXnWFsCGn8sKOQbY8GZOteBrd2dfGRG2xQ/qojAyiaoywqKj96YMw9C5vRVFU0k+/2dVufjNO4Ouj+jIMjSFUarh114izsSzCaUOePTHaV8d4apwRzeuuuy7kT9ktFpQJiYRLZ+kg7OK85JJLQn7uvffeSk+8kTh1Fk4YOHLz23NMDGJFymeb36FGpKqn8ViQyq+yCqvNart1/th112jLHf3CpaOdd31Wu7LA8M5o0wju2GAinjSJQDMg0OvE0DblrrvuGrY9ieW7W0gds+7gjWF0TqtK5IweWqOh99Hot6vfBnMSExKNrvyMzn6VVVYJK2Src9tWo4vLqpN0xER+/vnnxxZbbPGpewsN5CZlkxjl5dHlYUzcbTmRDtiqlxfbjGMST1dh1BtsETHbwoh8V367sic9Uc8IV6MfBNzE2t2BHjGrJ8vGeHrrt4nZVi3yicgqq3ZOemJSQMSQNpKn2tgy7Sp95SWpUEeN7drEo812Fg6ZQwhtZZMM2aLszB87eJB+2WIWZ2Maflu4kCby21sGRl1NjvBS1x37DgJjUkf+RpUPk29n7iR6tq6NPcpVGxIfi5XOwnTHzkKObivJFgk19Qn4dydsf/qh5kJyXZe7fpIYWmx0lhcLcgtGxNcihk6x98789oUdHEmC4SvvFoE9TccO0+iEAz2Nsyf++3Ks6Uk+0m8i0NsI9CoxtC1BL4yUjF4RSeDoMmzy0sH57WxCMVkgB7ZbTbx1fAZDA1r9PrqnuG1Bj85fV+4IEP0bhxYo3Fuhy3tX/tkjfSYm21zSp8/GvjZWu/vss091oo9+TWcS09pvj59lAFIYeSY58bRVUlr36n9bdaRFykk/i+lpAki07UeTVGNYBII0TvyN9l39Loqiui4Iye5KUtJV2O7Ya4fq0FP7RrTlz2XLiDF7hw3optXG9nhXcZu0SRRrnbbaH70/hK5+r5/6CUkLaaFDDiZU6dbuHZ/yYwtT37Hd2ujOzkJMG5UerBvdx+Q34qcukY7OwtsuJGkhxWxs68iixR/JYWfhhEH8bF135i5NiwdqI43u4pVWo11PfsPPVja9XzsG9Pbo6fYkjv7waxFB4taxji1eSLC7yoNFhYUBvTz4qp+u/PamvbFbPyI9tmgladYWe5qGerd1rAx1WGQN6Rzd2Fz7H5OnhUxRFGHh3xgeSe3swE+jn/ydCLQCAr1ODA1GSJ6B2gAwOhBM4vzRG0OeOvo3ybjjzurSdih3Az6y1d3BxAraVi3CKjxjwjAh+t1dIy8kQvKJAJvUuwqLGNgGJUEhUSMx7GzQIJUgieTf6cWu4qvtTb7179E9KWEru21DBJv/UREmhIMfhhTGc1SGRMZ2jm0pEhW6R4gL0jGqcB3dTAzIK8lpoxtdTtuDCHRtP6ryF0URyL96Jdmtw2gvJJL1e/1snFBqO4sPBMy7ScbEasAXh8nGARgqEg7IIAx0LE3M/BdFEbbxlKc2dKC41aaRgCE6CCD9ulr/VZtxyIJ9HaZ+IlOklaSTk08+eWXdGF9l0fBHvpFq/YQepb7GWRpO7GrHiyyySHVC2VYpNwYRg4PfozKNbQQp0da0AfEKh2w05g9J5a588saPctoKpebQFcm1+IB9VyTbVrMxx8EL5VJX4jZxN6oh1Gly646x4yF/yL98I1LK2Z2wveFHfWuDo4tLW1NnbjXQ9vlXVvmnluC9M6PPIb4k0HRMO/PT0U6emI729bvxpe6jjbrl6kG/ki9zBN1W45IFgbDsPXti7BjRadXX67am/rXvohiu4tCT+LrrlzoG7IxPjepJDkrVfcLYWNdFd+MdE38ZJhHoCwR6TAx1fFs2Jki6SlbR9eBFj8mEYrKk+0S3zqRkNes0pa0g+l4IkO1VWx0kWQbceouT9IQkUIejD4eMkc4Y+G2JmchMqAbCRh2PGhyDwoorrhiU/En1XA3hGgRpkErxh6Btvvnm1WfpvHc0OjdyQ0qAPNQTjMGHDo/8IF3IrC0Y24m2A5EP7wY5ek+2HWEFJ0/ER75JVm0j2pI2WSOsVr8GOpJDK+nGPMFc/NKnuyn/CAsJG50ug6N3hyBgivR6yqtJTTmcdKXPKA4TsXz6bbsWTk7E0uESTvokf8ogHyZ3fkzO6kV56QZRvjZAmtC5qR/tQp2qR2E7GuUQVv37LS11a5vOhOEwkm1PpwLpCyGcyq/9SINKgfYh7x3j9k5fzzUksJYPEwVJkrqhb6ktiF+ZTJykqsIxdMm8I3xOGCJL6kU+4S4OCwOnSymbM/yZmORdHJ0ZhBuuJlR5qP2qG3HAaumllw7badqMfkKSB3/tUBuGv/RJrGHgIIZ8IE0ImXKKV375V2YTlT7p5Kg8kMjpOw6DODSib2rDyDeJr8WOBYpTzrDWRkxwnZWJnTYlHXiqJ31OXCQ2ygtj7Ujb5B9JQVAtqJziFjf8iqKornLhR3+fddZZA84wtxh0ypUeGtULpE99IGzqUl+Ci3gQZmW1xW6c0OfgWvuXT33ReMVN/rRnpIWd+tYejVf6vac+I5yDZOpCH5XPRoPwyId+p29p3/qiulGH4kGS1LO6sgjwuzGO+ve0004bxjD1QF0ARuISvzzAUj+Vpjhgrd1YOEubaoLxRPkdxtDG6rg7PpEyKjLaQONugri1IeMMiRwjD8YbeTfe6JN1fMYZeaMzaKFYFMPrkx2yrh1q+/AmnRRWGH2Bm10TZNKYyM74YsyFmfpRRu2xTq9+WmzLtzalzHAwHrJTn9qgsOJgj6jBE5bGE+O03/xqp/zyA0fpWYSpC33PeCMeeSuKorqWDU7GQETR4lDfk7Y6QriNQ9Ko85vPRKBVEOgxMTQpG2hNonRSEEMDhwKTjujoOr2OZXLX6RE1HaYmIQYsHdPAbksM0SJhFIcOavLi38lJdqRAiAsdNgMAEuGUI70k7o3GhErH0WqU/or8mqykXfszgei0JsParvGJ9JkUDTQIpMnI4QqDG2mIU84IDHe6e6RkBjHK6oixgcWEZAVvsjFpGXxNMiYeE4x71kgxXSViojS4kJoYuAyojfkxcRmQbVkafEw0BmnhXNVgkkSipWUiMPGbzBAMuCHdBl51AW/kCY6IgTzB24S88MILV9/HNdjJm/jkA+EwQdsm5Vfc6g9JMfAZ6A3q2oEyIHoOVmgDwjcahJCUVPktHuDHXTmQGwMw7E2Q0lcGg7GJSdzIjfQNysJ1NPKt3VmUIPik0e7ZQxSRFxJcYUwq8m3y9s7QJTORITC2Ed0HJ1/CIr3s1L1ywVve5RlpQULF0ZkxyWo38NOWkGf+4A8HCwR1u+SSS1b3TbKTFsKpXhAu9Q1jGDiIRXK16qqrBnLLv/q0UDLRq1NtQv6lq11aHHjyp73qk/IAZxIjZYSVhYu8kGIiWY39hv9GI31tWZ/V5hAZ7sYHGNYYI0PslZc+pvKSYPOvv1hIWjDyY3cAORAWASFdpKepv3I3iWv/JFz6tTHEpK9dILSubZGG8QFxRkb4R7jhxL/6QGBgqa1yZ6edwUwaSIJxCqb6r3YLI4RaPhoNEomsy5P8axuIjTYqXeMBkqVd6z/Iujgb46h/qx8kT5mGDh0ayB+VA2Ot9oCkaD/w0K9hLSxpKlyNOcIh7Po5t1EZ+bEgoCpT+1N+edXu9Al1LG11Jh+wsdCo/VOpMCbrb8rGn7HVTghihagbK5XL+AMjCxuLdW1OWfRXfUtZ9Uv1pH70Z+OhcaFOr34a47Vr/c984ZAhHCxULQBgLg6Lb2QdVtzYqR/1AkvtyLig3SGDxlhk07ir/dVjn7oRhz6sDAQctsSV2bxnrpA3fVae9Hf9gF2aRKCVEOgxMaxJGsLBGHzpOtWFRipIvXQSxM2AocMiY/zYTvKuI5kQDEzsayPORlPb6/ikDNKThs5XuzU+TYQmR5OfeAyUttMa/SAbBgcTbKN9/duAS2IhfG1MTsrDD0nWrrvuWl3MXbvXT9INA4gJBOFlDw+Dn8FH+dnVxqDsoEL97mlCkk5tDEKkWNwYE/dGG20UtjO9M9IzEPtdG1iYvGHGjcRUOCRGPsSPzCMXcKJjVIf1VE/8mHSRSnYMsiTfftMRcj0FjBvzYwIpik9v5wjTaEzW0mCQZ3mRXwOuQZw90uxevjqcemucyPhpNOpH3vlXbgQWKTLpaKvsGfk1mddhERfYS0sayJl2oj6lR/pDymLBwtA3Y0zyCFUdT8enMkqvNuqq9iNe25TajTpGatQb95133nmkNqYeEDX9Rl/w26TrN0mRMPqZBZQ6VifsLLqcHpc+v4h5nQZ3h1BMqPCAO3cTIwkd964MKQmypK9pk/UkqH9KqzaNBEUfUB/KgBiqJxNxYxomfPbC82eRJRw/8trY9yzQ6Hxxkx8TsvwYf+QHBo3+tVvtTB2LnzGBs/O7Nvoce/GxUz/agXQ6Gu2tcbxALpFq4Wpj0VX/rp8d4/GuL2mziLkw6qH2r30gT4h8bQdr4RjtTNnViXGa3egM6az+pa3Xfi0WlLdOA5bIX/3uiTDW/o0l2pWxXsuzAcwAABAASURBVP2wt0DXBuGi/hBw74QG0iLRlIZxlZt+qVzstWXzg3QYCzthxNto9Fd9QBz8GWPreaHjmKqPGfv4q436rH97Iq7GLb8Zi0TvjWMfLLQr+VAu5aZzbs5hx+jTiLFxUt9jlyYRGIFAC/zoMTFsgTJlFhOBPkHAhGuryUSIzCBODGJSS+D6JOEmi5TEpDMJTpNlM7OTCCQCiUAiMAYIJDEcA9AySHsiQOJoe7uWzNhGJqEh3bDt1g6oUJmwZWu7kQ4XdYZ2KPcoyphOiUAikAgMKgSSGA6q6szC9CUCdPfoRtlGozfnZCXJIX02UsO+TLtZ4nbAAhm01U7/i45xs+Qt85EIJAKJQCIw9ggkMeyIYb4nAl0gQKeJ7pItZfp4dOToJCJIXQQZdNZ075S9NnQ3B10hs0CJQCKQCLQxAkkM27jys+iJQCKQCLQjAlnmRCAR6BqBJIZdY5MuiUAikAgkAolAIpAItBUCSQzbqroHa2GzXIlAIpAIJAKJQCLQGwgkMewNFDOORCARSAQSgUQgEeg7BDLmfkMgiWG/QZ0JJQKJQCKQCCQCiUAi0NwIJDFs7vrJ3CUCgxWBLFcikAgkAolAEyKQxLAJKyWzlAgkAolAIpAIJAKJwEAg0HvEcCByn2kmAolAIpAIJAKJQCKQCPQaAkkMew3KjCgRSAQSgcGNQJYuEUgEBj8CSQwHfx1nCROBRCARSAQSgUQgEegWAkkMuwXTYPWU5UoEEoFEIBFIBBKBROATBJIYfoJF/koEEoFEIBFIBAYXAlmaRKCHCCQx7CFg6T0RSAQSgUQgEUgEEoHBikASw8Fas1muwYpAlisRSAQSgUQgEegzBJIY9hm0GXEikAgkAolAIpAIJAI9RWBg/ScxHFj8M/VEIBFIBBKBRCARSASaBoEkhk1TFZmRRCARGKwIZLkSgUQgEWgVBJIYtkpNZT4TgUQgEUgEEoFEIBHoYwSSGI4RwBkoEUgEEoFEIBFIBBKBwYdAEsPBV6dZokQgEUgEEoGxRSDDJwJtikASwzat+Cx2IpAIJAKJQCKQCCQCHRFIYtgRkXwfrAhkuRKBRCARSAQSgURgNAgkMRwNQOmcCCQCiUAikAgkAq2AQOaxNxBIYtgbKGYciUAikAgkAolAIpAIDAIEkhgOgkrMIiQCgxWBLFcikAgkAolA/yKQxLB/8c7UEoFEIBFIBBKBRCARaFoE+pkYNi0OmbFEIBFIBBKBRCARSATaHoEkhm3fBBKARCARSAR6EYGMKhFIBFoagSSGLV19mflEIBFIBBKBRCARSAR6D4Ekhr2H5WCNKcuVCCQCiUAikAgkAm2CQBLDNqnoLGYikAgkAolAItA5AmmbCHyCQBLDT7DIX4lAIpAIJAKJQCKQCLQ1AkkM27r6s/CDFYEsVyKQCCQCiUAiMCYIJDEcE9QyTCKQCCQCiUAikAgkAgOHQJ+lnMSwz6DNiBOBRCARSAQSgUQgEWgtBJIYtlZ9ZW4TgURgsCKQ5UoEEoFEoAkQSGLYBJWQWUgEEoFEIBFIBBKBRKAZEEhi2He1kDEnAolAIpAIJAKJQCLQUggkMWyp6srMJgKJQCKQCDQPApmTRGDwIZDEcPDVaZYoEUgEEoFEIBFIBBKBMUIgieEYwZaBBisCWa5EIBFIBBKBRKCdEUhi2M61n2VPBBKBRCARSATaC4Es7WgQSGI4GoDSORFIBBKBRCARSAQSgXZBIIlhu9R0ljMRGKwIZLkSgUQgEUgEeg2BJIa9BmVGlAgkAolAIpAIJAKJQGsj0IzEsLURzdwnAolAIpAIJAKJQCLQoggkMWzRistsJwKJQCLQughkzhOBRKBZEUhi2Kw1k/lKBBKBRCARSAQSgUSgnxFIYtjPgA/W5LJciUAikAgkAolAItD6CCQxbP06zBIkAolAIpAIJAJ9jUDG3yYIJDFsk4rOYiYCiUAikAgkAolAIjA6BJIYjg6hdE8EBisCWa5EIBFIBBKBRKADAkkMOwCSr4lAIpAIJAKJQCKQCAwGBMakDEkMxwS1DJMIJAKJQCKQCCQCicAgRCCJ4SCs1CxSIpAIDFYEslyJQCKQCPQtAkkM+xbfjD0RSAQSgUQgEUgEEoGWQSCJ4QBXVSafCCQCiUAikAgkAolAsyCQxLCXauL++++Pv//972kSg2wD2QayDWQbaGwD+TvbwyjbwC233NJLTKR3okli2Ds4xm677RY/+9nP4sADD4zLL788TQtiMHTo0EFbb+uvv/6gLVtP+tvBBx8cBx10UFticfrpp8cPf/jDtiy7NrLRRhu1bdmVv9nMUUcdFbvsskuceuqpbW/WWWedXmIivRNNEsPewbGKZY899ohpppkmpppqqvjRj34Uv/zlL9O0EAbjjTde9+qrhcpUt8Fpp5120JatLmN3nuutt16su+66bYnFD37wg1hqqaXasuzaxkwzzdS2ZVf+ZjPf/va348tf/nLssMMObW8qAtFEf5IY9mJlfOlLX6qkEU888URsscUW8cgjj/Ri7BlVIpAIJAKJQCKQCPQHAu2cRhLDXq79KaaYIg499NBqBbTVVltVvx977LF47733ejml5ojuP//5TzzwwAPxxhtvdDtD77zzTjz55JNxzz33dBrmrbfein/961/x9ttvx0cffRSvvvpq3HXXXfHaa69V/hvdK4s2+gODp556Kj744IOmLfX//ve/qk08++yzVR61/TvuuCNeeeWVKt/PPfdcjIlOzcsvvxwPPvhgeFYRD4I/+s9DDz1U4aK9W0w+/fTTVbvvWLz//ve/Vfn1h45uzfCuXh999NGqLK+//nrQu37++ee7nTV9Xfs2Lmgr3Q44AB7//e9/V228WeuiryHRbu+99954//33+zqpjH8AEEhi2Eegr7zyynH22WfHZz/72TjssMPijDPOGEFs6iRNAL/73e/CIFrbeRpQkcuOov8//OEPce2111YTLH/MSSed1OX2iMMw/PSl+fGPfxzbbbddPPzww91O5uqrrw6kmX5JZ4Hg8r3vfS8QCxMEjGz/IYf8I0bf/e53K3fvA2HuvvvuT+G+//77xyWXXNKnxOX2228PenJ9MSF1bG81rhY2v/3tb6vyeiIytVvH55tvvhmnnHJKbLjhhnHeeeeFf/KqvuWdNP3nP/95rLLKKpx6ZHbdddfYeuut4+abb46e/+teCGXVXxuxOPLII+O6667rXgQ99PW3v/0tfv3rX1cLK21n8803r/StkOmOUdFh3mabbeLOO+/s6NSn72eddVZV9zUmN9xwQ3z44YefSvP888+vFsIILr+2Ci+44IJP+evKwoLihBNOCPqwt912W1fe+s1ee73ooovi3XffHSlNpPCnP/1pqIt6TBrJQxu8mFtgoM7aoLhtV8Qkhn1Y5V/4wheqLeXtt98+Xnzxxdh4440DsauTpAx+wAEHfGqgn3LKKYM+DKKBBNHDmHfeeSvC8f3vf79S2GUvnrnmmquSrt10002x9NJLVzob/JMoGcD56Uuz+OKLxzPPPNOjJOaff/6w4uwq0AwzzBAm4+mmmy4mmmiimHHGGSvpYe3fO8Vl7uxIII8++mg/+82o23nmmSdOPvnkatUMc5PljjvuWOW9twdMBILy/EsvvRSf//zn489//nN861vf6tXy0j8j/b3mmmtiwQUXHBH35JNPHtrfueeeGzPPPHOQio9w7PBj/PHHD21Se6+dPve5z8Vxxx0Xiy66aGjbU0899Uj1Wfsb3ROZRNxG529s3JV1lllmicMPP7zqb/JsoaIPW4SNTdydhV122WXjJz/5SUwyySQx22yzBT3XjkSkDrfCCivEsGHD6td+e2rn2rM+p+70v6IoPpX+2muvHTvttFNMOOGEsc466/RYleYzn/lMNe7pz6SHn0qgny2OPfbYOOKII6Kj1HPiiSeudDW1i/7MEoLe2K96O23Sv7/85S/Vbs7o4jbembsIPkbnN91bD4GWJYatArWJ0sBq8N93331DZ/rFL34R9913X5x55pkxzjjjxBVXXDFScQy+G2ywQQhr4lhppZXiG9/4RkUIf//731cn60xSyJ8OuuSSSwaStOKKKwa/zF577VWFHyniPnhZaKGFehwrcmEC7iqggXexxRarSKFJxkRt0qj9N7qzI8Eak61JYcfUOMxhIpxzzjljgQUWqHAnCdt0002reu0pWR5dPhC15ZZbrmortu0ROErbowvXE3ftBgFceOGF46tf/eqIoIjgqquuWhE+0hyHq0Y4dvihzSI4jfXFbokllqgILZKIWIw77rgdQo7+FXEdva+x86GspNMmvLnnnjvWWGONSqKH0O65555RL8jGLpVPQltgwBwe+oV0PnEd+ZdF2Mg2/fP2xS9+sTqwM+mkk1btQn8sik8TQws6iwJlWWaZZXqcuQkmmCDErX/3OHAvB3j88cfj2nJ3xjjdcTGCxMOkl5McZXSIstO7pLGj9DgWjhadJIHGl9FFYwww9lvIjM5vurceAuO0XpZbM8dFUQSyY9VnYLElZiImRbzxxhu7JQkoiqKSughj9d6VrhXSYLt25513/hRYyCRdIAOe1adtuX/+858jtrNJ8oS3GiaF5JckzNM7KaSBsuNWl3Dc//GPf4StFgOZxG0Hsyfxoj/FrtEYgA1G9FXEKZytR1s09I0a/fpdu9NB5E5Xcb/99gtluP7664Mum7QYZRCGlMU73SXvvWWKYuTJsSiKMLkZLBF+6cgvnOEif3AnEbE6h41yw0A9GPRhQE8LzsIYrMVD3QApET9j8qVvx62/jTzC9tZbb60kv551/jvLi7xTj1Deju7qWlj1o91xNzHZqoeXevbOvtFYDAjD1BKdup7hqc02+h+b30VRVFJrcdbSPHVqMaLvyot+JQ11q6zavPZZ198rr7xS6VWqM32Jf/G98MIL1SIRpsIz2oY49Av+6zS5NRpxPPHEEyEt+ahxaPTTX7/lWV/UxxvLUqcvf+pKfdIR5l99a+f6rjZS+62fr7/+egjDaA/s4am87Lz3lTnmmGOqq8dIac8555xOt87rtNWPtieP6kD+/NYWjJXq0Xvt31PbsF3OzZhQYyYuGCqfuLQbT4sV7Uyb02fE0WiEF4/4jJ3euWtjxg34y5cFq3YjDm1Lvo2ZwpKOKqt86d/ioCIkTn2x7r/qzm9hlFH/5E++9T11alyTfprWRGCc1sx26+aaxGTLLbestuoMAkiAAVJHQiJGVzJbq1arwpo8av86N72effbZJ0gmddLarfFpIKATuPnmm1eD7lVXXRW77757tdVnEKEz+J3vfCfo1pCA0Y000NhWufTSS+NPf/pT7LrrrmG7sc6vQZ3ek8HM9jeDHCKu9KKEEd7Wp4Gjzo9ByoBlW5TOIH0kA2FHncLav6c4xeXaEfkywJos2P/1r38NA5irgmBs0hTGgKhcJiXvfWFgUA+gJHu15MegTieQ2gAdrG233TZvwHAlAAAQAElEQVQQPpOh60PoKV144YWVyoG6MSjDGbE/5JBDApZItwGYJJlU2LaeCQtWfVGW0cWJCNpaXWuttSrdO/ejaU8XX3zxp4LSOTz55JNH0jls9GSyc68g6bk+AEdl174uu+yyIPn+4x//+Ck9rxo/Cyx9SJzaoMWQBYC2zG5sjD5mEpSWOGefffbqKiqTIL1AOoEmUrsB6lBasDn++OPj2muvDe1ZP2KvHm3TKRvSUbdbbYDk1zt/DDKhzZIQcdOmOyuPPIlfnFQv5MOELY7+Ntq+ccUirbEs8qHtuueVOoG2jxjSvzb21HUMH34bjT79q1/9KrQziwduyKe7GPUl731h9ENtcbXVVqtUc9SlPthVWsqh/evb2gqVC5J17daYaAw1XtVjn0UFPLQPhq61MU382jA9S3WqjIxxEvnSN5Cuzvq9NgVfer30s42p4jNGGk/kQ7s0piN90re7QW/d+GTusEgRtzqCs7ZsLtHG3M9rp8tYa66hMkNtwDgv75tsskm4rk07OO2006r+Xo+/8pGmtRAYp7WyOzhya6C3LWQQda2N7SQSQJNod0poe5XUyIBb+7e1iZAsv/zyQYePe+3W+JSWuxZJp2xTI24kkCeeeGJ1mtB2nUHBNppt66997WvVYQJbBwYGW+HcDCT1ZCUt5REXkoncIGEmKQMsexPXbbfdVkn26vzYmqKLZPAnPTWpI5v0K+Wv9tf4tM1ky83kUhRFtY1rO9021t577x0IC+JqK9OWprDiMsEavLz3prHyRsZttSKfJhNK2fQApWOwNbAjAAZZ5M7AqgwwlTckz2DqHREyWJsYYIh4wHOOOeao7sYUL2mhejZBSqO/zayzzlqpQCBN2hBCYvu5JkeN+bGNPM8881Q6to32fpvsTD7CI8EmU2WGk0nVJENCQm0CSRCmNlQrkDNbvyTw7OGy2WabhbogtWU3NoZ0XzoWGdrkb37zm9D+9FVt1ySrH+gzymDCRxonn3zy0BYs4LRneRCX8pmM5ZmdOIYMGVJJXb3XRv90cMNkDFfEQjup3eun/mhSvvLKKys9YxM4klK79+dT+7To7TiGIdcWBvAgkULkkQvYOaTkUA8yxa3jYpbKgbFB3NNPP31VHFKsr3/962HsrCz64A+Chaypa2OLcQ6B6yop421dP/ql8UAdK5c6V4/IvsMs4jCuWjAap7QfbUxdGhdgoO0ay9S9sd5Ok8OM1IX0edvt4qmNdOo8I9j6pEWLsQnJhC11JeMI0qpfUVUikDBuGtOROgfGLGiNla5es/BQp9y0eYQRaa7HLkRVHqidKJu5hWRTefUDfZl7mtZDIIlhP9cZaY/B0OoSEaDDpANZ0RlgrKBHl6VXXnmlOsVooKj9+j106NAgUTI50n2r3Rqfk002WaXkjswZBAxCBj8DkNUovRETrQGBvhA/JJP0oIQxmSFxVp31pIeE8S+d+eabLxABYfwWpwHPAMm/iYI/Rl6kxRgcESjGwCc//HQ07A1Mnh3dvCvP6quvHiYSAx6sxIm4cu9to9zIHGkZQu0dcSqKokrK4G5iNxmSKljRI1TTTjttpWhPAqwdGPzhaGI1wSOGpGlW3Q5dVJGVf77yla9UJz+Rj/J1QP5rawguIuYp39pF40KlzhhiCA9+arv6iUCrx6WXXro6vc8ehtow6S9JjbozkSFL3Gujnk2A4iaxRBiQa8RcmrW/sXlaSKgv7Ved0JN0ZYx6ofOpTMiDPqydyTtCYCKm9yvvFn7yoC/QuyNlMXki+Ooe6eHeaLQhfY0fWFhgdYat7UkSJdJVCzB5I+1vjKu/fiNx2nRjeto5qSepErJuLNFmEA54IP3GQmOJRUJHLKhj6D/wtWgUH3JinIRdY1q99VtetD1ETPqLLLJItdVvEdJVGsYrZdPu6KZqE9qBOtQvjHPCaqOe+ra2ZNzT/o19SJatXe1cOzZ+I1f0mIUZlUHwpGPxIj7EzA6FNilNOzbKZJ6RjnZtzJc/bcziRH00plEURZijLNKEhweCbBtaHo3BtX9zht/Kqfzab8exnnua1kEgiWE/15XJwypNp9XRGAM8EkZyZ6C3QrMC49Yxe1aapAIGx44Dae3XIG3SNAh0lLTUfhqf0jFIzFpKghrt/TY4moTpqejs7LwbAPzuaKyckV95oEtFQmBitUouiuFkqWMY7/wa7BE672NjDMxW/LZO4GkCl5+xiXN0YRE1q3QrdIQGpsKYaEgxkRerfeSQfVeG1Mm2GRyLoqiuOOpYh0XRNY5dxdsde5M2KauJRttpDKNOTfCNdmP7G8FEmkkNa7zkgWTD9rBJSJvT5k1wHdMzsVpwkIaQVhZFUR2Q6ehvbN6LooiiGG7EI3/6RL0tyE5/KIqiOixlwiUJQ/SpNKhzpAexIDXXj5AkfULYURllR/ZIYqTR0S+yqK2JvyiKIEXXfjr666t3dYbkIKWdpVEURfUlKFJv/RCx4w+BQgoZ9VoURXWzgfxz72hIbC2YSJX5QWKKoujobazflQdRJcnT9rwzFuskZZ5jnUgZgbGWZLDGA5krravT3IiwPmEBSFpK0mqu4N6V0Sb1GYvwOk75ha1FhTLVbcQ2/+jik462p225BaMoijDnsE8T1b26SHt3cGxVvJIY9mPNaUhWX1ZcVld10giewc6WkPverBZt7dYdmz8TswHY1oNJydMAww83T/5qQ9KEYCJctV3jk84MkmpysZqUPvLkvdGf1Z8VoXyLkzs9GNufJsh6wiIdEY7OIDsDHD0iAyDdI3bcDezStsI16dlqNZn93//9X5AKWHkb3AzI0hKmfq+ljfV77W51XhRFmDxgJMzQUnpqi4PujRW9crDvTSM9dSo/4nW1CT1KEiN1qaykI/KkXq3olZe9MiN/wtVGfdqmd/rV5GQ7if4PDGs/ffksiiK0A7giW8r27rvvVhcVu1eTpKFOX95NHnWdeFcu7toiN/F4h0/juzDq16RD/UEZSUv4pccHG5I122uksQi+Ni4NcTH8an+IGIJo+84kyn5sjS04xEA+O8al3ZI+k+pY0CkjKRY7edf+9RNbvLaX9VX5tnVKMkpNACE2YcMEVtLx2wRvcYQIK6++S1pKashePMrOyBfyYEtVOtqK3/omt942JN7yWKctfuVXdu3Wu3LATd1qC0VRBEkTyTCSo48rL2mrhRRpKl03dacM+pPwDFzFyZBoGRtsZxpH9CP2vW1Igi3KLI6K4hPiqY1ZzJ988skVgZWu/ClnjYfyyrfycTe28eN3/YSPdzsatnTtEikzia+2ow35rS/ob8YB8SB1yiw9CwvtQjy1sZsDT1vA+oywtpQt3o0ndk7gC2d4282R3zp8/bSgFoYbkqm+pGvxJR/8aQfaISM/ytyxfNz4rbHwuz+MvqbfdWaMIdzHNh+ItT5sfO7O4m5s0xuo8EkM+xF5HYzUgP6UE1110pTSDRJ0RXRuIn8TgkHHYGhisJ2o0xsYXcDLriiKoLtGB4tEyiDMnllnnXWqQYwksk6n8WmQJ8UwSEmXMrGJyQCMuNFZ0fENFrYUSChtUVMEJwWTronZtjHiV+fJwCouZIzulUnewRIrLIOUcho4kFYD8De/+c3qKzG2bAxa/Nt+MjmSuJh4RvWus0vH4ClOJEE5SQlNlEVRBOkpu940iB/sTI62W5BBeCgPokpKaAtMHcLRJEi31AQAbxIU5UL66C8ZjE2wiJDB2OCmXhFl2Pdm3kcVF2KoDSifbVnSLaQDmdloo42qoPJOCoE4wljdk6YonzojHUaALW5IUbUl9eodUbdgMJlsvvnmgRiSHNFvsqVGLw8G6p+ESLu27WYhRaJOeio+bVRmLLJst2lbiDm7sTEkL/T75NddhiYAadZxalf6qP6ondN3o+BP/5DkR30Ji0Sb/MVlUaJccNNX9BkSRf3IheGkO8psUuaOLIjXZG5Lmj6Yfm9xYWJ2ZyfiqF64k1DCRP+lG1bntbeeCIq8ILPKY3xhLIK0X+oEtVRQ/6ZWoU6UQ10bgywctQ246KvagvLCDU7aWVEU1eXeyA/cxV2XwRhkvNDX1UFt35tPbdACGLFCeOq44aytG6eNZRZNFiHauD5ska5PWwSqC27aBExs6xoLjAHGfmE3L9s9sizcmmuuGeJFOi3Mbe0iVPzASDsgMTaGGUvoqnrWefPUZxEfv6WnzxlvbO07iGJecKDPGGV8JIjQt9WD+OAtrHHHjo06QTQt7knilUf+jU/GO4dZlNPOAummdslduvCzSySP0rv22mtF3efGfGaOQdzMJcZMuMLO+KGuzKujyojy2L0YlR9tD97a86j8tZxbhwwnMewASF++ksyZZAwOGledFjKhc+pciJWOqRF711BJC3RmKziTFV0lnVR4HV5YDV8ntOJkrGYMTCYU/joaem0maXkykRsE+JGuQdBEg+iwQ/JMYMiAvBt8TMTcDGQmDURCuiQDJiuTlEEccZMPA7+VqgHQ6tvq2CAiTifoTLYmCpOM7VhESV5IWQyQyCRpSMd3298mQwMW3EgX5IuBi4HVYOe9Nw1pJOmQwVW5kATxw8OK0laobTYDP5Lvt4nU5EBvzURHYqveTBzquCiKgAuSRbpA8mQrEjkXd38Y7Qr5N+E5GSvf2p3T0yYVebDokDd5RIoRSWQIWTOpMurLRIk8azv1u7Ii+yZehJjUCzEykSIRBl5EyMLJ5II0msS0J7+labJCwORFGyVBgWdXbZ2/7hr4ix9xRUwsntRpY3iTjZPU2ru60idJbfghXdp7773DhGuiRHblSzwWdiZVpN+kbSKWhraO7Ckjogx7JNukaxuVlFLc1EuUH5HSV4wJ+g4CBgNEo/bLf28ZdayNy6c6UG6GJFzfRHwtehFH6gZIjfFAHWv7SLB2zsivsU85xWVC188tOi2ojEnKo+0oX10GZEnbFK626+2nfGjH8FcXdfwWKKTI8qVtOJBnfNWmLd4sSI2Z/CBFxiF+4eHgnfFMOS06hLXIYQ9D/UvdI37S0x8sDuBkrDVmKDedPmOcRZh2w29ttC+nnuVJOrZ9tUPuyDQSx17/1G61XxJB9WlsruMzztOl1e7czSof6t14pl/oowg7HVn9HwmzmKfPKH51ZvHo3dxl/Bha7tzIR18b6cFV+uYI5NCYqq3JO3Irv13lQ3j1rz925Ye98alxjmE3GE0SwyavVZIaE7MOptEbiAw4GvKYZF0HFtagPSbhmz0MombCMcCZjA2YzZ7nzF/PETDxmlgtLkjeSOR6HsugDTEoCoYMIhvq2cKR9GtQFCwL0esIIPIIIXLbWeRIooNZJO3ILoGLLXvzBf8WYgiwxTp38yQijSzyizBqj/y2g0li2AK1TApga4A0jq4HnSzSFgSvp9nX8K1ESdOsDHsavtn9KxepFB01mNm2a/Y8Z/56jgAJGWksKRnpbS1B7HlMGaJZEXAAyuKO1JWUS303a14zX82PAIkudQ5SAwyfYAAAEABJREFUWmQPESSZtci0NWw+NT8ijHYM7KSR+ttVIyklMW3+UvZODpMY9g6OfRvLx7HbvrVytm1jhWMFbXXzsXO3HrbFTKa2o2zxdCtQC3myYrR1Y7vWCrGFsp5Z7QEC9LFsmdmyRRhsp/UgeHptAQRsDdJvtF3vMIVtvBbIdmaxCREgAaSKYb600DB3UjMiJGHnt8WlLX2qMlQ2SAn5pSpD4pjEsAkrNrM0HAGDo8ZLj8t9ghTynZC0whnuY9R/DbYuYWUG4/abDuwUtZOPrsUYNRrp2qoI6Ad0S+kQOfTRquXIfHeNALLv4IrDA3ZNuvY5OFyyFH2HAGmgS8bpw5oDi6IIu0l02kkLO6bMD11gW8/0E5FHOs8d/Q3W95QYtnDNOkVHmd2JOKfcKDdryC1cpMx6IpAIJAKJQCLQ6whYaFDFIg0UuYNrjEWm90bjkKhDRHbmqCVZnDS6D/bfSQxbvIYdTrE17OQmnUE6OU4LWiG1eNFaMvuuE3F6+t133+21/LtfzenuXouwFyNyiMkJR/o7vRhtOPHthGhvxtlbcZlYnKDurfi6E49rYLSt7vjtaz8U8vuzPbqGhN5XX5erv+OHY2fSqr7Ih61Up5YRo76Iv9nidHDEHGh8kjcE0P3ATlMToMCDPqFdJfbcbSU7YKJetDfzqC1mNwA40eygCr1XfsQ5mCWISQzVcIsbDdd1MBRkHdN3nYzrZnSMFi9aS2XfxI2ku7rCKTn4u7PSlS2utDC41AWiN+WeQ7ourrap7T0NXlQF/GaKoggXJLvax3uzGIOuQ1DuGjTQypcB2QLFlTPea0OS7aJd9/+5PqOj6gMlcPo+tf+iKML9aAbn2q4ZnurQ9SUOv9T5oYvkvlH5re3qp7qlF6yuXXVS25tgXAOj32oj9WRTu8OQ0nv9XhRFuD7EXWu1XX8/1bc7Cul1GnM6pu+eQnpctb2J1HacK1qMSdpA7SYOmGjX7qys7T2VUT/ym3Fdk8uZYeJ9MBj9G5aN0ioLDn3AXY9UfepyIo++5AQvN1S4ZoabxZiroNxT6Mmu0bgqiC65emPvNgv3jnp6H6yGapUr1JRTO4JDURRBp97VcBZ1+qqreugTugoIQeRuLNMeXYOmPuBlG9n9s/qyRbo2bfwy9j3xxBODEsYkhoOoWl3262CKCZjUCiExsdaT9iAqatMVBcbuMiS5dbUQYmhid2+jy2fpSG266abBH2kLhWb15J4xg3o9aZpMhaFHWhfSitYAJ356MrX9QD/lxeBoq2XyyScP5MZE5G4zg29j/lwrw6+BFjFsVOR2PxusEIg6DP1BRMN2DrJZ2w/k0wSrfEiRi47lxd186pcqR0fibjvKDQLu9VRm9Uz1QziTl3tHHa5wjx2pGHuGZMfJSXfaeWfc3+eOPPdgipddfxvXArk6Rj6cEm5M3/16SAuyUttrA05/qnv3G7q7T/t3R6UbA7QF7R42sBXOokpc7m/0zrj3FPEWP2zYtbJx8TKplX7iPlllgYs+bgFpDCchZu/ELBLj4KGrylzDpd1ws83pTlDtx+EcOLNn9EXt0n2GxqKiKEL/cmehhQg/g9UYZy08XFtmwVmPpXSR3cGI2Ll/E97uBLbFzGjXFh8Wr+ZSYWGoH1rE6XvIo/DaoTbpsONgxDGJ4SCsVSc2SQx9cszE4xJsqx2DzyAsblMUiQTQpEYCJEMGdJdCIxAmNnVhtWlgd6EzAuiQjIuRvZsgSRgN9uqv48Eg5JCagMuUrValMZDGNoovG9hqsQUjL1bdyky6UV+GzZ5xcTsSPGTIkECSayJku9gATMGbv0Zj0HbRLikKbBrd+uj3KKNFbiy0fPVDWXk2gZCGmcy9NxoTOMmiBRoCABcn5hFd2++kEjAhEdM2hOXfxO1LKN4bzQorrBDaBgI6EH0ZsZdnddiYLxcZI/eNdtozgudmABdXK4/JVLlJBLUfuxvi8o4YktDoHyZmKjKN8YnDYgqhJm1tdGul39o7gkfqXOebBBAhNEZbeDTevUrKrK3pVw5KkHAhNcJamOlLsHKJM2EAe9gb95Fv7ZMdIx7kR/txPyS7NIlAZwgkMewMlUFi5wsWVpMmVYTCjfTNomNiIrHKJc6nz1FLGmybuF/KRIIw1CTI09cUrPLc3m81qJp8fQDpsNKjG2IVRyLH3sqcfxOU7QD++8IY2K0ikcA6fgOvSYC0iB2iZMVOMubKIF8zQAKQjfrdxECSQOrodLVwjcbKF1Ym0kb7gfhN6uNKIKvp7qSP0JB0Ic8IAKLkifRR7EaQOsZjm83XL0hPmoEMkM6oUyS9Y147e7eF5VStsnJHcrUVuk0kDfDQH0l3+OFmgQFTiwlhGg0CiUiR2vHb6NbXv9UbKQzJZWNatuuUU39ttNeO9VmnxtkjMMpPgkjaSKdLWBjU74ijdxJ37sI1Gtt53OtFRaNbq/zWln2JCZmr80yKbGsZuTP2GcssLJFnknU3LNR+4Ul1wXYnsgxjfcO4KU5tyeJDu4NjHa5+qgcLDGNvbZfPRKAjAoObGHYsbRu+TzvttGGVSM/JCtMq0qA9kFCYDEmbEAITgC2Qmhha6RoUbZ3IMzIrrySgpAmIFmnJD37wgzBRk+AoEwJICmeSQsp81ooUwkRGIufTcuLpCyN+hK1xIIa1ssG/TtMEyK9rEmwP+ZIN8utpK4MelTv5TBx1mManFb84lLnRfiB+I7ikmq5/6E769KZcAeHTZ4gVaZF6MskjQsrfWTywcGk53b7O3PvTjgRQ3m1JdSddZWusf1t6Fmnaus/Gedc3YQFLxMiEr81y6ywN+lCkixY+nbn3lZ2FGFKGcNRpICWIDkKD+Nf2nhYviD3C651BbJFB23H0JbV7bYC0Vd/VZ0kLLZT472i0H3YWecYAv1vJWAjRwbQoKIpiRNZJQbUBOKpf0kTEzThoIdIo9bPAVHaLXwtFmNLnRRhJE0kDjXu2U0ck0OHHoosuGvQbSa47OOVrIlAhkMSwgmFw/zFAG9Ct6h1Q2X333cNXVKwuB6LktjpMgLalSNEMiEVRBIJosqFL5xuhFIX5MxHS9bCVZOKgq0TCZJvKJOMS0qIowtajOJQV8RTeVzFITREZJ137orz0zEhw6olLGjW2HSd4gzZiQb/IIE5aYKvRNjHSZIB34z4CSFJAiig+piiKEJ/0YoD/mZy7SwplleQPCVYH6kY5HDywxW6CQohNeshxI+kx8ZGqNtqJbyAMsiM/3U0bEVDORv8mdUYbJYGDB2kR6RBJuC1DZMCBAvjaptYn6jhgRNJct6/avq+fyq4s2m6dFp1DbZEem0VQbe8pz0VRRKO9ciPGMKRviVT6EoXFnr5t8UAHziKPxFxfJwmLj/9ZGAmLXIrnY+tolacxQltuxJD0mFHPDpxY5BoH6B8ru/GiEcO6rMpPemzBrA3Rv1Q/ri5DtIuiCPEYR+AJ+zos1Q950Y5qu3wmAo0IJDFsRKMNflPqp+NiInIilk4LSUB/Ft0WCKLggm6SM4OWwcoAKR/1pGdbGIk1UZIoNEolED5SOf6ZRlLGv0HTiltctUEc+e0PQ1KkXPJdp0dSZLunfvdUD0irCVGZbB1R2nc6jv4eMm+S5XewGNI/xAAZ1hZs9cPL9jRpNsI8GMpK2mkRVJfFZG6Sd3iltvPULpBCCu7IIFJAMklKRwLuyV+zGYRWWdQXNQ/tlESMNMtWOFKDgNT55q6f1++eyLMxyHdu9U/x2Cp3Mh95PuaYY6pDTfwORkNSXhRFNC58EG1lNX5pD41jSO2v4zgCR2oIFpMkkg5KIH7GEQsQ6jbiTJMIdAeBJIbdQWmQ+TFhUXZGyhx2oH9o1YnI9EdRTRi+2EIKaIAjJSKBspK+6aabwpYdwiQvtovlywBKyZ0dg+yZfPzuaMRjckIsbVtzp39I+uh3bxvSDav1xkmQJBNZpVMlPQO6Sc/BBe+1QW6RIVdRsHPlDf1DRMlWka1ndtwYUhPl83sgjQmrsbzdzYsJjG4iVQHbZ4iTreKllloqkAY6UEhBY3ykZPBttBuI3+pT/rub9tChQ8NWaT2xk/4WRREWAXUcyBJpz8ILLxwmdaQZHsgBaY+2QHJU+/dExhBMv/vLqG/EtrH8xhF9CnFluJEsIiS2w+VNv/bUVqhA2B3wXhttXx8wHrBTdvE65e5wFjc6dNxqo78VxSdbsbV9sz+NYXZvjF11Xi2MbB/Tta3tjI/s7YpoE3Cr3aisGDO51Xaedh60sxp3Y6XFhW1jdWeBwV+jIX1tfM/fiUCNQBLDGok2fJIe7r333mErx8rc9RH9IT0kISExMgG46sRAZ+Jwotfgtu2224ZtFV92oQtjgjDA2W4yUdi+uuSSS4IeDgKJdDVW3/zzzx8U3UnbbFUjWLYskY5Gf73128BusjYp1nEa2BFeV3GYPM8888xA6moCyJ8JwopePdTSUGQAWTC5OjyDILLj34RhkhwyZIjXATX0Qx0g6iwT6gOJkNeO7ra6bKfZOuYGN/iZyNjbnmwk/Ig9HatmmMQQ2VqqLe+NRlmVWTuu7UnE5dtJXPXpgBI9sLo++bMgE8ZBMe8mcXjYZtVuLAqUnxsDI8QSYfTeXwah0y71vTpN0vxGo3/ZDib5k2fqIA6XybOyKzfCW4dXNpIs/V5Y9qRdiLBxiCRSv0DIuZGgWUjYbehvYiz9sTUILfWZRgwt8uzcWCRrJ9wsaI0ddC1hAye7Cp5OKTeeWpYnxNGJcXqFFlHsjHlIpPZFVcMYz56xQNHHYOt9QEwm2tQIJDFs6urp+8yZiOi4OeRRFEUYuA3IJrm+Sr0oinBPmRN4JCWMSdfWEQJFWmBLyuTiolITA707eUNIbDtRuP72t78dtcTTYEenRp5NxgZaky3yYuI1gdWDJj+9aRBbOmEG78Z4ldFJSsSWRAAJVJbaj4mAlMUpwXqicwhBuLXXXjuQJYroNQngF1FyxU0dx0A9EW55riVC8oHoIuu/+MUvAokdMmRIODDEjUH6SZaQQnXMjhTFfYXaG5zolcGSG0OfDFFqxI39QBj9xCRr8q7T91t5SGwQGnmvMTHxWpDYIta+YUaHsJZ+Ij8kisIjyOKEh7aKaJrctQPtnhtDoqafIBne+8tYbOmnyEZXaVr4FMUnkjwHTJA50mF6wlRYGvug9q+Pa/NFMTwc/BAf/UZb1zZgIk3SVOXuKC3j1gpGf1GXFhfae51nKiSuKDKe6QPGNwfvuBtbbAvb4YETHWSEmxtjbKOKYZywGGXHaHf8wpIutoU2e8bizOGnelxhlyYRaERgnMaX/N3eCJjQXa5MJ4XCspUoiVxvo0LiYTB0CME1GCbOesIgZXE6k3SCe00IPA2QJmbbxAZR+bI1y6/VNOkcO4Z/1z5wQzJdAcO+r4xT0lbtJu46DRMaTJEHh2IaB25+bDV2vL/PYG1bDckwgCNX/KoHeJA41nbsB8ogdggM4vfmm4idj8oAABAASURBVG9W2UAM2MGcUVdIT+VY/lHHDhY5lV2+jvhPeqHdmfiFt93GETFQdwgZss9uIA2yQnJNPQDxlRfEBgbKyyA7jcSdSoFtPNI/qhvC1IZESLsRb23niQgjCsqvfWgT7MWBdMKjtmPfX8aChZoH0tpZmtQe9MfaTRuxM6Ac7lK1CK3dPOnQNpIcdiRoMCEZtFuAGLFnSFG1fVJF761otB/jgLFCn67LQDJoXFPHNSms3bQPkj9SZ7sm+lHthihbBIuztvNEQo0X4nPgkB3jpLydjcartdinSQQaEUhi2IhG/q62lW3BGoxI6QzsjWQnIeocAVIMpMeBCveMde5rzGwRJld5kDBZ6Y9ZLL0fijQLIXfa2PZxb6Zg+9GEhwg0boP1Zho9jcuE7GodagykuT0NPzb+HagicUOqSZXGJq4xDUvlARGRD9LhMY2np+EQbgeySB1tl9YLh57G0wz+5d2tCvqzBXh/4kh31wLVyWcqKs2AR+ahORHonBg2Z14zV/2EAF0gukK1tMLdglbvDoH0UxYGJBmDNP2oMTWunCClRJjGNI7OwpGi2lJHSEg+O/MzOjtkdXR+eupOGogUkkjYDu9p+FH5t+3qdC7dV2RsVH574kaP1nZ3T8LUfm0Dbr/99qHMtudq+/54wsPJZQfFtIcxSVOfpvM3JmGFIdVCCu0mOOTArj+MbVC4k6JSIRnTNG3bj2nY3gxnR8ChOtK//sRRf7XrYhejN8szpnEZ09SpvtTuZkAmvFEkmsRwFOC0s1NRFGFLy+EQl0PTYSERc3BksBJEW6G2bMbUOGFpa9y1K2MaR2fhxGtbln5XZ+7dsaOw3x1/PfFDalZvfzlE0JOwo/NLnUBboyM6Or89cTcp2q7uSZhGv3QkSUkdgmq07+vfPndGYuw6ozFNy6LFHXd1+J4+1bcFBmkuYtPT8GPqX9siMSXxGtM4hHMgzbMZjG1hKib9iaO+BEcqKs2AwcEHHxxIMulpu5tm4xpJDJutRpowP65McEcWBXTK87Yj6K40YVYzS4lAIpAIJAKJQCIwFggkMRwL8JoraN/mhm4MhWX6hw5G2E6yvdx4uq5vc5CxJwKJQCKQCCQCiUBfI5DEsK8RHmTxkxq6d8upYDpvrkWwvTTIipnFSQQSgUSg+RDIHCUC/YBAEsN+ALmrJEjbnLjrqLPnKgz2Tno2GvfYueKg0T+7Rj+Nv/ntKu2xsXc60wnFo48+OnyxAjmk1O7wxtjEm2ETgUQgEUgEEoFEYGARSGI4gPi7y8qlpa5haMwGJe9vfvOb4dJbV1Osu+664e4yd365S8wXMVwWLMwuu+wS7k3z+SNfVeCXQdwo9/LTl2bzzTcPJyXd5bbbbruFgxLuIOvLNAdR3FmURCARSAQSgUSgqRBIYjhA1eGS2BNPPDHcXH/NNdeMlAtfPHBKy2WvrjTwVQWfQnLVhu/J/vznPw/buCSOv/nNb8JRf9dZIGf8Mg6IOGU7UsR99OJuNdJDl9s6+ehKhI5kt4+SzmgTgUQgEUgEEoEmRqD1spbEcIDqjFRw8cUXrySBiKErIBqz4isBRVGEbVv2nggYUrjwwguHu9hs3SJ/3PipjSsJbCmTMNZ2ff30ZQpSTXfazTrrrEEP0Z1nfZ1uxp8IJAKJQCKQCCQCvYdAEsPew7LbMdERpJPnE1kbbbRR/Otf/wp3dHUngqmnnjpI5nzayF1vdRj6hKSPjE9HubNqIG6394kwZTrttNMC4fWtThfLkm7Wec1nItDKCGTeE4FEIBEYzAgkMRyA2nWpqU+oIXl0AxE4JMqhk+5kxzdISQkbdfmuvvrq2HDDDeMb3/hG+Cybi5a7E1df+Zl++unDdrjTy7aWjz322HAZcl+ll/EmAolAIpAIJAKJwNgjkMQwxh7EnsTgFPFVV10Vf//738NXGHxRxBcNzjvvvLA13J24SAXFM9lkk43wTsfQoRR3Cx533HGBeI5wHMAfJIbK6bAMfcgzzzwz/vvf/w5gjjLpRCARSAQSgUQgEegKgSSGXSHTR/b0/0TtU3Oke/QAfXLOJ89uuOEGTqM0b775Zvgslgun55prrk79OunsG5zjjNMc1TvTTDOF8jL33ntv+EamZ6eZT8tEIBFIBHobgYwvEUgEuo1AczCHbme3tT3SLaRPOMEEE8TKK68cSy65ZGVcLzPzzDPH6aefHnQFlZLfjk9uvht61llnhUMotcSQX4Z/RvwOg9heZtgNtEFkbZs7We37mJtuumkcccQR4b7GxrwPdD77K31qA8pO8ttfaQ5kOspJamxhox0PZF4GIm1t3IEwGMBiIPLQDGmq+3Yu/9jWAfz0Ie3I0zgytnFm+ESgIwJJDDsi0ofviJ+7/kjyXnnllREpkRa6s5BOnk/N3XLLLeHaF1vL1157bdge9u5eQtI219Mw4qGb6ITzo48+Wl1hwy9ji9pVN0svvfSIdJrhR1EUFSl2/Y6T2KSIrtl57bXXepK9lvb7/PPPh+1+2/9Ol7d0YbqR+cceeywOOuig2GCDDWKNNdYIn1V86aWXuhFy8Hj55z//WUnKV1tttdh6663jySefHDyF62ZJLIQOO+ywsEOS5LCboDV4QwLpajvgZ75YZJFFQrtq8JI/E4FeQSCJYa/A2L1I6BI6jOEqGnqCdSg6d8sss0x1aMQ9hSaNV199NZDE+eabL+6777547rnnYoYZZqgIxe677x5TTDFFFfzZZ5+NL3/5y7HmmmvGgw8+WPnlH2lEDkkOK49N9kdZlM9W+q233hq/+tWvAiFusmz2SXac0HbwqDuqA32SgX6MlGTDosWF7RYD++67b3Va/bLLLuvHXAxsUvqoxQBpuQWe35dffvnAZmoAUqcC88c//jG0iQFIvuWTpIbE/PjHP64WWnvssUeYH1q+YF0WIB0GCoEkhv2I/I477lhJDbbddtuYbrrpRqTsPkOSQIYfuoc+M+e90ZASLrbYYuHi6zrwJptsUsXZ6K/+TSJV+2vWJ13IH/3oR0Gy6TQ1gkiS2Kz57Y18ObGtjnsjrmaPgwqBRQ81gnHHHTd8kceXelxh1Ox57638uUVAX7QgtKD7whe+ELPOOmtvRd8y8bh03x2sLZPhJssoNSK7QZNOOmmYQwgZ3E7RZNnM7AwCBJIYDoJKbOUiFEURJs6vf/3rce6554YvwiDApAv0aVq5bJn3iPHGG6+6pL0oioCHOiUx9XUf7+1gSO1dRG/Bs/fee1cS/uWXX74dil6VUX3/9re/DWWef/75K7v803ME6IvbFaJf7taJ+++/v+eRZIhEoBsIjNMNP+klEeg3BGw1GvhcbXPggQeG08upj9Rv8PdpQg5g+FQiNYKlllqqT9NqxsjpCJvcHR5rBzWCug6UleqMxV9tl8+eI4Bck7RrRyTPu+yyS9BP73lMGSIRGDUC44zaeVSu6ZYI9D4CJEwkCw4rDBkypNKpPProo4N+Zu+nljH2JwJO5dIjpQ9Ll7Y/026GtKhKuMeTGgnJYTPkqa/z8NRTTwUyQzWmr9Ma7PFTxaCC4MDeiSeeGCTQw4YNG+zFzvINAAJJDAcA9Exy9Ag4eUd/0iBoK+q73/1ukLaMPmT6aFYE/vznP8css8wSdGodjmrWfPZVvpR57rnnDtdTOandV+n0arxjGZlDRiRcK620UlXvpF5uIaBralt0LKNv2+BUMehlU1FoWxCy4H2GQBLDPoO2uSK2jecTeq48aK6cjTo3s88+eziF54CKU3i77rprPPPMM6E8ow7Z3K51/utnc+d27HJHr5D+qPs1TWa2FX0NhzRp7GJujdCunarvnFPf3tdff/3WyPxY5nKbbbYJJPj222+P2267rbqqhsTYFVtI8lhG31bBtRvthyF9dwjRoa62AiEL2y8IJDHsF5gHPpEXXngh5phjjnCybeBz0/Mc0EnzGcFpp522utz7/PPPD2XqeUwDH8IdfhdccEFFbl14fvfdd4+42Hzgc9e7OXA/JVWALbfcMlxN5FJ2xnUtvojTu6k1Z2z/93//FyQ8Rx55ZPhspT74ve99rzkzm7lqSgSQQfrXp512WnWvrbbkIwETTTRRU+Y3M9XaCCQxbO3663buXXGwzz77BL29OpAvj9S/W+HpZOsOO+wQlK4dStlzzz3jiiuuCKvnVsh/nUcSM/pBtthWWGGFSlfIwF+7D6ang0NTTTVVqCsHimrjWqLBVM5RleUrX/lK0LHTfl3yrP129TnLUcUzGNy0d18+oi83GMrTX2XQdlzzZFFpvNtiiy3Cp087Tz9tE4GxQyCJ4djh1zKh3Xe13XbbhTv0ZNoA4wsUfreScThlwQUXDF91cefj2WefXd3j6OLXVikHSZktNtvjDP2rwaorhBTSFVXORuOTkK1SX2ObT4dNttpqq6Av66Jv9W+iH9t4WzG8e1hXWWWVSGLY89ojcdeH3IHqLsyex5AhEoHuIZDEsHs49ZovEhS6fp6kB3XE9EfY23qzIiRBcqefd4aeFr++GsBfrSvIL39M7ceTP374lZbf9JykI76f/exn4esqwrH3ZC+cdGp/3h3+YFcbcbFn/Ga4yTNpmLjE6b22lwf2jDzXbtIRpnb3zq1+599vduKqjU9CuRONMruVtEHT5a+d+a3DtOoz850IJAKJQCKQCPQXAkkM+wvpj9OxnevW+tNPPz1++tOfVrY+iXfOOedU774na5uA3plvqtou8LWAO+64o/Lr8IWtGArdTvXZDiYJ9A1aV2D43JZP4S2wwAJx4403VicgvZ9wwgnVBbP0nSiB19/YdNrXNRpW8ZNPPnkgjBKiB0WyQcpBusiOQQJ92kwZ5EW+KZJzu+SSS4IUT/5WXXXV6tNn7B9//PGwhUhqQmKy/fbbR10eeFBGlz9fyPj9738frmDwlDcnOOHUlT4hSaj4lPG8884L8bk3DfmUdppEIBFIBBKBRKDJEWiq7CUx7OfqQKoQMXf1kdCRxlFIR4yc2px66qnjuuuuCwTujDPOqLZJhw4dGqRismoLcp999gmkzW8EznadqzDobXlH5OiwIU0HHHBALLnkkkES56CDOGxdrr766mE7Sxr0vxArUjj6UPw45EEfiL08sWNIAqWB4LlrkESP/SOPPBKIIpLqrjbSPOSO/5NOOqlK65RTTomTTz65+qQfRWrhSB3dc+Z03eGHH16Vk/9LL700pCtPSDSyx39XBnk+7rjjYokllghkFWFGSLvyn/aJQCKQCCQCiUAi8GkEkhh+GpM+tbHN6xuX1113XZDwkWwhbKRmm222WdAhsSWKYNHD8Y1V5PGJJ56o8uVJiuiqj1tvvTVc+0HCaEuVJNC3hxFBp9VcB4Eo0edCLpHHKpIOf+jtOfVLQucEKcLq6wwkfKSIjd75RSgp0Mu/O+mQMmVAbL07dYr4IcAupiadXHTRRUOe3E+orPyL19cQkD86MwgrpXxSz8033zx8Go8e5JVXXlkoh1f0AAAQAElEQVRJO/kflYHXWmutVRFUZJlu2x//+MeKFI8qXLolAr2OQEaYCCQCiUCLIpDEsJ8rDuGaZ555qitXkCKfNEIW6fuRCi6yyCKx0EILBYkdAub5mc98JlzV8sADD1RXnDioQAIo64gl/8IhjE4fs2cQJc/uGH59iu7ZZ5+NP/3pT3HXXXeF7emOYSeccMKKvNq+dWExknfVVVeFLeY777yzurOMPiCiJ+/smVqyKD7EURn8ZpST8VtYxFB+HDKpy/X5z3+e82iNcMin61FcruvUMskq6aF8jDaC9JAIJAKJQCKQCLQxAkkMu1f5vebLFidJmgt/H3roobDtaxvVvVQkcO7ns91qKxlhRKJs79pu/sMf/hCkfzLjpCPpmrusjj322BCOHp8tVxJGBIu/2tSkqH5+7nOfq7Z3SQfrE73Il0McBx54YHXvWmcSRgTPlwtsMyOPQ4cODYTQ1rata4TM9jRSRqooL3PMMUcgkUgwQqvcJJTypoyetVHeGWecsSKfMFEuW8y1HmPtrztPcR111FFBf9I2+zHHHFPpL3bEpjtxpZ9EIBFIBBKBRKAdEEhi2M+17JTw7373u0oq56DJrLPOGq4f2HDDDcM2riddPGSR9Ev2bA2TKM4wwwwx8cQTswokjk4dydwPf/jDcBjk4Ycfjplnnrm6ABWBQ0B5fuWVV4LeHxJGx/HRRx+ttmYROcSpJob82opFOG39dkYM+XHylySObqI82r52DQViS+KIrPrtKxfuTbQlzZ8vmDhIcv/994f7CMWFKCsb4usdYXXoxuEZ5RKXgyo+pca9p0YZHYaRLumq9JBu9dDTuNJ/IpAIDGYEsmyJQCIAgSSGUOhHQxeQVI4+n990+Nwt+Mtf/jL+8Y9/VJ+NQuLo6tXbq6RxyCJpXGNWES9b0z439be//S0OPfTQQB533333uOWWWwLJ5B85Qs7o+knHFi/i59Qy0kQXkT+GDqG0G+3Y10Zc8k8HkKEDSHpIvxDZc2iEBJFu30YbbVQFs9VN6keCKB8IojQ4ys/VV19dfRXDO7PwwgsH6ah4YHLYYYcFKSK3MTWklogmPU66mfKAII9pfBkuEUgEEoFEIBEYjAgkMeznWnXSdsiQIUEiNsUUU4xInQTQSV56gsgdglY7krb5ZjBpWm1XPxEmYegt2jqlj+g3MkZnkT/6fCSQtR1yh8hJj8RSWiSMDoqQKJI6NuZNHLWRF4dFkEvx1eG5i1M+O9qTPJJsKjMjrHiE4Vf+Z5ttNq+V4Z8fbvLoIAm7yrEHfzp6VU5x2nJ3qIekEwF1cjq3lzuile+JQCKQCCQC7YhAEsN2rPUOZab75xAJySS9wXXWWaeDj8H3uv7661e6kc8880y4ZscBmsFXyixRIpAIJAKDGoEsXB8gkMSwF0F1ObQLoVvNuPLGNTgkar5Cst9++1Wf72q1cvQ0v/vvv38ghrbhXQ9EB7OncbSKf7qfrZLXvsyng1FUNfoyjWaN2wGs66+/vi36dmd1MGzYsLYte2d4DLSde26vueaacNix3U0v0pBeiSqJYa/AODwS9+7RoWs14+oZhz8QpH322SeaNf90LOkc9mb+6EWeeuqp4fTzuON+UJb9iEFpppjipdhqobJszW76OH8rzHxlLH/VVbHVESUWbWbWP+OMmPeuu9qy7Op76uefb9uyK3+zma9deGFQI/J1q3Y3wxlE8/xNYtiLdUEfzt17aRaMvsDAIEK/sS/iFmdRRJnvwWkmnLAs1+xpZpw6Ysayzy/YhmaussxTlaYdy67M7nPwTFOOA03QDoaUeaA/7haMdjclFE31v6+JYVMVNjOTCCQCiUAikAgkAolAItA1AkkMu8YmXRKBRCARSARGi0B6SAQSgcGEQBLDwVSbWZZEIBFIBBKBRCARSATGAoEkhmMB3mANmuVKBBKBRCARSAQSgfZEIIlhe9Z7ljoRSAQSgUSgfRHIkicCXSKQxLBLaNIhEUgEEoFEIBFIBBKB9kIgiWF71XeWdrAikOVKBBKBRCARSAR6AYEkhr0AYkaRCCQCiUAikAgkAolAXyLQX3EnMewvpDOdRCARSAQSgUQgERgQBN5+++2455574qqrroobb7wxXnzxxU7z8dJLL4UvbN10003x2muvdepnsFsmMRzsNZzlSwQSgSZFILOVCCQC/YHAhx9+WJHC+++/P5599tm46KKL4phjjonnn39+RPIffPBB3HDDDXHUUUfFzTffXPljN8JDG/1IYthGlZ1FTQQSgUQgEUgE2g0BBI/EcK211opNNtkkdthhh3jooYfi1ltvraD46KOP4rbbbotzzjknVl555dh6661jnXXWic9//vOVe7v9SWLYizWeUSUCiUAikAgkAolAcyEw/vjjx7LLLhsTTjhhjDvuuDHllFPGbLPNFm+++WaV0ddffz1OOOGEWHzxxWOeeeaJ999/P5DFyrEN/4zThmXOIicCiUAikAgkAmOCQIYZBAjYWv7MZz4T8847b1UaOoV0Dl955ZX41a9+VUkML7744nj33Xcr93b7k8Sw3Wo8y5sIJAKJQCKQCLQxAv/6179iuummiznnnLNC4W9/+1ssvPDC8a1vfSv23XffsOV85plnxhNPPFG5t9ufJIbtVuNZ3pERyLdEIBFIBBKBtkHgmWeeiVtuuSU22mijmGiiiapy/+c//4npp58+Jp988phkkkkqYmj7+bnnnqvc2+1PEsN2q/E+LO97770Xr776alDy7SyZd955J15++eUgxu/MPe0SgUQgEUgEEoHeRqCOz/x0+umnx+abb14RQHOS+WimmWaKF154YcTcNMEEE1QHTzzrsO30TGI4QLX973//u7pP6U9/+lNccsklMWzYsHjyySeDjsMAZWmsk/3Nb34Ta665Zpx11lmdxvXXv/41Nthgg4o8duqhly2vvfbagC/j+oFejj6jGwUCz/0n4sIbI86+LuLm+yPefe/Tnj/4MOKexyPOvz7izkc+7Z42iUAikAj0BgIOktgWPv7442Paaaet7jG84IILwnYxsrjKKqtUc/B9990X9ApdazPZZJPFHHPM0RvJt1wcSQz7ucqsTv7+97/HT37yk7jyyiuDqNq9SmeffXZsu+221T1Ko8rSW2+9VV2+6RLOUfnrys0pLIq2ROdd+RlTex3u3nvv7TL4AgssEDvvvHNMPPHEXfrpLQedfdNNN42NN964Mkhpb8Wd8YwagWdfirj81gjk8K5HI/Y+aThBbAz15jsRB5wecfjZw0nhG281uo7ud7onAolAItB9BEgDf/3rX1dCi0MPPTR+9rOfxV577VUJKcxHCy64YAwdOjROPfXU+OUvf1kJbdZdd92Yaqqpup/IIPKZxLCfK/Opp56Kn/70pzFkyJDYddddY6eddootttgiNttss4owjY6wIYSXXnrpGN/ITlI5NuFHBRfx/KjcZ5555kqi6DTYqPz1htuf//zn+NGPfhRWfsz3v//93og24+gGAsOej1hx4Yit1ojY7dsRy34x4penfhIQKdzlmIhHnon4ycYRP/tWxDILfOKevxKBRCAR6E0Epphiimq+tXt0/vnnx/kfG3Ov+Yg+od0s8/GWW25ZCWkWXXTR3sxCS8XVFMSwpRAby8zaNiaq1ghdnjnOOONU9yp94QtfiMMPP3yEMiw9PascEkV6eS7opA9x9NFHV5JGR+u9k0Byd4M7/8LJ4kcffVSRR3ZvvPFGJR7nX3ifBEIQ5YMb6Zp7nKTFTpz1ex1efOIV/yuvvBLCiUM+2HGrjbzKk/j+97//VdbCk1b+97//De4spcOfvCPE3tmPrZGn3/3ud9Xqj6TQoGBbYGzjzfDdQwDJm2XaiHHL0WXCCSIWnyfifx9LBD/8KOKkSyJuvCdir80jJiuFx+9/0L1401cikAgkAmOCAF3BWWaZJWadddaRzOc+97kR0U044YQxwwwzVO7mjHHKuXmEY5v9KIfuNivxABfX3UhDhgyJqaee+lM5oQCLMPo+40EHHVTdzv69730vvvnNb8btt98eDzzwQFxzzTXx6KOPxgEHHBAPP/xw+J4jPzuXW7Rf+cpX4uCDD65I4OOPP15tV++xxx7Vp38uu+yyoD9B7074/fbbrworHGnlSSedFAsttFBcf/31VVrucvrxj39c3edE7O6WeBnebbfdgoj997//fZWHDTfcMA488MDqUAl3pE++ENCNy23cHXfcsdKbfPDBB2OXXXaJb3zjG+FUGL/nnXdetYpzC704ba2zH1uDfC611FKBDO6zzz4BH5LasY03w48ZAraWN/nq8LAvvBxxyc2lFHHBiBNLgrjxvhHbHBzx+HPD3fPvoEUgC5YIJAItgkASw36uKKSF2Nrt610l7RAKSRddCMqyCA69wC9+8YuxzTbbVJdyHnbYYbHAAgsEf1ZBp512WiB5tlBJ8u66664g9RMHf04MI35bbbVVzDfffJV0cp6Pb3h/4oknYplllglkzwpKmvycccYZlT8SveOOO646sTXeeONVhHSuueaK3/72t7H77rsHsov4KQ/J4Gc/+9n44Q9/WEnsEE2kUplfKSWNJIT88b/nnnvG9ttvH0ipsnlyG1ujXPCBCX0RhBoxHtt4M3zPEfj3KxFP/zti468MD/vUCxFvvR3xzaERv9g04sgdh+sinnzZcPf8mwgkAolAIjCwCCQx7Gf83ZE0uiRduomU2a4l2bvxxhvDNjDS1TEs3Tlk78QTT4wjjzyyIm9IIInk5ZdfHuuss06lYLviiitGR9H4NNNME0svvXR1d5NPBPGL1JGuuRG+KIpKrO7bkYim9Ndee+2gkzH99NNXWVl44YWrTwvdeeedwR1xnHHGGaurAOgUkiDanp599tmD3ypQ+Ud84kFWJ5100lBORLN06pX/tg6kT19kw1KqSYrZKxFnJN1GwBbxLfdHLDVvxAKzDg/21jsRE4wfMVvZfGwzz1far7hoBH/DfeTfRCARSAQSgYFEIIlhP6O/xhprVFvByFfHpBE6enh09pAkN7DbHhamo9/63Q3utmiRMqeuavtFFlmkkuQhfNttt1217Yuk1e6Nz6IooiiKyko8CKnTzyyKoqi2ZJE47x0NIojsTj755CPi6Oins3f6hHfccUeQHPpN31I8XeWxszi6Y0dS6cQZotsd/+mndxCgS/jAkxH3l2aFhaNcNAzXM5xskoh33ouoTyGPUza7yUu7qSbvnXQzlkQgEeg9BJoxJnNErbvebPkzhxPiNFu+epqfJIY9RWws/a+//vpBQuZwBF0/DUlDt1177rnnVvp99ADpDh5zzDGx2GKLVdJCyfKDgCFStoltObs7cNlll43vfOc7gVTyp9Occ845YQvXtvAhhxxS6RdKR3hP4W0hv//++4KMMNwp3soLXUckVTyLL774CIkj0uh0tEBO/ErPdrUOIW91nN4RTenxq6z1+5AhQ4J00tb4CSecUJ0SdWK7hwAAEABJREFUo8soX/yOjbGV7gCKOByeYZZcckmvafoBAaeOL78l4ue/j5hisohzrovqWppTL4+Ydbrh0sIz/zqcHNI5fPiZiG+s0A8ZyyQSgUSgpREwJ9FFv+iii6pymFuM9YQMjzwy8mWo5iGCBztnVK7Md+anKmAXf8yhrlyjelTHR/3LnMz43RjUbtg///nPMLexNye7x1e63lvVJDHs55rzfUZ6b3QMf/GLX1TH4kn8EDnSveWWW676NE9RFNXhE42RtE7j0ygRMI2Qf6Rt7rnnDr/pABZFUX11hBRRp3Da2GEUcbh4mnRPeI1ZGKTOLfCklzqbTmML2oERJJSkka4gMvftb397hEQQ4fu///u/4E4v8Otf/3p1Eeh3v/vdipzqtC6U5o5AnnzyyeGgiTSldeGFFwY9QAdcdGr3N8rnSiutVG1rj22VuCfyBz/4QZU/90PSl2zXi0pHxrLv30gDEcDtfxtx0U0RWx0Yscl+EbscGzF0kYjJPxux/ToRT70Ysc0hEbsdP5wsrrRo3+ctU0gEEoHWRcC8g7DRVV9ttdWqgphP6JLTV3fbRmVZ/jFnIYtUrBBC85l5yKHM0rnT//z84Q9/qD44IYw51FxJuELH/9Zbb63uQUQe6whuuOGGQCSlx87JZ6pU4pE3dq1okhj2c60hZ1/60pcCKbL165QvIua7jbaNZYcunkMkLuBcffXVq1O/TinbDkVwuDm0QRdRh9AxnAC25axzeJJMIlzM/vvvX92VSMfQoRHhndRdYYUVqgMiVlT0C7kjrOyPOOKIsJXtIm73AUpX3hgHVOjtIbTyKC1H/R1E0UlIMZEx7wgtP8svv3wgkzqYsKSmiKOVHIkkArfeeuuJfqwNHOErf9JysEb+xjrijGC0CIw/XsR6y0Vc+ZuIh04f2cwz0/Dgi8wZcfD3IvbZImKP75RE8evDr60Z7pp/E4FEIBH4NAKPPfZY9dm6r371q2EO4oOgxYcM6psu2DFI3bXXXhtu+rCb5jYMc475iHtHQ8hi54oQxi0ddNMJLwg2CBq+9rWvxdChQ4NuPKml8E8//XQMGzYsfDWFTjs787u5jrDEvIxYsu9X0wuJJTHsBRB7GkVRFNV2stUFcjfrrLMGaWFRFFVU9OLcp8SN7h03DVyjY/yedtppKwne5JNPXknrvGvU4mKnE3jnd8iQISPuRxQ3O/4nmmiikMZss80W7lGsEi//IIdufK/ddMKiGJ63emVUu8undMpgVT6EkZ70/Wa8K4PfjEMvSKi8CM9OB5eueMbWOMWtTOKVz96Kd2zz1Q7h6QxO/fmIOWaImHPGkU19LRg/U0423G3ItBETT9gOyGQZE4FEYEwRsGVMqGDeMpfU8Zh77HLV7/WzKIpqziO1o54kPNUlc27tp/FJmmgbGAEsiiIQy9rdnFcURTXf+s2e9JK0EHnsmL65zaFKksVWPfQ4jkKmSQS6i8Bf/vKX6s5CJ6XrTtLdsOkvEUgEeoxABkgE2h4B6lN2o6b/+DaM0QFCgEKSR/2Krv4VV1wRtng7+5oJCaBbQAgw7KZRn7KbR1pIsODmDjtbJIdUtwg9kEJSxiWWWKLTrBB6IKLUtahodeqpiS2TGDZx5TRj1nQM+oA6WTPmL/OUCCQCiUAiMLgQIPGzXTx5uUPW3ZKRDlIrsgVtm9ihSoSxY3jby8gbdSyfxNt9990D8aMrb4uY7rx7dqlyUU2ip2hL2XaxA6TUrtybSzpZx22Xys7Vs88+O+JgSu3WCs8khv1dSy2e3tZbb119DUWnKIqixUuT2U8EEoFEIBFoBQRI6LqbT7tZDp8I4ythpIdHHXVUkOB1jMNhFoSRxJAuOgJIz96XwvglNRSe4e+CCy4IOoikmA6ZUIdCAo899tjq8KUwRVEEcsiPvESL/Uti2GIVltlNBBKBRCARaG4EMne9jwDdve6SLDqCbtqwpYu4OejoPturr776UxI829Mkkk4l17mmx2gruH73dE2br3zRQ0QEn3vuuerjEbaaHd6kT0hPkd/ayHNRtJ4AJYlhXYP5TAQSgUQgEUgEEoGmQwDBcvDExxc6Zo5Ujh0y6Fkb0j3kzeETbg5YTjLJJNUhEtek2S52QARh9JUst3OQMArjHkLb0HVctprvvvvu6mMPrnxjT7pYFEVFDp1QdhDGgU5u/ItLmvLBrpVMEsNWqq3M6wAhkMkmAolAIpAIDBQCJH+uWkPAGvNA38/1aIiY62kuvfTScEUMMkay5wCJz63Siyfxc1cuN1ekufvXNjKC9/Of/7zaZnbHsHsLfdCBqdN6+eWXq49PLLXUUtVpZ/Zu9/BxiVNPPTV8sMJdwW7X4Iasits1b7aU2bWSSWLYSrWVeU0EEoFEIBFIBNoMAWTOfbQkfb60VRffNrB7Cn00wWdk3RGMRBZFEa6M2XXXXcPHDujG84fMCYv0+SJYfdUMKeBPf/rTcL+vwybuFSYB5JdxZZvDKTXxY0c6uMEGG8TOO+8ce+yxR6y77rrhsAo3BJY00nU23lvNJDFstRrL/CYCiUAikAgkAm2GwPzzzx90AV0dY2tY8ZE35BDhY5xaLorhOn0kdd7doMEPncGiGO5GSogUIpziKYoinFrmlz1yyb42/ImrKIaHr+3FY4sbYZQXOpCuv/FFMeRSmNpvKz2TGLZSbWVeE4FEoLsIpL9EIBEYRAhMPPHE4StbThbfdNNNTVmyF154IZBCW8yLLLJIU+axO5lKYtgdlNJPIpAIJAKJQCKQCAwoAiRzO+ywQ5DqDWhGukicpNFnbF1t04WXlrBuHWLYEnBmJhOBRCARSAQSgUSgrxCwJexDC30V/9jE65ob9yGOTRzNEDaJYTPUQuYhEUgEEoFEIBKCRCARGHgEkhgOfB1kDhKBRCARSAQSgUQgEWgKBJIYNkU1DNZMZLkSgUQgEUgEEoFEoJUQSGLYSrWVeU0EEoFEIBFIBJoJgczLoEMgiWEvVqnvJA4bNiyGpekzDHxmqK/w/eijiLLqBqV5992IYc+neenViP+UfX5YG5pnyzK/Vpp2LLsyv9PGZVf+ZjMvlvXhzr9nn3022t2UUDTV/ySGvVgdv/71r2OfffZJ00cY7LvvvuETSH2F8QcfRFl3g9O88EJZrpO7ZWKfQezv/Osjzv9iicOq7WeOWTbi1nK826dNzdNtWu5mre8zy/pwH+Gxxx4b7W5KKJrqfxLDXqyOY445Jk466aQ0fYTBiSeeGPPOO2+f4TveeFHGPTjNTDOV5do1zdZrRmy1envisN/WEV8px7uT2tTM3qblbtb63rmsD/f9+T5xu5sSin7+P+rkkhiOGp90TQQSgUQgEUgEEoFEoG0QSGLYNlWdBU0EEoHBikCWKxFIBBKB3kIgiWFvIZnxJAKJQCKQCCQCiUAi0OIIJDFsygrMTCUCiUAikAgkAolAItD/CCQx7H/MM8VEIBFIBBKBdkcgy58INCkCSQybtGIyW4lAIpAIJAKJQCKQCPQ3AkkM+xvxTG+wIpDlSgQSgUQgEUgEWh6BJIYtX4VZgEQgEUgEEoFEIBEYFQKvvvpqnHXWWbHnnnvG4YcfHvfdd99I3t98880488wzY/fdd6/MaaedFu+///5IfiLa4zWJYXvUc5YyEUgEEoFEIBFoSwQQvNtuuy2mm2662HTTTeOjjz6KAw88MB5++OEReDzzzDNxwQUXxEUXXRSXX355vPvuuzHuuOOOcG+nH0kM26m2s6yJQCIwEgL5kggkAoMfAURwiimmiGWXXTbmnHPO2HbbbatC33nnndXzgw8+iH/+85+xzjrrxD/+8Y9AIrfaaqsoiqJyb7c/SQzbrcazvIlAIpAIJAKJQBshMP7448ciiywyosQkgbPNNlt85jOfqexee+21OP/88+P000+Pww47LO65557Kvl3/DDJi2K7VmOVOBBKBRCARSAQSge4gYGuZmX/++SvvCOJGG21USRSvuuqq+OUvfxmPPPJI5daOf5IYtmOtZ5kTgUQgEWhVBDLficBYIvDXv/41Fl100Zh11lmrmCaeeOJYe+2144c//GEcc8wx8eyzz8Zf/vKXyq0d/yQxbMdazzInAolAIpAIJAJthgBdw7vuuitefPHFWHfddWOccT6hQEVRxIQTThhzzz13/OxnP4vnn3++zdD5pLifoPKJXf5KBPoTgUwrEUgEEoFEIBHoUwQ+/PDDePTRRyv9wU022STee++9eOKJJ+Ltt9/+VLozzDBDRRA/5dAmFkkM26SiR1dMK6jvfOc7Ix3fH12YdE8EEoFEIBFIBEaPwMD6QApvv/32OPTQQ+PGG2+MffbZJ37+85/HueeeG++88048/vjjI+Y+v6+55pr46le/OrCZHsDUkxgOIPhjk/RBBx0UM800U8w888zxm9/8psuoVlhhhbD6WW211aoVUlce//e//8Wf/vSneOmll7ry0pL2w4YNq/RGHnrooZbMf2a6dRF48MmIvU+O2P34iDc6CCUeejpi3V9ELL5txJ+vjXj/g9Yt5+hy/lTpYb3SzFyatUpza2k+Kk3+Hz0Cj5VeDirN8CMS5Y+G/zeXv5cpzdyl+Utp8n/XCCB7u+22W9x0001x/fXXx6WXXhpXXnllTDLJJJVx0GSHHXaI9ddfPy677LLYeuutq/m16xgHt0sSwxat35/+9KdBgZakz2WcROIdi3LJJZfELbfcEmussUacffbZ4ch+Rz/1u6P7LvT80pe+VFu1/NOps1NOOaUaBPxu+QI1UQEyK6NH4MRLIs64MuKx5yI+amBCz/0nYr2SFG69RsS5+0X88aqIWx4YfXyt6KMsapQwxMFl5u8uDRLz/fL5Smny/6gReL10vqI0x5bm/tI0/v9f+XJHac4vzV6lWbc03stH/u8Egdlnn70ignfccUf861//GmHcZzjeeONV0kHz6DnnnBPf+973YrLJJmvbOwzBl8QQCi1q5pprrlhyySUrJVmrIIq1dVF83ufII4+MlVdeOaaccspqVVS7tcvzb3/7W9x7770x9dRTt0uRs5xNhMA+W0asv8KnM3TK5RHzzhKxRrkGm7lsmmuVYp/9Tv20v8Fg44NiXy8LMltpPleaEpJgd1f5O/+PGoFJS+fvluYbpen4f1hpsXlpyuYT60SE2/jeKZ/5PxHoDQQ+Joa9EVXGMRAIIId0IU499dSRtordxeQ4/iyzlDNQQ8boWfzoRz+Kb33rW/GrX/0qXn755cr1vvvuqz4R9Pe//7169+fqq6+O73//+7HNNtsEyRvi6Yb4Bx98MPbff//qpvi99947zjzzzOrzQcI0i3nyySerrfEtt9wyXEXQLPnKfLQ3Am+Vs/edD0es+Mldu7HInBF3lHbPEq8NMnimKcszbWnq70dMUv5GEG0rlz/z/xgisEAZbsLS2KY/tHweUJqFSpP/E4HeQCCJYW+gOIBxID2rr756PPbYY3HzzbROojpldcYZZ4g4mf0AABAASURBVMRPfvKTT+Vsp512innnnTd23HHHOOCAA4I/dzZRxEXy6i1pdzjtu+++sd1228WGG25Y3QaPSNq6Zu+370r69qTtatvQn0psgCzeeuut6i4qZUpp4QBVQibbKQKvvRnxcrkPOO2UnzhPXM7wdAyf/+8ndn3yqwkiJekqBaUxfRPkpdWzcG9ZgPVKs39p3igNSWz5yP+JwFgjkMRwrCEc2AiKoqi2k5G9XXfdtTphhagts8wyMemkNiNGzt8000xT+XdwZfHFF6+O708//fSVBJA0kG8HURxooWux4IILVtvR22+/feyxxx5BV4+SLkJoGxtxPOyww+Kzn/2soANunD679tprY6WVVhpxeemAZyozkAh0QKCWoDVad2bX6N7qv18tC3B7aejD2fosf+b/sUDAgZSryvD7lebXpTmpNPk/EegNBJIY9gaKAxPHiFQRQCTu1ltvrY7fu8Bz4YUXjnHHHXeEn/rH7rvvHv/4xz/iuOOOCye1avvGp+1lUrcppphihPViiy1WKeNyqy2bhQzW+fF85pln4uKLL47bbrstfve73wVl4qeeeir+7//+r1I45idNIjBQCHx2oojPlfupL2FJH2fi1VKCOF7ZVadrkCJ+7DSoHpeVpUFmFi2f+b93ELAt/+Myqg1Kc3Vp8n8i0BsIJDHsDRSbIA4Ssq997WvVNx5dOTPffPN9Klf07kj9Jp988iAB/OIXv/gpPywmmmiicFLLcX7vjLuePL/whS94NK1BVlddddVwylo5kWansZ0y8z3Mps14ZqwtEJik3DZect6Iv/3rk+Le/lDEEvNETPvJOuwTx0Hy69yyHPYvli+f75bGSdvykf9Hi0D3PMxcekO6y0db/Kfv7gqye+65pynL6yJtevtNmbluZCqJYTdAalYv999/f3V4hHTPp3wcKkEK559//phqqqmqbL/xxhvx73//O2wPk6Y98MADFWl67rnnKr3EV199tdpOrjx//Mcp5m9/+9tx9NFHV3c68XP66adXF4JOO+201XZ1ve38cZCmeXz+85+PNddcMzbaaKPKIMvy7B7HeeYpZ9+myWlmZLAj8OGHEW+/E/FWyYQ+bLiuZvNVI+54JOKqcl/14acjLvh7xI++OTjRcH3j4WXRtirNZqWZtTRDSlMWvfyb/7uDgGtr+Kuffm9X/vleaZ4pDSxPLJ9bl6Zd/iNdJ554YnWtjDKbj9xN6LBkx50wByUJThrNd7/rvLeQIxtk8wc/+EF1fc0hhxwS//nP8BNh4icoMa/Qz3/hhRdGCvj6668HlSpzJQfz7x//+MdwBQ71JnatZJIYtlJtNeT1iCOOiA022CBsmWrkTz/9dKVX514m+oVWLAsttFB1IMVN71tssUXQKVxiiSVCw3eymH7ga6+9VukN1lGTqhVFUUkUjzrqqPj1r38dq6yySswxxxzh0InDJw6sIKIOr+hIddhmfMonfcoJJpigKbKXmWgfBLb7TcQVt0U89FTE0mbxj4s+Vbn/d8H+EUeWYrTtDon47tcjlu1ceP9xiNZ9/LXM+pmlma409hoIRe2YD1IeXJay9/4jgruX0f2tNJa03yif9V2Fa5e/XRTO7o/lb9f/IN3lz0H/HykzL/3whz+sPvCgwK4lu/DCCys1qcaDkIQi5ig7RrUhSFluueUEG8k4hHnSSSfFxhtvHO4ApoqFfLr6jfGVFGnOOOOMsd9++40IazfthBNOiBVXXDE+97myc5cunptvvnm4N1G8pVVL/R+npXKbmR2BgFULMbqV0ymnnBIaK0cN1pdOEDkXeXJnzjrrrOqCa183oWNYr3xcfD333K6dFTqicQsambz22murzqZDFEURDq8cf/zxIU6rIdflDA/ZnH+VR37h0Zw5zFwNVgROK2f1+06JqE1jOWefvpQUluTw6sMi1lk2go5ho/tg+b1GWZCbS3NfB/O18j3/jxoBW+9lE4kau8tL74uUxn+4lmuOuKl8KdcWMXm0xz+HH0ni1llnnWouqkvtkCRBR0dVp1deeaUShJx//vlxfmmEJRyxk1SH9bQ1bb6040SgQv2ISpIvothdIzFEMpHLOeecM+6++27BKqGKeB3GFK6yjKgeLtWm0uRLKpVFC/0Zp4XymlntAwSI3w8//PAgCZx11llHrMD6IKmMMhFIBBKBRCARGGMESN+uu+66aherO5H4ZOyii35y3MlOGUFIRwJpu1fciGdRDL8fgB87aMOGDasOciKNVLPo6iN90veJvbfffjvWW289r58yCy+8cFxxxRWVytenHJvYIolhE1dOf2TNFvTee+8d9CmI4h3e6I90M41EoGUQyIwmAolAUyBAgud6te7OU4jdOON8QnOoVZEudixMURTV18GoYCF/3EkJEUWk0YFMeurUp0gWd95550AkH3744WBPwihMR2P3ztZ1LWHs6N6s758g1qw5zHz1KQK+auIKGjoVzb4t3KdAZOSJQCKQCCQCTY3Af//730DUxiSTdBPpDXY2zyGPCCNdQjr0DrD4CpjtY/7d0kEqSM+Q3iE77p6udfvDH/5QfQjCHb8kinX+JplkkkraiETWdq3wbEdi2Ar1knlMBBKBRCARSAQSgV5CAGEj+aMn2FmUtph32223oG/oy1/uv3Wlmy3kjv5JHpFJ+oq2p08++eTYa6+9qo8q0OPv6L/V3pMYtlqNZX4TgUQgEUgERoNAOg9GBEjgbO/2tGzCIIa2dt1U0Vl40kRE0EHLtdZaK0gn3cjRcdv6scceixtuuKH6IpitatfAkSjOMsssIX7Sxo7xO6Xc0a6Z35MYNnPtZN4SgUQgEUgEEoFEoEIA+XJKuHrp8Af5c1WNO3s7OMV7770XJIC2foti+OESdq5kO/TQQ0d4t3XslPGPf/zjWH311YNEkGSw9uCeQrdcbL311uEDCuzdGyxdXx7z1THv7Bmk0XU2CyywgNeWMUkMW6aq2jujWfpEIBFIBBKB9kbAaWBXwNjKbUTizjvvDAdDbPt6+ixqo7v7ehE8d9rW9kVRxMQTT1wdOmHnGreddtopnEL+/e9/H0svvXQIw6020t1www3DRxNqO1LCgw8+OE477bSwVb3pppvWTlVciGJjuiMcm/hHEsMmrpzMWiKQCCQCiUAi0CYIjLaYtm4322yzcIMG6V4dwLUw55xzTtRmjTXc9Fi7RnXnobt/P7GJsP275ZZbhvsP2SOCZ555Zjhx7Koadh2NE8jS6mj/5S9/OVxyvccee4y45Jrk8vbbb49vfMM15B1DNPf7OM2dvcxdIpAIJAKJQCKQCCQCwxFwkbS7CW3pNpLD4a7N8dfWsgMsPo0nv82Rq+7nIolh97FKn4lAItATBNJvIpAIJAK9jABJny+fLLvssuFzd70cfa9E595C28prr712tb3cK5H2YyRJDPsR7EwqEUgEEoFEIBFIBMYOARdKL7/88mELd+xi6pvQiy22WKy77rrR8URz36TW+7H2hBj2fuoZYyKQCCQCiUAikAgkAolA0yCQxLBpqiIzkggkAonAQCOQ6ScCiUC7I5DEsN1bQJY/EUgEEoFEIBFIBBKBjxFIYvgxEIP1keVKBBKBRCARSAQSgUSguwgkMewuUt3wd9xxx8URRxyRpo8wOPLII6vb6/sK4w8+iLLuBqd56aWyXOekufK2iKtub08czrgy4q5yHDuiTc3zg7fc0Yp1emFZH3fccUe4O7DdTQlFU/1PYtiL1eEGdDecp5kp+gqDCSecsM/i/iiKuPuDpQaleTsmjplWjLY3U84bMcVkETNN3X5m2ikiPrtUWe5ftqeZoBzrZ0oTzYLBF8q6mHTSScNXRNrdlFA01f8khr1YHWuuuWZ1RN0x9TTr9joW7q5yI31fYVuMU8SCK0038KYP8jDhJOOV9RFtbxZdNGLROUsclms/85XFImabrv3Kve7HdV3y4li3HO/TlG2gCXBYuszDHHPMESuttFLbmxKKpvqfxLCpqiMzkwgkAolAIpAIJAKDHYFmLl8Sw2auncxbIpAIJAKJQCKQCCQC/YhAEsN+BDuTSgQSgcGKQJYrEUgEmhmBRx55JPbYY4/YeeedR5hf/OIX8eKLL46U7fvvvz8OOeSQOOigg+Lpp58eya1dXpIYtktNZzkTgUQgEUgEEoE2RODDDz+Mf/3rX3HhhRfGNddcM8K88MILMc44w2nQe++9FyeffHLstddeMe+888a3vvWtmG666doQrYjhiLRl0Udd6HRNBBKBRCARSAQSgdZH4IMPPoiJJ564IoYI4p133hmuP1tuueVisskmC+4XXXRR3HfffXHwwQfHGmusETPOOGOMO+64rV/4MShBEsMxAC2DJAKJQCKQCLQ8AlmANkFgvPHGi2WWWaa66kyR33///XjmmWdirrnmigkmmCCeffbZOPvssyv3G2+8MZDE//73v7y2pUli2JbVnoVOBBKBRCARSATaA4GiKOJzn/vciMK+88478cADD8Scc85Z2f39738PW8lzzz13JVk89dRT4/jjj4833nijcm+3P0kM263GB3N5s2yJQCKQCCQCicBoELj99ttjyJAhMcUUbreMuOGGG2Lo0KGx8sorx1prrRU///nPA1l88MEHRxPT4HROYjg46zVLlQgkAolAIpAIDDoExrZA9AmvvPLKWGqppaIoiiq6+gCKJ0OS6GMKr7/+euXebn+SGLZZjb/88stxxRVXxF133RUfffRRm5U+i5sIJAKJQCLQzgg88cQT8dJLL4WvrtQ4zD///MH+rbfeqq3is5/9bHz+858f8d5OP5IYNlltW8l8/etfD8bR+s6y9/zzz8ePf/zjys/3v//9T93D1FmY2u6UU04JYRzZH8zE0Mkz1w18+9vfjquuuqo6dVZjkM9mQmBw5uV/5fzyy1Mjvr5bxE9+F3HfEyOX89+vRJz7t4iD/hjx1MjXqI3ssUXfnnghYssDIzbeN+KK2yI+bFiDvvVOxAkXR6y/Z8TR50W8+r8WLWQfZ7tsInF0mcYGpdmuNNeXpvE/7bfDS4uvf2zKphbvlr/z/6gRuO6662LttdeuDp3UPldbbbX4z3/+Ew6ekBKef/75Me20047QQaz9tctznHYpaKuUk54DMnPrrbfGT37yk06zrfGefvrplRjcJZxTTTVVp/46s9x4440rETpxemfuY2qnM62//vpjGrxXw7nI1HUExx13XCy55JKx9957x8MPP9yraWRkicCoEDjk/yK+smjEoTsMJz6rlV35VTP5x4GOKgnRT0vCeF452yORH1sPiseLL0ecfmXEnptFLPvFiJ2OiHi6gfz+9qyI2x6MOLBkO8+8FHHqFREffDgoit6rhbi6jG220hxSmplKU8IVN5fP+v+z5Y8zS/OX0lxYmgk+NuUj/3eBAIkgYrjKKquM5MPVNFtvvXV14ORrX/taEL5sv/32MdFEE43kr11eep0YtgtwfVXO8ccfv1IWW5yjAAAQAElEQVSKXXfddSvR9hlnnDFSUq+99lo8+eST4fj9EkssEZNMMsmICzpH8tjFi7uciMi7cB4ja6e5HO9/8803xyh8XwSyIpx00kljzTXXjGmmmSaaKW99Ud6Ms3kQIC3b+CsRyywQMfv0EbtvGvF2Kcq56MZP8rjPFhG/3CpiMGpzPPufiJ9tHDFk2oi1vxwx/ZQRL702vOx3PRpxYYkDTOaYIWLDlSKQ45fbU5VrOChd/LXcX610m6U0u5dmutJcW5r6/3Xlj9VL41IVvHrv8nf+HzUCiN7JJ5/8qfsJ6RUuvfTS8ac//Sluuumm2GWXXWLyyScfdWSD2DWJYZNW7korrVSdkCL1arxPiTTs7bffjtlms5b8JPOO1V966aXxm9/8prq9nYSs3ip2Z5PG/tvf/jYuuOCCkbZVkTrbrr/73e+qsLfcckvw/9RTT8W5554bN998c/z5z3+unuK744474phjjqn82qLl13OfffaJxx9/PP7whz9U90O9++678de//rW6RPSEE07oV4kd3RG6Ia+88kr84x//iBVWWCFmnXXWT8DKX4lAHyIwyzQRc8/0SQKI0XjjRXx+sk/sWvzXKLO/8BwR440bgezdeE/EiotGzD9keJAHn4qYaeqIKScb/o4483v9XcPf8+8nCCz/yc9wRGLe8n3S0vhvCV4KnOOE8mWn0vy1NPk/EegtBMbprYgynt5FwKWb++67b3XX0rXXXjsi8uuvvz4WXHDB6rb22hIJ+/Wvfx2O4COMiN4OO+xQfefRljHCePLJJ8fUU08dROmNR/DvvffeaoU000wzhc8GOaZ/ySWXxH777Rff+973KlJ42223hTiI13/2s59V/kgut9lmm+oQC9JlJUYaKX2/kUkKvrPMMksgk7bFEcs6z339HDZsWKy33nqBsCLSn/nMZ/o6yYw/EegUgYeejphrxojlF+zUedBarrdnxB4nRoxTRLmrMbyYz/83YuIJP3n/7EQRE5Z7oA88Odw9/3aOABXNctc9lvvYebzy+YvSfLs015dmm9LcWpr8nwj0BgJJDHsDxT6K44tf/GJ8+ctfjvPOOy+cJmYcGll++eVHSpE+Ir2JnXfeOWxB77777hUBPPDAA6uDKUjaN7/5zerbjw61NH7/8aijjoqdy3AbbbRR7LXXXnHttdcGqeG2224bJJWkb/vvv3/stttu8e9//7uyo6e4xx57VMQTyZxnnnliyimnDMf7STrl87DDDostttgiNtlkk0pvw0EaUsvop38zzzxzJR2l90iKSqrZT0lnMonACATeeS/izKsi9t86Agka4dAGP/5UEkNb6nQK6230994fXvBi+GPE3/c/GPEzf3SCwEml3YqlWaA0/k9Q/nHoZN/yWTaveLl8Hlua/J8I9AYCSQx7A8U+iqMoikpqZzv3zjvvjGOPPTY233zz6hh9Y5I+50MiRj+RvcMoiy++eNh2fvXVVytC59b3oigqZdrPNxzBt92KtDk8Qg+PhJG0UHzi8h1J8ZJgklSeeeaZQaIoH/x2JgV84YUXqk8LSVu8bpnn1yeJxNkfhs7IpJNOWl1USt/QZaX9kW6mkQjUCHzwQcT15RapAxhLzlvbts9zms9H7FaKtFZbajg5VvLJJvE3ggTML0QRKZxuSm9pOiJAd/Cm0vK50mxXmkZC7TfJ4eyl/cml4ad8dPk/HRKB7iKQxLC7SA2Qv0UXXTQWWWSRoKdHKrjiitaNI2cGiUPGXnzxk6N/CJut46IowlYqgjZyqOFvSBti6EALG9I+nwryu6Nx96GtZPa2rscdd1w/P2Xk57HHHqvyjHjyIM7G/LHrDzPJJJNUt9u7eqA/0ss0EoEagbsei3jtjYil54tK5w5JdFVL7d4Oz8+MHzHTFyLmmHF4aeedJeK5/0S8TkmutHqsZDNvvBUxdOHyJf+PhABSeF9pc09pfliaUvgc95fPV0vT8f90pUXJv8u/+T8RGHsExhn7KDKG3kYAmXruuecCufPJHsfn3W/4gx/8oPreI51Chz6QL2kvtNBC1UWctnfdxcT+nnvuie9+97vVFu/0008fp5xySnUo5Omnn670Fh0s4WfVVVetTmLZal5jjTViyy23jPvvvz8QRnE3mquvvjocSrFdbFtZ/v73v/9V8bopHvlEMOXN9vKuu+5abW07GUznccIJJ2yMrk9+06E88sgjqwMy8qOMr7zySnzlK1/pk/QGLtJMuZkRuOQfEVsdFHHonyM23T9izV0jDj87YtyGEddJ5fdKqSKJWTOXpad5c1XPAWdE/KdkMO5vfOSZEovVh8eycCneom958qVRndS+uBSHLTpXxMzTDHfPv58gQHcQITy1tPpmadYqzTGlwanvLZ+3lMb/B8o/tpo3LZ/t8J+AwfzVjGV99NFHK737ZsxbT/LUMEz1JFj67SsEEDhbn0jg5JNPHuOMM0589atfrQ5SIDe2h93N58TvqaeeGosttlhFIJ1edsKYbh29OuEdv6f7t+eee1Y3vc8111xx6KGHVnf7ucdp3nnnje985zvVhdfIoPsRSSjZ77TTTtXp5OOPP776jqTyIo4kk4gq4kqSaVtZHqVJ1/GII44It8gfffTRVb6vvfbaQFSRVNvS4ulL4xofkkz6knQpnbbeeeedwzZ4X6abcScCNQLnljP6dw6IuOPhiBtKcc/FJUlkliolhxOUEjT+XP78vUMj7nwkYqnvDZeisR8M5guTR+x/WsTcJVM58MyIPTePmH2G4SWbZKKIfbaMuGdYxPTrRzh0sstGERPYEx3uJf+WCDxemhKecNr47+Xvi0tzeWkmLo1rbEr4Yo3yt8PvTib/tvw98j0VpcUg/P/QQw/Fr371q5hvvrIzfVy+iy++OMx1DB16womPnUY86JjXu10jLBt+2A37xje+EUOHDg3zpcOVtTM1LgcZzXEOUtb2noQO4q3925lyx7D5j/tYmwGKIInhAAHfVbKbbbZZdXCExI40jj9kj36h074Og2iopHKIoJPIQ4YMCRI6dx66tkbjXXvttStSWRRF5eaeQW6InkuxSRfHH3/8oIeHRNEHtI3MXlx08kgEETsHYOSDVJDE0Enm1VdfPRBBN8QjYCuvvHLIzyGHHFLpQNJzPOussyrSet9994VOJ46+NsrkYlISTfi5WgfRLYqir5PO+BOBCoH1lot46S8RH107svlJSYAqD+WfE39WSsyujPjg6og3yxl/uilLy0Hyf7NVIt64bDgGp/w8qqtqGnvfFJNGnFxKUP97YcTvd4mYAdMZJGXvrWLMWkbkFLLt5I/K37U5sPxtbYEU/rv8/VRpDi7NhKVpxLh8HXT/7YZRe3Iw0hylgNSkzFGzzz57MOYhu2zcakMwccABB4Sdttqu8elTeOZM6lonnXRSuH3jpz/9aeXfrhO1KWkSbiB9DmUKb452MNRuWy30oLpkPqX3b4fNHMpvq5kkhq1WY5nfRCARaFUEMt+JQCIwBgggWMibg5OzNtxJS4BBIGGHyx26dsoaP+BAoveXv/wl7Kx1lay4N9xww0pNS9y+PHb33XeH3TECE9LAGWaYoVLLckATIXS1m/zY1WuUXkoDOUQi7eoRULBrNZPEsNVqLPObCCQCiUAikAi0EQLInx0qu1O1rrodsBtuuKG6h5eUzrVk9A9rWOyqkdpReSJNrO07Pu241XFyc4MHcjnllFNWO2p21UgR7ajZtXNDhzt6Xb/mpg12wjUaYfmzW9Zo3yq/kxiOTU1l2EQgEUgEEoFEIBHoUwSQPF/W8iGGOiEfVHC/LvUo17Odc8451UFKEj1+6COSBi61VM/OayOgpIbiRxJ/9KMfBd15hg4jKSEVJbr/PrcqrY5mvPHGqySQvkAm7x3dm/09iWGz11DmLxFIBBKBRGDAEMiEBx4BBM+2bFF8oklZFEXQKXewcO+9944f//jH1Ylgkj26h0iZw5SN0sBRlUQaDndKZ9NNNx3hFbGk23jBBRcECSG9elLIueeeO5yO3nrrrYN/N4fYYhbQgUySRNvQSQwhkiYRSAQSgUQgEUgEEoF+QsBNFMstt1x1AAU5I/VzY4aDKQ6U0Ad0yASRc6Cks2zRKbzzzjurK9s6cxevw570DkkOHcS8/PLLw1VsO+64Y/j4gzg6C9tqdikxbLUay/yOJQIZPBFIBBKBRKCVECiKorrtYnTSN1ey0QmcZZZZKimemzQYOn/0BukTkjJ2LLsTy//85z+rj0n4tKuTx/QTG/25os32tKve2Lv1gpSRfzqM3pFGbrUhNURa6/dWeSYxbJWaynwmAolAIpAIJAJtiAByhew59FEX30ETEkGHUFxlc91111WfYkUMZ5555lh22WVHGFe+IYf11rI7e7faaqtA9kgQd99993BV20YbbVTdibjWWmuFLen4+J/DL8IggE4os0YIbRk/+OCDQTrpmpxa55B/+ZPnzoio8M1skhg2c+1k3hKBRCARSAQSgTZHALmiS2j79oMPPqjQIK27/vrrqy98OQxiK9nHHyrHDn98HhZJq61dKeNdvKeddlo4dezaGfcj0h30u/GKGySRVLExfiekbSMjhbfddlvssssu1RfIpOFaG+SQBNN7q5kkhq1WY5nfRKD9EMgSJwKJQBsjQDLnyybuJXRABBSkc6R8iJ2nOwjZd2Z8ucQXsGq3hRZaqPrCiQ8x+CCCOBqNk862nWv/iOUmm2xSHXap7TwXWGCB8FGHww47LGxZs2NsQyOejPdWM0kMW63GMr+JQCKQCCQCiUCbIWALlxTP51+feeaZpiy9q3J88cvVOr725S7DpszoaDI1MMRwNJlK50RgIBAYtxg/tl/wz4PSTDnRLCWkb6eJP0TM9fuI5Uos2s0s9s+I6b/bnmVX10suGfF2We9pmgOHc88N27EOaJQD02j/0zOkN/j973+/0ukbbYAB8HD//fdXqbo6xx2I1UsL/kli2IuV5sJL9xylWaa676m3cfDNZtcF9Ha8dXzvvvtOzLnwtIPSPPjQfWWdTNj2Zr/9to79D9g2llm2xKLNzCbfXjTO+dPvYpkFy7L3g2m2dO65+5ZYZrGy7GmaAoef7LxeHHroobHBBhvEd77znW6ZzTbbLPbZZ5+gW9jdMP3pT3ncebjFFlt0qzx13nqRhvRKVEkMewXG4ZG44NLJpTQ3Rl9g4PNHthL6Im5xjjv+OPHDU5cflGaqmSYp6yTa3vziFxG7796eOJxxRsT6y5dlP7o9zQKztme5b2zS+j74exEbb7xxnHrqqW1vhjOI5vmbxLB56qLJc5LZSwQSgUQgEUgEEoHBjkASw8Few1m+RCARSAQSgUSgOwikn0SgRCCJYQlC/k8EEoFEIBFIBBKB9kHAPYM+k/evf/0rXIHj+8rtU/pRlzSJ4ajxSddEoJURyLwnAolAIpAIdEDgww8/jJtuuin++Mc/xt/+9rc444wz4pxzzokkh8OBSmI4J6dHpwAAEABJREFUHIf8mwgkAolAIpAIJAJtgAACeNlll4WbRFx/43Swk8733ntvC5a+97OcxLD3Mc0YE4FEIBFIBBKBRKBJEXjggQeqz+D5hrKvqrg8m7GtXH9yr0mz3i/ZSmLYLzBnIolAIpAIdA+B9JUIJAJ9i8C7775bbRu/8cYbVULIoc/j/fe//w26h5VlG/9JYtjGlZ9FTwQSgUQgEUgE2g0BksI333wz3I2LJL744ovx6KOPxhRTTBHjjTdeu8HxqfImMfwUJL1tkfElAolAIpAIJAKJQLMgMPXUU4evqFxxxRXxwx/+sDqA8sorr8Rcc82VxLCspCSGJQj5PxFIBBKBRCARGGMEMmBLIUAquM4668RJJ50URx55ZNAvnGCCCWLhhRduqXL0VWaTGPYVsn0Y7zvvvBOUZJ2iuvXWW+P111/vNLWXX365+qYkf88880zlxwmso48+uvo9WP+4imDYsGFV2W+++eZ47rnnIhWKm6O2qfQ8+GBE2YSbI0P9nIsPPohQ/v/8p58THuDk3ng74pFyCHq0NO+XGAxwdjL5RCDME6+++mpcc8018ec//7mSHH72s59NZEoEkhiWILTaf8QQ4dlhhx1i9dVXj0svvbTTIiCAq6yySvz2t78NROmjjz6K1VZbLRZffPEYzP/uv//+uOiii8I2wWGHHRY/+9nPqgtMe1Dm9NoHCCBFl1wSUTbb+Pe/+yCBFogSKdxyyygXLS2Q2V7M4rEXRGxxYMT+p0e8Nlzfvxdjz6gSgZ4hYA497rjj4pRTTom77rqrIoVzzjlnzyIZxL6TGLZg5U422WSx7bbbxvrrrx/TTDNNXHjhhfGfDiIIUjLkkTLtd7/73fjyl78cRVHEmmuuGUsttVQLlrp7Wf7f//4XJKVf//rX45e//GXsu+++YVV43nnndS+C9NVnCJSC2yjH4rI++iyJpo6YtPTccyMeeiiiXKM1dV57O3NfWTRiuiki3iwlh70dd8aXCPQUgXHHHTeWWGKJWHXVVWObbbaJ2WabradRDGr/SQxbuHonnXTS2G677eLqq6+OjhdznlvOQBtttFHoAJ/5zGdauJQ9y7qtgGWXXTZmmmmmKqBV4AILLBBPPfVU9Z5/Bg6BP/whYqWVIqYoCcLA5WLgUr7nnigXLRFlcxy4TAxQyouUwpjpphygxDPZRKADAnQMl1hiiZhnnnnCnNHBue1fkxi2eBOYb775Yrnllqs+5/P+++9XpaFPSAdxgw02qN7rP9dee20lMdx7773D/U2/+tWvqpvfDz744Nhxxx1jyJAhceCBB4Z46OQhl26EJ220BU3s7mj/P//5z9h6661j6NChcfjhh1dxPvzww3UyTfV0JYFb7r/yla80Vb7aKTO2kEuhdkw4YZSS674reTPH/OKLEWecEbH55hHjj9/MOc28JQKJQLsjME67A9Dq5bdV7LM+9OmGDRtWKdT+/e9/D1Izq6LG8rm888477wzkDjG03YxAiuOggw6KffbZp/p25L///e+47bbbYuedd47ddtst/vrXv8Ymm2wSDq4gl4jWddddFy+99FKsscYaFUn83Oc+15hU0/x+5JFHwtb7l770pabJU7tl5L77hm+f7rRTu5V8eHltIR9/fMS220Z84QvD7fJvIpAIJALNikATE8Nmhay58uXG9q997WuBmP36178OdzE9//zzseiiiwa3xtyut956MeOMM1ZW7nGy1TzxxBOH7dYJS3HOHHPMUZ3eRRwRzVlnnbUStXP75je/GbPMMksghssss0wlXRSHMOuss074XUXcRH+cOkNg11133UoXs4my1jZZefXVKBcZEWUVxEQTtU2xRyroxRdHLLxwe24hjwREviQCiUBLIJDEsCWqadSZpE/37W9/uzphRd/QLe5jq0z71ltvhW3YOmV3PA0ZMiSc5qrtxm/yPbHf/OY3Qb9wwQUX/BRJrsuQz75FoBRQx157RZRrjrIOIlZcMeLyyyNmnjnimGP6Nu1miP2FFyJOOCFirbWiKv/000dceWXE+utHuehqhhwOcB4y+UQgEWg6BJIYNl2VdD9DTuCS7gnxrW99q9ym+kIccMABsfLKKwdJoG8+0hWs/fBX6w+6usZvT5I1bvzW78jU3XffHVdddVWlc+jU8wMPPFDpM/LPCNOMxinkY0rWAZ+iKCopp21xW+fNmN/BnKcVVoh48smIDz8cbq65JmKVVYbbbb/9YC758LJNM81wIlyX/9lnI7761Yhzzokou9NwT23y9wNt4KOIdjuR3SbVO2DFJAgx1g9UBhxsNJcOVPp9kW4Sw75AtY/jfO2110opxAnl5HJOdWv7laUIgp4g8uMbkEsvvXR1UnmPPfYIV7e4r+mmm26KM888M5544onq8z++EXlCKcqw9UzK6P0Pf/hD6GSudqGj6J7Eo446Kn7xi1/EoYceGg6zOIRiO9l3JR1y8buhuAP+kx6lext333336qqaFUsRFXP77bfHdNNNN+D5ywwkAu2IwK/PjLjxnoi7H4s4pZQYv/d+O6KQZe5NBAgnHIR0XRud+ca4zU3nn39+/OlPfwrzZaNbx98EBr6AUtubE//yl79UO3CEIdKp3TzNt+YZvxlz56mnntrlhyb4aTWTxLDVaqzMr+tnFllkkXB585Zbbhmzzz57aRvhvsJDDjkkJppooph11lmry6wvvvjiQPDoFn7xi1+Ms846K5xGpi+41VZbxQUXXFBua61fXe/i3Q3wTvBONdVU4fTyPvvsE6uuumpFCvfaa6+QtvROPvnk+N3vflfpGlaJN8kfZXeHIXLrRvvaHE/7v0ny2M7ZWGihiIMOilK63Z4ouKqn7KKl5L29yr/sFyMO/X7EsT+KWKFsA+PkzNPCDaA5sk7I8Y9//CPcmuE+3zpX5jxzl10u85w5q3br+KQadcQRR4T5rHYzRxKk2HU77bTTRroj2OHNYcOGVXNs7Z+wRDznl0TULl1t38rP7J4tWHsausMlQ4cOjaGlqfUJnb51GESREMMVVlihcueHHiJi6Dfjffnll6/cFypna5LG2r93B07c7+Q3/wsvvPCIzqCzsSNVHDJkiOSaxiCGSLP8NRr3VTVNJts4I5NPHrHgglEuMNoThAkmGF7+ct3VVgAghkMXjmAWmzti3Jx52qr+e7uw1J6QN984bhzbHZo855xzqq9dEXS4jcJ82VX6l112WTxLv6PBw+WXXx7mSvcc2iammsT5lVdeCTd++EiEeYYd4+Cna93c5mEnjV2rm+yerV6Dmf9EYCwRyOCJQCKQCLQSAq+//nqQ3tGFr/ONlNk6JsGjQnXfffdV9/XW7h2fJI7iIUBodCMQcfiS3qAPRDB+U7lCQhulk3U4ghT2iONgkBomMaxrNp+JQCKQCCQCiUAi0PQI+NIX3cH6mjSHJh2WJEmU+b/97W/hVgrbu+7dZddokLdbbrmlurVi8sknb3QK17qJ/+yzz4555503Pv/5z4e4kUhXtY3TiR4E8khdCzntqO84UuQD99KjlJMY9giu9JwIJAKJQCKQCCQCA4nAgw8+GLaIJ5lkkiobJHr33HNPLLXUUtVHF37wgx/E2muvXenQ2+KtPDX8QfRsB7vOrCiKBpcI9wLT11999dVjiy22qK5tI4lca621qsOZ+++/f6XPf/PNN48UTl6Q1c6I6EgeW+AliWELVFJmMRFIBBKBkRDIl0SgjRFovIINDCSGCBk9e4dG3LtLT9DXv2wL81Mb5O2MM84IxI/0T9hGY1t4rrnmCtvUyJ6DizvttFOlY//73/8+3ACCeLqx40l3cX0ccVEU4QSzuD62atlHEsOWrbrMeCKQCCQCiUAi0H4IkBYiYIiY0tvKdRDF1TM1EUT6vvCFLwSSyE9tSAuRw+222y6YU045pdJF3GWXXcInYmt/tpsdZlluueVi+umnr04nv/DCC+FAiwOYdBEff/zx2nv1RESLYmQJZOXQYn+SGDZHhWUuEoFEIBFIBBKBRKAbCJDoIYD0/nhHDBdffPFwlYxtZrqGd955Z7ixg4QPyaNv+PDDD1fX25AC1mbzzTcPJI9Oots3xId0Orzi4mynk9mRRPLnpLLt6VpCyY3xpTAnlEkcvbeySWLYyrWXeU8EEoFEIBFoEQQym72FwPzzzx9IGAleHaet31VWWSWOPfbY2GabbQIJtF086aSTBmJ40UUXhcMhtf9RPZE+1+GQFiKD/Dqk8s1vfjNIEX1AYejQodXhFG6IKMLoAIrtZ3atbJIYtnLtZd4TgUQgEUgEEoE2QwDZW2yxxYJUry667WUHTnzp68QTT4yf/OQnMeecc0ZRFNUnYn3Zy8caav/1c5111onrrruufq2eDqY4gGLLuCiGbw3bmnaZ9pFHHll9RWyzzTaLWjqISD799NOVNHL88cev4mjlP0kMW7n2Mu8DikAmnggkAolAItD/CNg69oEFUsHbbrut/zPQkKLtbJdiTznllOGewwanlv2ZxLAXq26//faLPfbYI00fYbDnnnvGY4891mf4fvjBR3Hx0fcPSvP6f94pcYu2N+eeG3Heee2JQynoiJvvL8t+Qnuap15sz3Lv0aT1ffoVEb4z7HTvmBifPaVPeOCBB8aYhO9mmNHGLf2jjz466B2SVo5JvL1IQ3olqiSGvQLj8EhWXnnloOOQZpU+w4EicV/hWxRFzLvM1IPSfGaS8eJ/sy/X9ubtqeeOt6eeqy1xeHOmxWLm+SNW2bY9zeTTtGe5m7W+F101wqdbbc+OiVluueXi+9//fuy2227VFu6YxNEbYdZff/045JBDqjlvTOMbziCa5+84zZOV1s/J0ksvHcTbaZbtExx0OgrAfYVvUfaG2RaZMgajmWDCcQdluXpaV1PPMklMPfNn2xKLGeedPKabLmLZZdvTTDppe5a7Wet7vvmiugZmkUUWiXY30WT/xmmy/GR2EoFEIBFIBBKBRCARSAQGCIFWJ4YDBFsmmwgkAolAIpAIJAKJwOBDIInh4KvTLFEikAgkAoMIgSxKItC3CPz5z3+OCy64oG8TaaHYkxi2UGVlVhOBRCARSAQSgUSg9xC4995746CDDorGy7J7L/bWjCmJYWvWW0vnOjOfCCQCiUAikAgMNALPP/98+FTerLPOOtBZaar0kxg2VXVkZhKBRCARSAQSgZZHoOkL4GslN954Y6y22mox1VRTNX1++zODSQz7E+1MKxFIBBKBRCARSAQGFIGPPvqo+pyez9zN596cAc1N8yWexLD56iRzlAg0HwKZo0QgEUgEBgkCpIW+muJO3AknnHCQlKr3ipHEsPewzJgSgUQgEUgEEoFEoMkRuOyyy6rDJg899FDYTn7llVfiySefjAceeCDee++9Js9932WvjjmJYY3EIHu+/vrrceWVV8YJJ5wwomRXXXVVnH322SPeR/XjtttuC99/5OfFF1+swl133XVeRzIffvhhDBs2LI4//vh4/C0bV+gAABAASURBVPHHR3Lr6kUn/OMf/9iVc9onAolAIpAIJAJ9hgAp4WSTTVYRQWTwjTfeiJdeeimefvrp+OCDD/os3VaJOInhANTUNddcUym8fulLX4qbb755pBxopOxr8/DDD4/k3t0X9zJttdVWcdJJJ40Icv3118cll1wy4n1UP+6+++445ZRTQodB+nbccce46aabPhXEh8N9RHzXXXeNp5566lPunVlYmR38/+zdC7xmU/0/8O+uSOX+c6tcZlJSbkOkXDK6SBeaQimEXBqhC0oIM+RSiUJILkNUkju5FIaQRuTuX0lDSleheaH54f877z32sc/jnJkz5zzPnOd5zndes85+9lprr73WZ90+67u+67u/8Y3+gprmp5Off/75sffee8fdd9/dtHSbkdCMx2bGed+4K47Z/vq47Dv3xVP/6f4V6n8e/W/cdsWf4+Jv3xP/eGhGM2DMNBKBRCARGBICDpx86lOfisq99rWvjbXWWive/e53B9I4pES76KGXdFFZOqYoG2+8cRx99NHxl7/8JT75yU9GnfytvPLKMWXKlHjb294WCOQb3vCGIZULKRw3blyf1c/kyZPjtNNOG1R6O+64Y0ybNi1e9apXlXlcdtll+31u6aWXju222y4WX3zxfsMbPVddddW44YYbYp111olbb721LOdtt93WGG3Y92effXbsv//+cckll8R/eqSnw06wSQnMfOrZ+P2v/hEbbDkmtpm0Zvxu2j/ixvOmx3PP/v8mvaE9k/nl+Q/GZSfcG/fd+PeAQXvmMnOVCCQCzUSgU9Kab7754qUvfWmnZLfl+Uxi2HKI+3/Bm970pvjCF74QTkfttdde8cADD/RGXHDBBcNJKSemej275Mdhhx0WtqZtQZMafulLXwpkuNnF+9znPhff/e53m53ssNP735nPxthxi8fSYxeKJZZfMFYbv0w8899n47nnupsYbrLzSjFhr1WHjV8mkAgkAolAsxE49thjgzCl2el2anpJDEe45vbbb79SCfbwww+Pxx9/vN/czJgxI6688spSAnbooYfG7bff3isJvO++++Koo44KhGt2kjdSs6uuuqqPziHjnvQIJ02aFNdcc01JUmXgqaeeKreNDznkELe9zkkuW9Rf+cpXSqOgSG1vYO0H5d3rr78+SCg5v2fOnFnGoOf4ile8IoqiiI17JKekoohiGTgK/rxqkflj0aVfEQji/bf+M2Y+/WystvGr42XzdUJXHAUVlEVMBBKBRGCUI5Cz0Qg3gNVWWy0OPPDAuPHGG6ORiMkaQnX11VeXpPFDH/pQSd7Emz59ejzxxBOxxx57xPzzz19K3SZOnFhuzSJ7nq27c845J3beeedym5o/3cGtt946/vznP8db3/rWOO6444Je4y677FKSQukioeJWjo4iXYwll1yyJH3IahVWvyKC8vfBD34wFltssTj44INLJV9xPv3pT5e6HA632IJ2Lz1ho8n9aPLtcfZBt8WDd/075nt5bmGMprrPsiYCiUAi0LYI9GQsiWEPCCP5/2Uve1lsttlmYTsZoSP5e+6553qzRJqGtG2//falhO3II48MR+3vv//+8lDFI488EptvvnlsscUW8f73v78kebvvvnvv89UPpHDcuHG9kkbEzTH9j33sY+VzSOciiyxSni5+5zvfGe9973t741ZpvOc974n1118/bNOy/3TAAQdUQb3XRx99tCSfu+66a2y44YbhUIoDNvQKRaJj+LrXva7cKn/lK18Z7ukxChtNbrvD3hLbHvqW+PcjT8XPT/99PDWj+w+gjKb6zbImAolAItCpCCQxbJOaI6nbbbfdSlJ17rnnxtNPP13m7Mknn4xXv/rV8Zvf/Cb8rhziRhpHadYJXNu/tqLZZSofnMMfeoyI4COPPFK+i/TxjjvumMNTLwSTLvb3LvmTp6lTp/bJ72c+85neh1dcccU466yzeu9H6483rL1EfGivVeKff5oRTz4+c7TCkOVuLQKZeiKQCCQCc4VAEsO5gqu1kY844ohSeufE8h/+8IfyZSSKzMAwvcI0DM977723PNHsAAtp4QknnBD77LNPIGp77rmnKHN0K6ywQuy7774lEXVF5Lx/jg8+H0EeSASfv+29yC+CesYZZ5R5FPDggw9GVR736Z5HoIh45cLzx5LLL5jbyc9DkpdEIBFIBBKBkUUgieEI4u/wBx2/KgvsJyFpDmUgV/yXWmqpUifvmGOOKW0srbvuuiWhs2VLykfiRxq3ww47hK3oTTfd1GOlkwZjnZX00f0zzzxTSgjpGF533XWlnT+6fraot9122/I5f4S7OvhCAkjCyLwMcsqeod+2vcVx2MR7PLPEEkvEeuutF6SepJrr9uTXdvXf/vY3Ueepkx/5kr95+uLZvGz6XY/GDybdFn/+f4/Hs888F3df/9dYYdXFYsHFXj6bp7oj6H+ffjaee/a5eLbLTfN0R21lKRKBzkDAoUqqVSOVW6bRzJMj9f5WvDeJYStQnUOa7BcypHn88ccH0sTeXvXIa17zmvIwigMhRVEEQubk8pZbbhm+LGLLGJF74xvfGKR2DFizCSj+2LFj4y1veUtpH9ABFdvP4jjxPHny5HI72j3JICmeE8Ke87z0kNDLL7+8/MrJBRdcEHQAJ0yYEMsss0x5mlle2FU86KCD4qtf/Wqsueaa5eEVEk66kFtttVUw0I2ofv7znw96jAjhDj2kdY011oh5+Q9mH/3oR8sT33Qvb7755nn5+gHfRUL4r4efjGN2vD5OmHhTSQrX22JMvOSlPeLDAZ/q/IBzj7gjfjD5N/GvvzwZx+70izRy3flVmiVoIQKZ9JwR+O9//xunnHJKIIWvf/3ry8OY9PE32mij2GSTTeLMM88M82V/KT3TIyA577zzYtMeQQodfztylW6/9OjICxPHAdAqDYIGevN183Jje+bdbbbZpvykXhWv069JDEegBpE/pMwqg0Pc6tlYaaWVApmyLcvfqd0TTzyxbPh33nlnIDykeMsvv3x8+MMfjg984AO9jqFpBz2QNxJF6SOJTgZX95N7SCIS+JGPfKT3OWkgiE4vI6G+TuJZ+ZQHjR8J9Tk7n9p7Sw8B5e+U8kUXXRTicg6TMEfDpA0TOcjhxIkTS0PZ4s8rh/zKT+Xe9ra3zatXz/Y9S62wYOx5ygZx1C83K6+rb/zq2cbvlsCt9lujLLNyc7bPu6VsWY5EIBGYtwgwlUbw4a0OZiJ199xzT7lbxYrHpEmTgpCDNFGYeHVnjmQZA3k0txKEXHzxxSHuySefHAQgzMCxvEG44Vk7T74c5nCmA5T8ODtkX/ziF8tdsscee4xXx7skhm1ahchVUcxeiuRTdHQMf/CDH8Sll14abAwihP3p/jUW07eK11577ZgyZUr5rG8oM0/DhE1j3LwfLgL5fCKQCCQCiUCzEEDS7AIRRFRWLcaMGRMsbxCoVDthvipWl/hV70cIzZMEJL7qZecOiaRuRRpI4GGHjBoWySQiajeMCpeDl1U61ZVQxQ4bFStxK/9OvSYx7NSa68m3r6NY5bzjHe8IDikkMVxllVV6Qmf/f4UVVgjSR/qMTNDY+rVaIoaf/ZMZmggkAolAIpAIjBwCdPOpRZnH5MJXwljveGnts3aIHT92fsWpOx+G8Ezlh9ix7kGH3o6dHTM7bAQ0CyywQLklTScfmZRu9Vx19Y7lllsupk2bVsat/Dv1msSwU2uuJ9+MQ5P0+RIKo9JE36uvvnq8/OUv7wmd/X+SRlvDd911V2lc+6STTioNXOsIs38yQxOBRCARSAQSgZFDwJxnrkL8+ssFKSFVJipPdQJYxV166aXjlltuKbeOSfjoyIuHWJpXH3744aCn7gClA5XUpRBGUkkSRLqL9A2r9IqiCPGQSybbKv9OvSYx7NSay3wnAolAKxHItBOBRKBNEaj0/vrLnoMlBCWkiSuvvHJ/UcqvgJEaMqtmS/qyyy4LhywRRs85GMrPhx8QSAdG3/WudwX9RZZDfOSBYAVBrF5A7x8ptM1d+XXqNYlhp9Zc5jsRSAQSgUQgEUgE+iAwderUINVD6voE1G7e97739X5O1gFF+oPUqBq3ifkjkKSIDpZccskl5VfBJk2aVH469re//W0t1e75OXqIYffUWZYkEUgEEoFEIBEYtQj8z//8T9jKtWVcB8FJZYdPmJopiiJY1bC9W4/jty1jp4lZ4PDxBVvEto2FVQ4RJE0kKUQYSQfZxmVVZOGFFw56hQ6rVPFdF1poofB+vzvZJTHs5NrLvCcCiUAikAj0IpA/RgcC48aNC9u2//73v8sC0xNkgubAAw8M27xOJdMvZHzaoUpxd95557jiiivK+O6RSPZ4bUuTADpVXAb2/EE6b7zxxrC1PGbMmB6fCGR0ueWWC++5/fbbSxNtTMaVgT1/HFxxQrqeTo93R/5PYtiR1ZaZTgQSgUQgEUgERicCCBlbgz7UAAGSw2uvvTZWXHHFGD9+fK8jOSTdIyFEJpmnEf+0004LtgsZwnbIhF/d0ROkq8hqh2eFOexiSxlpvPDCC4MlD/Z9hXm/vPiQg3j8OtklMezk2uv6vGcBE4FEIBFIBBKBvgjYxt1ggw3itttuC6ePWeIgLfz2t78ddcc+4QILLFBa6thjjz1irbXWKhPy24cfmJ+RVulZ++MZOookgDXvcAqaRJIFEBLJKoz5nH/961/hQwpON1f+nXpNYtipNZf5TgQSgUQgEUgEOh2BIeS/KIpekud08BCSaNojDqd861vfCp/Ws/XctIRHMKEkhk0E38qFUcx0T5Sf72sFDsT7rUhXmi8t5ovtx57RlW6x+ZfrynLNbX1tsOSusf6SO49KLCYse3jMnLlLT998fFS6Z59dZ1SW+4kn2rO+n3zynPBBBluzDnXMrTN1b7fddsHMzK9+9auY2+ebFd+Xx/bcc8/wmTy6i0NJV1naySUxbGJtfOITnwji53QfagkOvgvNIHer8KVX0qq0RzrdBx98sCV10k+52vo9tpmOPfbYts5jqzA1ef30pz8dlWWHKdMirulaMz7PLa4OfpD27bXXXrH//vsP2TkkgpwNJ43hPEuocNxxxw05/97dRBrSlKSSGDYFxlmJHHnkkX30G0xC6frqfAwHj2OOOSYoHA8njdk9y8zA7MI7OYyJhU7Of7PybvHGNSu9Tkrny1/+ctDL6qQ8NzOvTpc2M71Ma3hj+6677louUhLHb88iEG30d87EsI0ym1lJBBKBRCARSAQSgUQgEWgdAkkMW4dtppwIJAKJQEcgkJlMBBKBRKBCIIlhhUReE4F5hIDPNd1xxx3B7tY999wTdBvn0avn2WscEmJAdurUqfG73/0u3Ndf/thjj4XTfD45Vffvpt8PP/xwXHfddTFt2rTw1YTGsjG1oQ1wv//97xuDO/qeAv5NN90Uv/jFL8J3Zhkgrgr09NNPl5hoG/fff/+L2kYVb7RfYQY7GHJc3OO+AAAQAElEQVSVMecKF1/d0La0H+NIf22sijtar8ZWBqz1NQaoB8LB10+mT5/eGwz7v/71r6ENe1Z77g0cBT+SGHZlJWeh2hUBA5VBnCK8gzQOQvzyl78M1vnbNc9DyZevAzzwwAPx61//OpRRmat0kMLzzjsvDjjggDjrrLMq7666Ouyj7CacKVOmhC8w1AtIYX3fffctjeQylGuhUA/v5N8m0ak9C4I//vGPceWVVwZTHkiMMlkU3XrrrSEMqaFf1s2LA2Ueqnv00UfjlltuCW3oxz/+cXzve98L7UZ6iMupp54al156aTz00EMh/OKLLxaUroaAxeeJJ55YHgwx3taCen8ijgcffHBcddVVvX5IOCPYxi3t9Dvf+U4wYt0boct/JDHs8grO4rUXAgZ2n0yaMGFCUL5eddVVSyOtCGN75XToufnTn/4UDrtsvvnmsfvuu8eiiy4ayECVIqOx73//+2OBBRboWmkRYugbq5/85CfjAx/4QFx00UVV8cvrhRdeGDvttFOce+65pYNHGdAFf5C+tddeO7beeuuyjKRe2oSikdpoG1tssUXssssusdhii8W9997bdQsjZR2uYzR5/fXXDyZZDjrooFJ6RYol3enTp8fNN99cYqyNbbPNNuHE+T//+c/Ify8g4Msk48ePDyT7Bd8XflmoIICMU7/gG+GUM0PVsIU/iT7pfz1ON/9OYtjNtZtlazsEfG9z5ZVXjvnmm6+cDJGjN7/5zaVl/rbL7BAz5HuiK620UllGA6+vEvhUVJWcsvuCQDd8OqoqU+P1He94Ryy00EKlNwyQw/Km5w9yRIpImmYr9bWvfW1YLPQEdcV/ix2GfouiKNUknAZ+/etfX5Zt2WWXDZO1z4yxX4cYvvGNbwyTcBkh//QisPrqq8cSSywRpIMkWHDUb0TQh9jNfeSRR8pw9vOEiS883SwE9EF2Dmfd9f0LV1vFcIZtFWr3xsLNV0yMXRayyCVi6JkqXjdfkxh2c+1m2doWAVut7HiRpqyzzjry2XXOFswRRxxRSgyZGeq6As6hQCZtW1DXX399KTWsov/9738Pn9NCGJm4YobJJF+Fd8vV9ib7buuuu+6LFj5XXHFFfO1rXysXDxVp7JZyN7McJIRnnHFG7L333rHjjjsGkiJ9iwm7DlQxLrjggrj66qtjn332EZRukAjQASaVffvb397nCX6INsl2FWCxq98i6JVfN1+TGHZz7WbZ2hYBelhWs/ReTJJIQttmdogZo1dGEmZVXtffGWJyHfcYnSSSHZM7gkSNQCFWWWWVOOyww+Lwww8PW1V0TCm4C+smp02TBNoub9QjnDFjRpAYWyBxpDTdVPZmlcWBEtJVhPDMM88MW8jSLooi3ve+98WSSy4ZdOi0M+OJsHRzRoDqzu233x7jxo0r1RnqTxibi6IoFy11fxLu4bfTeort+zuJYfvWTeasixHYdNNN43Of+1zQtfr5z38+oA5MJ0Pwnve8p5R0bLjhhvH973+/k4sypLyvsMIKpR4daY9PdjmlXSU0//zzx5gxY2LbbbeNt771reEwUhXWLVe6Wfvtt18suOCC5eGIerm22mqrsm3Yrrvsssu6Vte0Xuah/Lbtro2QKpNAk8JLx5amxZavjXzlK18pdVinTJkiKN0gEKgWKtR6iqLo84S+2cfj+RsEnXv+tqsvSQy7unqbWzirJStYkoDmpjw6UyNNo4+1yCKLlPqG3YgCUmBVXhR9B99uKeucykGS4yCGyYaUojE+HVM6TnTvGsM6/Z60kH7Xaqut1u+JTu1e+6fHheh0enlblX9fZKI/CMeqDSE2FpQrrrhi0H8jNXRPZ7VV+eimdJ3o/sY3vhHvfOc7gz4wws3PQmbxxRePhRdeuDwNXpX5zjvvLA/U0Ymt/Lr5msSwC2rXFpXtKANDf65ZgwVbWp/97GcjV6ZDbzROvzFBwWQLou205pve9KYXbWcM/Q0j/yS9SaZatEuLCCd0N9tssxdljG1DGHAvCuxgD3b66BXSYTKRkwY6jIEgKpaTo7bZkSEHUeBUhQnvdMfEh4lU3WvnyuiEunLBxLa57Trh2godRARaeLoXEGDCiKka/USb0ZYsssQoiqIk20yt6D+25ZFHCxDh6V5AwBawu+rqNxNK+mjlSO1ZCah0oj/+8Y+XlhToGsLYeIZEenY0uCSGfWq5M28YEL788stDA2YqgsK7rSsD8s0331yaMTCoDFQ6CrUGaxPVQHH4G7wRmdmlJV66gRGgb8Z226GHHhp0hhBFW66khwM/1Vkh2qDVuMM1yqi91E/lam8nnHBCIIxMlZx//vmBTHVWKQfOLan66aefHpMmTQq6hRZtn//858tDOJ667rrrwgT0zW9+M6ZOnRprrrlmOK0urBuc8h544IHx9a9/PdQtiWhFfJn9cOiEjiWTIIjMRhttlKeS+6l45mcmT55ctqFLLrmkVDlwgltUaggOTehf2pKDPoiLQynC081CgPqGAzrINdupCN6skNn/nTBhQnlgyhY+SSKpIvI4+6e6JzSJYRfUpYl3yy23jE984hOhQTtNZbC16vnUpz4VthtmN/GSKLIzNydiuN5663XVBDYSVe90roF84sSJwc7dhz/84VLXbCTy0qp3IgFIATuNFOS1TVuK1ftsL7Pbx2CvgZetNouOKrzTr7ZI1TED1uqXcwq5KpcJfOeddw7+7373u8N2ajfpLn3sYx8LpNd4pJ4tCmyHKj+dQm1jxx13jE022SToyDlAIWyeuQ550ac//elgv9CYDkN4IdKyTwXhM5/5TNjB+ehHPxrsGIrTTe1IOYfrXve614W+ds4555Q6rQOdgKenaZyq3ucgj7nTHOqAGD1PmFfh3X5NYtgFNWzlaFVeFC/W40ISDRhOtdm+sbVj6wqZVHRH8K3cSXmEEbdbXTGf4d6Vn7jpho+AgZ3pAwTRFUkafqrtlQKdMQcvDMJ05xqloUggiQcMOFtg3TShVbp1yjZ27NhSUlgUL/RNekqwsWDzW/z2qsHh5cakWpXPgkB9Vyna8tQ2YEO65b4Ky2tfBOi6wVEbWmqppV4kVTWmV1g24tw3pdF7Z5Gmn2lv3KKLLtovGNoivKvAoihKPUPE0hhm3K7CRsM1ieEoqGU6KDfeeGMcf/zxccghh5SfByKtQRSZS6ED5ei+7R06QMynTOrZBrMVuNtuu8U111zTzocjRkENZhETgUQgEUgEEoF5g0ASw3mD84i+hS4XcyG2beh++RTVtddeG8xE2NohcaQ/Icxqn46QwwJHHXVUqf+EVNKbGtFC5MsTgUQgEUgERikCWex5iUASw3mJ9gi964EHHoiiKEpdQ1t2zB7Qa3LKuDFLRO/s69nqI1WkHG9rmdSxMW7eJwKJQCKQCCQCiUB3IZDEsLvqs9/S0BG0bewqAp0muhb9HTYRBxk89thjy2+aMkTrmXSJQDMRyLQSgUQgEUgE2hOBJIbtWS9DzhVixz6Ya5UIxVpbwUweCHOg5KGHHipPxTot6LSV+PzpHLKo7xSW06LiS4fdNVfxSA/7I5XCR5NjeoZ9sZEqMxtn6rVV71fHDicxL9OqdwwnXd801WaHk8ZQntUH9JOhPDvUZxwOs7gb6vNDec5OATuDrWxjQ8lX9QwVmWp8qvza8froo48G3e12zBtzWfLXjnkbap6USbsd6vOze05fMHfOLk43hDWJGHYDFJ1fBoMPSR9bYT/60Y/ihz/8YVmolVZaKbbffvtgP82BEjbk+PksmxOkDCzbbr766qvDCUJW388444xwT7qIAJmEHfl3veGGG8JEVSY+Sv+wD/mTn/wkZsyYEU5409k8/PDDA/5sZ/EbCBoDF6msw0D1ONKC8be+9a1gJLge5vd1110X6slvTj3THW3VwM5I8cUXXxxOsXsf4+n0TtnJFMavcox2H3300cH8DBWFmTNnVkF9rswmaVdMlrDxx34mAiKSq7bF1MlFF13Eq4/zSTA4iyfA4H/22WfP00nXxHDppZcGO6Hy4OQ+W31HHnlknHbaaX2+liAcmdMXtQ3O4gyxhIMyKqu0+IlfOXq+9913X3Ub7If6ugUMej1b/IMOsnauLSt3VQ5tzjhQf70DbMqibWijFhX18P5+azP6ADyV3yKEXT59aPr06S96RNuov1fbgb1+86LIbeJh8SaP1eIKmaWioy3wr/dd/Zl/3U2ZMmXAz2Uag41BDGHXi2vs0A89a+yuh3mfhX/lJ1/abb2tVWGdePVFGJjol/Kv3cJDu9JG+VXOokKbMqaxcVgJP4QTftx9992hPXuWTWD+2qnxy9w60BgnXqe7JIadXoO1/C+xxBKlzSbGdb/4xS+Wn0oSjOyxJ8cmFvth7Iv5jmllKoJdNXbXxo8fX9pU23///cvv+LJbyCbZwQcfHMzhsI2IMJoEmRiR9mh0DIo7qc1+2PLLLx+Mphpk3DPN4hDPQAOtSYzhWkZ+DS51/EyQBnlpGqzq0jDpIYbMUlTPMLqK2F955ZXlVxAq/2ZcTcAWEO9973uDuQaDoYGQ6SPps/tlIvPbiXYkbcKECeVnozx30003CerjDLYkbbBiw4+kGpn0vIjSQIzXWGONMLgz2s6/cggD80v0ZPlpk2zgmegQLX6tdPLvIJbJlc0z5WD/Ux70L5OwCRmJq/KB4DA+rFxItsnHYgueyvfmN7859Cllr54x4SPhzBlVfg6JMV1y7rnnBrJZ+bfqioCzb8rOogNp2uryPW2dLT1tca+99urNB/LDT9vQvhF+2AyUN5O19qPczIGMGzeuNMWCKJuAmQ358pe/3Ju+dCy2OGOce854JL62Nhgi6pl56ZAu9ax86tnugjI47Ges1W9h4Osa8uUrHNpJ3SEnwhqd8hqzYV0nPPCwsPROfQKZr9LXf71Tv6vSYwpn4403Lo2Ra7+VfydeLSzgbadr5ZVXLotgbPZBAWTcmFZ69vyBn0WP+MY4WJ100km946iPRXjGWFS1R+2WeTHjHMynTp3ak1J3/n9JdxZrdJZKhzfQVq5O3pBDtrCEmXAQmAolv5ERHcCkZfAVz72OID4SiZTw59xXz4+mq8EVsdtwww0DniZptugM9CZuRNpga2LtDxd4IuUmNUSjHgfxQ8J8IoxUEUEQjkyccsop4esZ6oof5zcDwiTF9UFP2HCcfJ188slBnUDdI2Kcd5EuM/xKR5X9S+8RZnGhXXzkIx+JcT0TvRW4sLoj6dMOkQ02xaTPDpsBGq4IhqvnpWWi9LxVugkOOfLlh6KYZRMQKZYnRAxZF7eVDlFHgJzgX3TRRUO+9BVtwQTCoDfS6Gsu8kHSRqrFCoAJSjmVuSiKIKnwmbx11lmnTAcJ84z2hBiQ8Gsr/Dh21JAyfRy55tcqR9qC4DLsa/cAvhYhFoqMlzO8zA8hkwfE44Mf/GCYjF0RItgIa3SII8miccYCU/1p80VRBKzGjBkT3kPqqF17Xl+QH4ta0xEdCAAAEABJREFUdc6PMz6ZpGFp0ubXTo5UHUF22E8fKYoi9B8H/5RRHWsXlRS4KIr42c9+FhaHnMWjdqWcjeUqiiImT54c+gOSU4WrF2MBsqcfITDarXDSNG1SHbrn5IvxdQay9Wd9n3+nORiQQJuXYKJ9KYO+aRGjHtxXDhG0EFcP6kc7QqoRd3Esbo1RG2ywQWjTFkcWdsKM99I0xnc6mVae/lwSw/5QGR1+WcohIGDgNdAiLh43YJgQTdjuGZ01kJvI3c+NM+AYsJCDoigC8TPpkiyxwG+SbkyPtEo8pLIxbKj3yA9SalCt0kB8q98GXxO49/IzsMLBb8SPTmt/eYWJycpVXPqt4rovilnlNcAbxGGMfJmobLUiK8wtea7u5IXk8MILL6x7t+Q3wmciQPy9QPlN3H5zygEX5XJPQmQ7FskmjUB8+XPKhsxwyigtkzYyjCzCRby6E8diDyGDUT2smb9JK5FfbUu6Fo0WPX5z8oZQKK979a/MFjAIXaWiIqzukEUSGpJmCyNE2TafxYB42pD2r+6lp26lSXrsE3t1oiw+J29wk2f37eTUpbZZkVmfPURaqjxaVFgcVCRG+7bYrML1QaStuh/MFWawgyESblxyb8GiH8FdO2pMS/8mnfTOxrBOuNeGLCyQbmPQnPJMPabel7VluxEWmMZci4069hZGdge0NWmr02WWWSaQUf2XXze5JIbdVJtZlpYigLTYGjTB9TdJebnB2EBBuuV+bpxVq9W+LQxSQ9I626wGOgPeQGmZtA36A4XPrb93SnOg5wyctj7ZumyMY4C2DeNzf41hjfcGWQ65UkYrdGWm14P42JpExJGHLbbYovHx3ntfNlB+JKLXswU/vAMx629i9Tp5NhFX2PkNI3VnO9nWX6W4rmywUlYSM2VHHEmPEEPES5qNzuSlDXpXY1gz7qWrnAjNQOkpg3paa621eqNotyRYtpwRoIrs9Ebo+WHBI23EWtm1M7qm/PQt3wznR6eLqgHiZIK2CFPHPUn0+x8xpbvZb+AIeVrIWEio24GyYOEgvCKDcKvi6kPavrJXfoO5ksAjeXAlfdxoo40CiTn11FNLNSHh/aVTFEUgqaSK/YW3ux8s9QtkbTB5hS3CbDEiflEU4bftaHqg2me1MBKuLZKEI5TujVfqTR3rM/y6ySUx7KbazLK0HAETt0HBoNL4MpObrRsDRl0y0BhvoHsrVLqhe+yxR+y5557loQ86bSR3Vvy2L3bYYYfyEBFyGs//Y3uSpOb522FfTPIknwMlZLJG/BxgaoyD3JB8KktjWOO9uAjEmmuuWQZ5TrltydJrNSkiDQiIgdnkZisWcSZpKx/q+aP8BnJ103Pbsv/y610DvYAETFlM9uIoD0nvvvvuG/S+SMroQwqjc0aXd+LEiaU+rzblII1tdhON8m+99dZxwQUXlIebPMOpF5OXbXn3zXYWNiZAee8vbTiTYLN1aiKt4qgfW70II7035LEKq64mVYSJTpdtcVvSpO226CwQSLO+8IUvlHj4DrA0tEXSSxO5tuEZ26z6WpWud7d6e71612Cv8quOBlpESIe0CRb9xSFpto1pcSHuYJ209B/fB/YdZdJbuptw1o9IbKkI7L777kFiVqVbFEVJILWtyq+TrtQOLMhJTAeTb5LpoihK3dao/ZOGMF6NizNhVbszbtkZgpc+IX43uZd0U2GyLIlAKxEwKBgcBnqHSdU2rC0hA/RA8QbyNxBZ8VrVmxCcFtx8883DxOekooGIvhqyYECq0imKotRTq+6He0U6lbW/dAzAiAu9G4NjPQ6JEF05pHF2BMozJCIIxk477RS2cfgVRRG2WG3HWq3T90EYkEyHfegZfulLXyoP+9g28gxXFLN0DuXbfaucib6/tGFlG46OEgmheqziwYh0WRl22223qMgrfwsIZRWurh1oQawQYBgfeuihpWWAuhSnKGbVtXdW72jmVfseKG1hcCehI9Wsv5dUir+FjfZqQVMP91u6nL4BI8SStJikV9raAYmo7WFEmcQLsREPYURu3J911ll9yHJRFH3uvWuk3ezaojD6bTBcZZVVyo8P1PMrXB+3a1D3H+xv7ckYAksLRn1Iu9R3HV5C6oU7lAH3erreXb/vlN9zm28YKVu9/H4bd7W3opjVz8ThpK99apfuOX2YvzbtvptcEsNuqs0sS0sRKIqiNOdjMGh8ka0Mh1Ks8pEbujp1qVZj/NndG8hNDLYXSR6lbVBHuBAHUheTaT0NA1r9fji/DYAGycY0SC1JZkxmBk8kR17EQwpJEitiiyQhf8IaHVLrdCTle/m2dYMI1eMhQ3TpbLnyp98DC1ucJrxp06bx7uPku49Hk2/ktbHu4USSSLJJOqjuKmlR4+uRwLFjx/bxRjZJcWzjVSSJpIyUGHFUJlKz+kNIWFHMIsN1/2b8RthMePLVmB6Sod3JpzgWAcpbj2fxom241v39Js1BCrWLajKVju15V3E4bcF2MiKIJGpnMHDaVJ8geW2sB+l6tl2cOlJG7aOeJ2Vz4ARuDj5YTCpfPQ5JIpJd31quhw/2tz5Iik0/zjP6L5z1H4fF9DtxhHHqvk58+HWK00/6w3ug/FP3UFbtShz1od9pX8K0O9vEwjj9W1jjglcaRdH0vuiVI+qSGI4o/PnyTkKgKIqgeG9w56q8G2CdmnRKzck+tiKZrDEp2Jajd2Uyq+K7et5A5uq+7gzmtjNI5fibaE0SpFJIlcEdSRHGGfANWn43w5EmSLOelkFTmRDWqoxOTdoeNLmwsce+HcKn/JMmTQqnSekj0q8jaVJe5MK2qntbwuKSkJkgq/cp4xVXXBHM/yDZ/BEqeo0IN6Js4ObPyastVnXjvlUOxvJWpY+cmMTVvfp12paUj76b7SU6T3AT328S0GqS5schwMrF3I17BEdd80fCHCKoT0bukW8TkvjNdtoaQtpIVhBx9W8r3FaxekPeLAjUu4MW6trCgTTG9q+8SYc0FG7KYTuT9Feb4Sc+8y318niH9j1+/HhJlFJkW9vUNCyQpKMPlIE9fxBN6fb8bJv/2ieyog6rTFkokhQ6iERvFob0MulVVnFcHaSxaPK7chYbDjFp65Wf8UUb1NYqv+qqr7GFqd/IC3/14hljEnLqgBgnTHz5Q9Ldd5pTRm1C/2jMe4UP8leFaV/0wI1DxtrqSh9YHJYXkEF42wVSR3RghXFwNA7ByyKAXze5JIbdVJtZlpYjgDQZ8KsByKSOECAyBmJbNRyiwpk4GXwWT+YQIPFNfgYkW2RIhTDORGoSoIPlPfxIWugdGryY+BBmQBLGIUvNnBjpySEm0uaQmwMOOCCU0WCpfBxSiMggCkysmOT5c56hg4j4kvwhhMqOMCKPSLR4zNrQ11RG7zJ422ImMYM1P47kENnYZ599wjYzcxz8OeUXJi/uW+VIeEwG1WQPI+VRPnlWHvpciIvJApGnF7f99tsHMmSruNI/jJ5/8BCHJKyaoNU50yHagS0/p7hJj3qil//phZEaS7/0aPIfBE1+tLUqaSfenQq2YEFalJMjATXBImZwoP9qC9mkWkkMTawkoiTL0maexkGSSgdOGqTsRTFL6qIvwJfZI/HlQT9ig9W7GW2GTxUmnGRHn/C7XZw8qzv9oMoTvUGLCAsE+HEIGgleFcc4URRFkFpVfq6ItK11bcY9IkeXUPtBvA855BDevQ4m6kVd6l8CYE2HVVx1Qo+z6nfSQ9Qb3+u5TnAWkMYb+NXza8yir4scWtgg5sJhYkwxhtFb5k9HtqoL4w/TQsZdpmv0Y3rBnuVI1NWJXYxW9UXvGSmXxHCkkM/3diQCpFIkKlaRVo0GEoaXbXVSiq+cQUgBEQEDC8V691bte++9d5hArUKFkUQJ4xA+BshJhdxXDlkjlWO6Y+utty4VxYXZCiEBqKQr/IbrTNwma4MliYTVOKmQCa0qn6sJiT6ZiYbkjF/lSM0MviQ9JIRIEWkUKVMjVib9itSZ8ElL6rbWlEc4o8eIpPgV8TCwe6dBXrxWOpOmAzG2UE2kttQRwkZcEBfbciS+iCIjxsgSQkuqUeVRW1CXJrSimEWMhNlCZeCcdNYhAfH4K6ttawQVgeTXCqctITTIvHJqu8g8nOtOmRBDZB3xJRlGNrSfophVHhg5VKOM8qo90JN14ITO6FZbbRVV+YTrCyZq9e2+cspMwuwZJLDCkRSxKIqoS3OqZ0b6CjfjREXm9AHqFvp9haMFkq35Kq/GE4sw7afyc7XwQyT1RfdFUQSiaaEmDX2Cf+XgjjjW2wkSKA8wlBa1DPHVMXNPpGXaN79Oc8YNOpvwJvms8k8nVT+CuYWFPlmFGccd6DOmshig/FW7Qva0Q7sjFr4Idr1OLHSQUONUUcxq61W63XBNYjj3tZhPjGIEkB1mZUgHWb63chwpOBBCeTDANxLJ4eYJOSMpkr7V9nDTa8Xzti7lzySITLXiHfU0SYEcIkGCELR6WKt/IxfeSzJiAmvl+5AyUhZbl6SiFkCtfN9Q0yZV1UZJIRGDoabTqufUE+kxEtyufYhEH7kkDXZauVVYtDrdoigCSbOQRZjtPLTqndQZqAchnXSDW/WekUw3iWET0Wc7io5RukOjFRjQyaGr1Yq0pYnkuc7J+QoJYiA/pGVzit+qcPpJBihb1baYZ/ce20qzC28MowdFR5DkqjGsXe6VX12Qvg6275mkuaGUQX17FhnxeyhpDPUZZSVdJmkaap2oU1uXg8mD7/jajhxM3JGKo+/ZKnToazD1YUIffF6HP4YdffTRQTp++umnh7zOy3cP9l3yBTuqMWxqDva5ZsQjuSTFa0Za0rBzo39o58rFrxXOosluCklts9JvIg1pSlJJDJsCY4ROZXI67LDDIl1rMGCyBQlqFb62IQabtu0HumUjWecGQAOrAXFO+XZ4YE5xGsNtoxj8bIs3hrXDPXMbdDXhMNj8MHVia3Ow8RvjwQLmJrXGsFbe285ywAM5HOp7pIFEDfZ52CKIttkG+8y8jIdwKQ+d3cG8l5R/MPGaGcfBKmMWMt/MdJuVFuy0Z+oOzUpzsOlQRbGlPdj4g4mnHLbr9dPBxB9KHOOHOnX4bijP9/eMPDeJijQlmSSGTYExgm4IPZp0K0U7YpB5ynrJNpBtINtAtoF2bAPtptuZxLBJxDCTSQQSgUQgEUgEEoERQyBf3CQEkhg2CchMJhFIBBKBRCARSAQSgU5HIIlhp9dg5j8R6FYEslyJQCKQCCQC8xyBJIbzHPJ8YSKQCCQCiUAikAgkAu2JwLwkhu2JQOYqEUgEEoFEIBFIBBKBRKBEIIlhCUP+SQQSgUQgERg+AplCIpAIdDoCSQw7vQYz/4lAIpAIJAKJQCKQCDQJgSSGTQKyW5PJciUCiUAikAgkAonA6EEgieHoqessaSKQCCQCiUAi0IhA3icCfRBIYtgHjrxJBBKBRCARSAQSgURg9CKQxHD01n2WvOrgrtUAAADLSURBVFsRyHIlAolAIpAIJAJDRCCJ4RCBy8cSgUQgEUgEEoFEIBEYCQRa+c4khq1EN9NOBBKBRCARSAQSgUSggxBIYthBlZVZTQQSgW5FIMuVCCQCiUB7IJDEsD3qIXORCCQCiUAikAgkAonAiCOQxLBFVZDJJgKJQCKQCCQCiUAi0GkIJDHstBrL/CYCiUAikAi0AwKZh0SgKxFIYtiV1ZqFSgQSgUQgEUgEEoFEYO4RSGI495jlE92KQJYrEUgEEoFEIBEY5Qj8HwAAAP//DBw/4AAAAAZJREFUAwBKy3jORAu23wAAAABJRU5ErkJggg==\" width=\"609\" height=\"406\"\u003e\u003c/p\u003e\n\u003cp\u003eThe data represent the number of drug-related problems (%).ADE, adverse drug event. * Drug-related problems belonging to the green and yellow categories were not used in the calculation of preventable ADEs.\u003c/p\u003e\n\u003cp\u003eIn the in-person pharmacotherapy clinic, 281 (68.9%) of 408 DRPs with potential to cause ADEs had an estimated progression probability exceeding 10%. Among these, 128 (31.4%) were classified as extreme-risk ADEs, with the remainder categorized as high (42.1%), moderate (11.5%), or low (15%) risk (Table 6).\u003c/p\u003e\n\u003cp\u003e\u003cimg src=\"data:image/png;base64,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\" width=\"609\" height=\"618\"\u003e\u003c/p\u003e\n\u003cp\u003eThe data represent the number of drug-related problems (%).ADE, adverse drug event. * Drug-related problems belonging to the green and yellow categories were not used in the calculation of preventable ADEs.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eCost outcomes\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe analysis used hospital reference data to quantify clinical costs associated with transplant rejection. The mean hospitalization duration for rejection episodes was 4.6 days, with an average daily cost of $167.83. These values formed the basis for evaluating direct medical cost outcomes in the study population.\u003c/p\u003e\n\u003cp\u003eIn the virtual pharmacotherapy clinic, 17 medication order adjustments yielded $142.84 in savings from treatment optimization. In the in-person pharmacotherapy clinic, 125 interventions generated $768.07 in savings. The number of preventable ADEs was 128 in the virtual pharmacotherapy clinic and 300 in the in-person pharmacotherapy clinic. The estimated 39.36 ADEs in the virtual pharmacotherapy clinic corresponded to a cost avoidance of $30,552.43, while the 97.48 events in the in-person pharmacotherapy clinic corresponded to $756,666.94.\u003c/p\u003e\n\u003cp\u003eImplementation costs for the virtual clinic included $353 for setup, $2,652.46 for vaccines and medications, and $265.20 for miscellaneous expenses (10% of the total). Costs for the in-person clinic totaled $6192.73. The resulting marginal cost-benefit ratios were 11.1 for the virtual clinic and 12.3 for the in-person clinic, indicating strong economic feasibility for both programs.\u003c/p\u003e\n\u003cp\u003eNonmedical cost savings for the virtual clinic were also notable. Among 82 participants, 52 residents of Tehran saved $8.40 each in transport costs. The 17 patients living nearby saved $29.52 each through combined travel and meal reductions, while 13 patients from more distant regions achieved $61.65 in savings from transportation, meals, and lodging. Additionally, it eliminates approximately 196 miles of patient commuting and saves roughly 6 hours of travel time per visit.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eSensitivity Analysis\u0026nbsp;\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn the virtual clinic, one-way sensitivity analysis showed that BCR was most sensitive to cost avoidance variations, with a 20% reduction causing a substantial decline, while pharmacist and miscellaneous costs had minor effects due to their smaller scale. The Tornado diagram confirmed cost avoidance, vaccine/medication costs, and savings as primary BCR influencers, underscoring the intervention\u0026apos;s value in preventing adverse drug events and complications. Monte Carlo simulation (10,000 iterations) affirmed robustness, with BCR ranging 8.32\u0026ndash;14.91 (mean 11.19, median 11.13; 95% CI: 9.34\u0026ndash;13.41), supporting the virtual pharmacotherapy clinic\u0026apos;s economic viability under uncertainty (Figure 1, A and B). The BCR of 12.34 for the in-person transplant pharmacotherapy clinic proves most sensitive to variations in total cost avoided and personnel costs; a 20% personnel cost increase reduces the BCR to 10.59, while a decrease elevates it to 14.75. Monte Carlo simulation across 10,000 scenarios reinforces this robustness, yielding a mean BCR of 12.42 with all values exceeding 1.0 and a 90% probability interval of 9.21\u0026ndash;16.12 (Figure 1, C and D).\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis study provides the first comprehensive evaluation in Iran of the clinical and economic outcomes associated with pharmacist-led virtual and in-person pharmacotherapy clinics in solid organ transplantation. Across both models, transplant pharmacists identified a high burden of clinically significant DRPs, many of which carried moderate to extreme risk for progression to ADEs. Interventions targeting medication optimization, vaccination gaps, supplement use, and glycemic control contributed to meaningful improvements in medication safety and generated substantial cost savings and cost avoidance.\u003c/p\u003e\n\u003cp\u003eThe virtual pharmacotherapy model provided notable clinical, economic, and operational benefits. It reduced travel and time burdens, improved access for remote patients, and prevented ADEs that could lead to hospitalization or graft compromise. Sensitivity analysis conducted at both clinics confirmed the model\u0026apos;s robustness, with the CBR primarily driven by avoided costs associated with ADEs. Even with variations in pharmacist service costs, drug costs, and administrative expenses, the program consistently demonstrated high clinical and economic efficiency. Overall, these findings support pharmacotherapy clinics as a sustainable and cost-effective strategy in organ transplant pharmacotherapy.\u003c/p\u003e\n\u003cp\u003eThe heightened vulnerability of SOT recipients to infections necessitates diligent vaccination planning. Due to chronic immunosuppression, these patients face elevated risks of infections caused by influenza, pneumococcus, hepatitis B, and tetanus. Vaccination can markedly reduce both the incidence and severity of such infections. Influenza remains the most prevalent viral infection among organ transplant recipients. In a study by Yeo et al., conducted over one year in 308 transplant patients, pretransplant influenza vaccination significantly reduced infection incidence (odds ratio 0.19, 95%\u0026nbsp;CI\u0026nbsp;0.04\u0026ndash;0.99) [10]. Similarly, Harboe et al. evaluated data covering over 11,000 person-years from 5,745 solid organ transplant recipients and found that influenza vaccination correlated with reduced all-cause pneumonia admissions (P = 0.035) and mortality (P = 0.001) [11]. Consistent with these findings, the American Society of Transplantation recommends annual influenza vaccination for all transplant recipients aged \u0026ge;6 months who are at least one month posttransplant, with high-dose or booster formulations considered when clinically indicated [12-14].\u003c/p\u003e\n\u003cp\u003eTransplant recipients are also at significantly increased risk\u0026mdash;up to 41 times higher\u0026mdash;of developing invasive pneumococcal disease compared with the general population [15]. However, pneumococcal vaccination remains underutilized. Long-term surveillance data from Canada demonstrated a substantial decline in the incidence of pneumococcal disease among immunocompromised adults following the widespread adoption of the PPV23 and PCV7 vaccine programs, with incidence rate ratios falling by 43\u0026ndash;90% [16]. Such evidence reinforces international guidelines advocating pneumococcal vaccination to prevent both sinopulmonary and invasive infections among SOT recipients [17,18].\u003c/p\u003e\n\u003cp\u003eSimilarly, hepatitis B virus (HBV) infection continues to pose a major threat to patient and graft survival, as it can lead to liver cirrhosis, hepatocellular carcinoma, and posttransplant complications [19]. Vaccination before transplantation significantly lowers infection risk and improves posttransplant outcomes, including reduced HBV reactivation and enhanced graft survival [20-22]. Current clinical guidelines accordingly recommend routine hepatitis B vaccination for all transplant candidates with chronic liver disease to improve posttransplant safety and long-term prognosis [23].\u003c/p\u003e\n\u003cp\u003eTetanus vaccination is another crucial preventive measure, especially given its potentially severe impact on immunocompromised individuals [24]. Patients with chronic liver disease or those undergoing surgical interventions, such as transplantation, are more susceptible to tetanus infection due to immune dysregulation and perioperative exposure [24]. The American Society of Transplantation thus advocates updating tetanus immunization before major procedures to minimize postoperative infection risk [25,26].\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eBeyond vaccination management, the pharmacotherapy clinics addressed a growing issue among transplant populations: the use of dietary supplements. While many patients seek to improve health outcomes through supplements, these products can pose serious risks due to potential drug\u0026ndash;herb interactions [27], immunomodulatory effects [28], and unregulated contents [29]. In transplant recipients, such interactions may alter immunosuppressant metabolism, increasing the risk of rejection or toxicity [27]. Our team systematically reviewed patient-reported supplements that use identified high-risk ingredients, and discontinued several products linked to potential graft rejection, immune activation, or uncertain efficacy. This pharmacist\u0026apos;s oversight highlights the importance of medication reconciliation and education in minimizing preventable harm within vulnerable populations.\u003c/p\u003e\n\u003cp\u003eBlood glucose management represented another critical focus of virtual and in-person clinical interventions. Hyperglycemia, commonly triggered by surgical stress, corticosteroids, and immunosuppressive therapy, markedly increases the risk of infection, delayed graft function, and mortality [30,31]. The multidisciplinary approach adopted in our clinic\u0026mdash;integrating telemonitoring, patient education, and individualized pharmacotherapy\u0026mdash;proved effective in sustaining glycemic control. Pharmacists adjusted or discontinued metformin, when necessary, due to renal or hepatic compromise and initiated newer agents such as sodium\u0026ndash;glucose co-transporter 2 inhibitors in appropriate candidates with chronic kidney disease or cardiovascular comorbidities [32,33]. These interventions underscore the capacity of Telepharmacy to manage complex metabolic conditions safely in the transplant population.\u003c/p\u003e\n\u003cp\u003ePharmacist-led interventions substantially advanced DRP resolution, particularly through vaccination management. SOT recipients face an increased risk of infection due to chronic immunosuppression. Our clinics markedly improved post-intervention vaccination coverage for influenza, pneumococcal, tetanus, and hepatitis B vaccines. Despite short-term cost increases, this approach promises reduced morbidity, hospitalizations, and graft compromise [34]. Systematic dietary supplement reviews and tailored glycemic management further mitigated underappreciated risks in this population.\u003c/p\u003e\n\u003cp\u003eVirtual clinics offer distinct advantages over traditional face-to-face consultations, including enhanced accessibility, reduced travel and indirect costs, lower air pollution, and location-independent personalized follow-up care [35]. Prior research has substantiated the economic advantages of telemedicine interventions; for instance, Evers et al. reported mean patient savings of $131.34 \u0026plusmn; $82.27 per virtual visit, primarily attributable to decreased transportation and lodging expenses [36]. Similarly, Chi et al. observed that telemedicine consultations improved clinical outcomes while mitigating productivity losses from absenteeism and care disruptions [37]. These efficiencies hold relevance for transplant recipients, who require frequent monitoring yet often contend with mobility limitations or geographic distance from healthcare facilities [35].\u003c/p\u003e\n\u003cp\u003eVirtual care further promotes treatment adherence, care continuity, and patient satisfaction. Real-time access to clinical pharmacists enables patients to address treatment side effects, optimize dosages, and receive prompt adjustments to immunosuppressive regimens [38]. Hesser et al. documented enhanced self-management and patient engagement via telehealth platforms, underscoring the value of such interventions [39]. Moreover, for immunocompromised transplant recipients, minimized exposure to hospital environments lowers the risk of opportunistic infections, reinforcing the safety profile of virtual follow-up [40]. Our findings are consistent with international evidence demonstrating the value of clinical pharmacists in transplant care. Previous studies have reported benefit-to-cost ratios ranging from 2.4 to 4.2 for pharmacist services in transplant settings; the higher BCRs observed in the present study likely reflect the high baseline risk of ADEs in SOT recipients and the inclusion of cost avoidance related to hospitalization, graft-related complications, and cardiovascular events. The observed economic benefits of virtual clinics align with prior telemedicine studies showing reduced travel burden, indirect costs, and improved access to specialized care [41].\u003c/p\u003e\n\u003cp\u003eFrom a societal perspective, both virtual and in-person pharmacotherapy clinics demonstrated strong economic value. The virtual clinic reduced nonmedical costs related to transportation, lodging, and time lost, highlighting its relevance for patients residing far from transplant centers. These findings support the expansion of Telepharmacy services as a cost-effective strategy to enhance equity of access to transplant-related pharmaceutical care, especially in low- and middle-income countries.\u003c/p\u003e\n\u003cp\u003eSeveral limitations should be acknowledged. First, the cross-sectional design precludes causal inference between pharmacist interventions and clinical or economic outcomes. Second, the virtual and in-person clinics differ in observation periods, which may limit the direct comparability of outcomes. Third, the pharmacist\u0026apos;s fee of $2.35 per 45-minute session reflected local rates but diverges substantially from international benchmarks (e.g., $42 per 15 minutes in California) [42], potentially underestimating service costs elsewhere. Fourth, the study was conducted at a single center, limiting generalizability. Finally, infrastructure and personnel costs were not fully captured, which may underestimate the true cost of implementation in other settings. Future studies should adopt longitudinal or controlled designs to directly measure clinical outcomes such as hospitalization, rejection episodes, and mortality. Multicenter studies and international comparisons would further clarify the generalizability of economic findings. Incorporating patient-reported outcomes and productivity losses would enable a more comprehensive societal evaluation.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003ePharmacist-led virtual and in-person pharmacotherapy clinics play a critical role in identifying and resolving drug-related problems among solid organ transplant recipients. By preventing adverse drug events and optimizing preventive care, these services generate substantial clinical and economic benefits. Integration of Telepharmacy into transplant care pathways represents a sustainable and cost-effective strategy, particularly for healthcare systems facing resource constraints.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cdiv class=\"DefinitionList\"\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eSolid organ transplant\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eSOT\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eDrug-related problems\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eDRPs\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eAdverse drug events\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eADEs\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eTehran University of Medical Sciences\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eTUMS\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eBenefit-to-cost ratio\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eBCR\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eU.S. Dollars\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eUSD\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eIranian Rials\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eIRR\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eHepatitis B virus\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eHBV\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate:\u0026nbsp;\u003c/strong\u003eThis study was approved by the local ethics committee of Tehran University of Medical Sciences (number IR.TUMS.TIPS.REC.1403.024). The study was performed in accordance with the Helsinki Declaration for human studies. Patients whose data were used for data analysis signed informed consent forms. All analyses were conducted without disclosing patient identities and instead used identification codes.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication:\u0026nbsp;\u003c/strong\u003eNo personal information or images of patients have been published.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials:\u0026nbsp;\u003c/strong\u003eThe data have been entered into an Excel spreadsheet, which can be obtained by contacting the corresponding author.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting Interests:\u0026nbsp;\u003c/strong\u003eAll the authors declare that they have no conflicts of interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding:\u0026nbsp;\u003c/strong\u003eThis study is a part of a Clinical Pharmacy residency thesis and is supported by Tehran University of Medical Sciences (grant number 1402-4-246-69201).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; contributions:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMahnaz Sadat Hosseini: Data curation, clinical and economic data analysis, writing original draft, editing and finalizing the manuscript.\u003c/p\u003e\n\u003cp\u003eSeyed Hossein Hajimiri: Economic analysis of the results, manuscript editing and finalization.\u003c/p\u003e\n\u003cp\u003eSimin Dashti-Khavidaki: research idea, data curation, clinical data analysis, supervision, validation and manuscript review, editing and finalization.\u003c/p\u003e\n\u003cp\u003eMohsen Nasiri-Toosi: Clinical data analysis, manuscript editing and finalization.\u003c/p\u003e\n\u003cp\u003eMarjanMoghadamnia: Clinical data analysis, manuscript editing and finalization.\u003c/p\u003e\n\u003cp\u003eMonavar Talebian: Clinical data analysis, manuscript editing and finalization.\u003c/p\u003e\n\u003cp\u003eAbbas Kebriaeezadeh: Economic analysis of the results, manuscript editing and finalization.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements:\u0026nbsp;\u003c/strong\u003eWe extend our gratitude to Dr. Maede Salahshour and Dr. Soroush Kohansal for their assistance in the collection of patient data for this study.\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eSu Z, Li C, Fu H, Wang L, Wu M, Feng X. Development and prospect of telemedicine. Intell Med. 2024. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.imed.2022.10.004\u003c/span\u003e\u003cspan address=\"10.1016/j.imed.2022.10.004\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMetzger GA, Cooper J, Lutz C, Jatana KR, Nishimura L, Deans KJ, Minneci PC, Halaweish I. The value of telemedicine for the pediatric surgery patient in the time of COVID-19 and beyond. J Pediatr Surg. 2021. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jpedsurg.2021.02.018\u003c/span\u003e\u003cspan address=\"10.1016/j.jpedsurg.2021.02.018\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLittauer SL, Dixon DL, Mishra VK, Sisson EM, Salgado TM. Pharmacists providing care in the outpatient setting through telemedicine models: a narrative review. Pharm Pract (Granada). 2017. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.18549/PharmPract.2017.04.1134\u003c/span\u003e\u003cspan address=\"10.18549/PharmPract.2017.04.1134\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGreen BB, Cook AJ, Ralston JD, Fishman PA, Catz SL, Carlson J, Carrell D, Tyll L, Larson EB, Thompson RS. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA. 2008. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1001/jama.299.24.2857\u003c/span\u003e\u003cspan address=\"10.1001/jama.299.24.2857\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMaxwell LG, McFarland MS, Baker JW, Cassidy RF. Evaluation of the impact of a pharmacist-led telehealth clinic on diabetes‐related goals of therapy in a veteran population. Pharmacotherapy. 2016. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/phar1719\u003c/span\u003e\u003cspan address=\"10.1002/phar1719\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSingh LG, Accursi M, Black KK. (2015). Implementation and outcomes of a pharmacist-managed clinical video telehealth anticoagulation clinic. Am J Health Syst Pharm. 2015;\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2146/ajhp130750\u003c/span\u003e\u003cspan address=\"10.2146/ajhp130750\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMaldonado AQ, Hall RC, Pilch NA, Ensor CR, Anders S, Gilarde JA, Tichy EM. (2020). ASHP guidelines on pharmacy services in solid organ transplantation. Am J Health Syst Pharm. 2020;\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/ajhp/zxz291\u003c/span\u003e\u003cspan address=\"10.1093/ajhp/zxz291\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePharmaceutical Care Network Europe Association. PCNE Classif V 9.1.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePascarella G, Rossi M, Montella E, Capasso A, De Feo G, Botti G, Nardone A, Montuori P, Triassi M, D\u0026rsquo;Auria S, Morabito A. Risk analysis in healthcare organizations: methodological framework and critical variables. Risk Manag Healthc Policy. 2021. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2147/RMHP.S309098\u003c/span\u003e\u003cspan address=\"10.2147/RMHP.S309098\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYeo YT, Song J, Ng EG, Lee NL, Kee TY, Tan CK, Fan PY, Lee PH. Increasing influenza vaccination rates in solid organ transplant recipients in an outpatient transplant center. Proc. Singap. Healthc.2020;\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1177/2010105820960159\u003c/span\u003e\u003cspan address=\"10.1177/2010105820960159\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHarboe ZB, Modin D, Gustafsson F, Perch M, Gislason G, S\u0026oslash;rensen SS, Rasmussen A, Biering-S\u0026oslash;rensen T, Nielsen SD. (2022). Effect of influenza vaccination in solid organ transplant recipients: a nationwide population-based cohort study. Am J Transplant. 2022; \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/ajt.17055\u003c/span\u003e\u003cspan address=\"10.1111/ajt.17055\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDanziger-Isakov L, Kumar D. AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transpl. 2020. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/ctr.13563\u003c/span\u003e\u003cspan address=\"10.1111/ctr.13563\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eUyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein S, Hayden FG, Harper SA, Hirshon JM, Ison MG. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/cid/ciy874\u003c/span\u003e\u003cspan address=\"10.1093/cid/ciy874\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGrohskopf LA. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices\u0026mdash;United States, 2022\u0026ndash;23 influenza season. MMWR Recomm Rep. 2022. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.15585/mmwr.rr7101a1\u003c/span\u003e\u003cspan address=\"10.15585/mmwr.rr7101a1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKumar D, Humar A, Plevneshi A, Green K, Prasad GV, Siegal D. Toronto Invasive Bacterial Diseases Network, McGeer A. Invasive Pneumococcal Disease in Solid Organ Transplant Recipients\u0026mdash;10-Year Prospective Population Surveillance. Am J Transpl. 2007. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/j.1600-6143.2006.01705.x\u003c/span\u003e\u003cspan address=\"10.1111/j.1600-6143.2006.01705.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL, Johnstone J, Kitai I, Krajden S, Lovinsky R, Muller M. Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs. Clin Infect Dis. 2016. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/cid/civ803\u003c/span\u003e\u003cspan address=\"10.1093/cid/civ803\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDanzinger-Isakov L, Kumar DA, AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transpl. 2009. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/ctr.13563\u003c/span\u003e\u003cspan address=\"10.1111/ctr.13563\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/cid/cit816\u003c/span\u003e\u003cspan address=\"10.1093/cid/cit816\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePark JS, Gayam V, Pan CQ. Preventing hepatitis B graft infection in hepatitis B patients after liver transplantation: immunoglobulin vs anti-virals. Aliment Pharmacol Ther. 2020. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/apt.15999\u003c/span\u003e\u003cspan address=\"10.1111/apt.15999\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLee Y, Seong J, Ahn S, Han M, Lee JA, Kim JH, Ahn JY, Ku NS, Choi JY, Yeom JS, Kim BK. Hepatitis B reactivation and vaccination effectiveness after solid organ transplantation: a matched case-control study. Vaccines. 2024. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/vaccines12070804\u003c/span\u003e\u003cspan address=\"10.3390/vaccines12070804\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eReiss G, Keeffe EB. Hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther. 2004. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/j.1365-2036.2004.01906.x\u003c/span\u003e\u003cspan address=\"10.1111/j.1365-2036.2004.01906.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePoland GA, Poterucha JJ. Hepatitis B immunization after liver transplantation: what is the answer? Liver Transpl. 2005. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/lt.20538\u003c/span\u003e\u003cspan address=\"10.1002/lt.20538\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDanzinger-Isakov L, Kumar DA, AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transpl. 2009. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/j.1600-6143.2009.02917.x\u003c/span\u003e\u003cspan address=\"10.1111/j.1600-6143.2009.02917.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBalloni A, Assael BM, Ghio L, Pedrazzi C, Nebbia G, Gridelli B, Melada E, Panuccio A, Foti M, Barbi M, Luraschi C. Immunity to poliomyelitis, diphtheria and tetanus in pediatric patients before and after renal or liver transplantation. Vaccine. 1999. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s0264-410x(99)00064-x\u003c/span\u003e\u003cspan address=\"10.1016/s0264-410x(99)00064-x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePedrazzi C, Ghio L, Balloni A, Panuccio A, Foti M, Edefonti A, Assael BM. Duration of immunity to diphtheria and tetanus in young kidney transplant patients. Pediatr Transpl. 1999. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1034/j.1399-3046.1999.00013.x\u003c/span\u003e\u003cspan address=\"10.1034/j.1399-3046.1999.00013.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDanziger-Isakov L, Kumar D. AST ID Community of practice. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transpl. 2019. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/ctr.13563\u003c/span\u003e\u003cspan address=\"10.1111/ctr.13563\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHosseini MS, Dashti-Khavidaki S, Talebian M, Nasiri‐Toosi M, Safaei M. Allograft Injury Following Nandrolone and High‐Dose Dietary Supplements Use in a Liver Transplant Recipient: A Case Report. Clin case Rep. 2025. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/ccr3.70721\u003c/span\u003e\u003cspan address=\"10.1002/ccr3.70721\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePolak E, Stępień AE, Gol O, Tabarkiewicz J. Potential immunomodulatory effects from consumption of nutrients in whole foods and supplements on the frequency and course of infection: Preliminary results. Nutrients. 2021. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/nu13041157\u003c/span\u003e\u003cspan address=\"10.3390/nu13041157\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePelvan E, Karaoğlu \u0026Ouml;, Fırat E\u0026Ouml;, Kalyon KB, Ros E, Alasalvar C. Immunomodulatory effects of selected medicinal herbs and their essential oils: A comprehensive review. J Funct Foods. 2022. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jff.2022.105108\u003c/span\u003e\u003cspan address=\"10.1016/j.jff.2022.105108\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShivaswamy V, Boerner B, Larsen J. (2016). Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev.2016; \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1210/er.2015-1084\u003c/span\u003e\u003cspan address=\"10.1210/er.2015-1084\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChakkera HA, Mandarino LJ. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation. 2013. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/TP.0b013e31826e592e\u003c/span\u003e\u003cspan address=\"10.1097/TP.0b013e31826e592e\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDavies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P. (2022). Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022; \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00125-022-05787-2\u003c/span\u003e\u003cspan address=\"10.1007/s00125-022-05787-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eArvanitakis K, Koufakis T, Kalopitas G, Papadakos SP, Kotsa K, Germanidis G. (2024). Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential. Diabetes \u0026amp; Metabolic Syndrome: Clinical Research \u0026amp; Reviews. 2024; \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.dsx.2023.102935\u003c/span\u003e\u003cspan address=\"10.1016/j.dsx.2023.102935\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVigan\u0026ograve; M, Beretta M, Lepore M, Abete R, Benatti SV, Grassini MV, Camagni S, Chiodini G, Vargiu S, Vittori C, Iachini M. Vaccination recommendations in solid organ transplant adult candidates and recipients. Vaccines. 2023. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/vaccines11101611\u003c/span\u003e\u003cspan address=\"10.3390/vaccines11101611\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eArvanitakis K, Koufakis T, Kalopitas G, Papadakos SP, Kotsa K, Germanidis G. Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential. Diabetes Metabolic Syndrome: Clin Res Reviews. 2024. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.dsx.2023.102935\u003c/span\u003e\u003cspan address=\"10.1016/j.dsx.2023.102935\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEvers EC, Fritz SA, Colditz GA, Burnham JP. Perceptions of telemedicine and costs incurred by a visit to a general infectious diseases clinic: a survey. OFID. 2022. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/ofid/ofab661\u003c/span\u003e\u003cspan address=\"10.1093/ofid/ofab661\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChi NC, Demiris G. A systematic review of telehealth tools and interventions to support family caregivers. J Telemed Telecare. 2015. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1177/1357633X14562734\u003c/span\u003e\u003cspan address=\"10.1177/1357633X14562734\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTolu-Akinnawo O, Ezekwueme F, Awoyemi T. Telemedicine in cardiology: enhancing access to care and improving patient outcomes. Cureus. 2024. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.7759/cureus.62852\u003c/span\u003e\u003cspan address=\"10.7759/cureus.62852\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHezer B, Massey EK, Reinders ME, Tielen M, Van De Wetering J, Hesselink DA, Van Den Hoogen MW. Telemedicine for kidney transplant recipients: current state, advantages, and barriers. Transplantation. 2024. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/TP.0000000000004660\u003c/span\u003e\u003cspan address=\"10.1097/TP.0000000000004660\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShokri F, Bahrainian S, Tajik F, Rezvani E, Shariati A, Nourigheimasi S, Shahrebabaki ES, Ebrahimi M, Shamoon F, Heidary M. The potential role of telemedicine in the infectious disease pandemic with an emphasis on COVID-19: A narrative review. Health Sci Rep. 2023. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/hsr2.1024\u003c/span\u003e\u003cspan address=\"10.1002/hsr2.1024\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHosseini MS, Hajimiri SH, Dashti-Khavidaki S, Nasiri-Toosi M, Kebriaeezadeh A. Economic Evaluation of Clinical Pharmacists\u0026rsquo; Services Provided for Solid Organ Transplant Patients: A Systematic Review. Int J Organ Transpl Med (IJOTM). 2024. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.61186/ijotm.2024.15.1139\u003c/span\u003e\u003cspan address=\"10.61186/ijotm.2024.15.1139\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCalifornia Pharmacists Association. (2024). Medi-Cal Medication Therapy Management Guide. [online]. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://cpha.com/wp-content/uploads/2022/05/Medi-Cal-Medication-Therapy-Management-Guide-v2.pdf\u003c/span\u003e\u003cspan address=\"https://cpha.com/wp-content/uploads/2022/05/Medi-Cal-Medication-Therapy-Management-Guide-v2.pdf\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Accessed 15 December 2024.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Drug-related problems, Economic analysis, Telemedicine, Transplant pharmacist, Pharmacotherapy, Virtual clinic","lastPublishedDoi":"10.21203/rs.3.rs-8712266/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8712266/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003ePharmacist-led pharmacotherapy clinics play an essential role in optimizing medication use and preventing adverse drug events (ADEs) among solid organ transplant (SOT) recipients. Evidence comparing the clinical and economic value of virtual versus in-person transplant pharmacotherapy clinics remains limited, particularly in resource-constrained settings.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eThis cross-sectional study evaluated SOT candidates and recipients who received pharmacist-led virtual consultations (October\u0026ndash;December 2024) or in-person consultations (September 2024\u0026ndash;May 2025) at a tertiary transplant center in Iran. Pharmacist interventions included medication reconciliation, identification and resolution of drug-related problems (DRPs), adherence monitoring, and vaccination review. ADE risk was estimated using a validated risk-matrix approach, and a partial cost\u0026ndash;benefit analysis was conducted from a societal perspective, incorporating direct medical and nonmedical costs. Cost savings from medication optimization and cost avoidance from estimated preventable ADEs were calculated, and benefit-to-cost ratios (BCRs) were derived.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eA total of 232 patients (63.1% male; mean age 50.3\u0026thinsp;\u0026plusmn;\u0026thinsp;12.4 years) were evaluated. Pharmacists identified 1,607 DRPs and issued 2,268 recommendations, with preventive therapy needs being the most common DRP category. An expert panel estimated 428 preventable ADEs across both clinic models. The virtual clinic generated direct cost savings of \u003cspan\u003e$\u003c/span\u003e1,882.93 and cost avoidance of \u003cspan\u003e$\u003c/span\u003e30,552.43, while the in-person clinic achieved \u003cspan\u003e$\u003c/span\u003e768.07 in direct savings and \u003cspan\u003e$\u003c/span\u003e75,666.94 in cost avoidance. The resulting BCRs were 11.1:1 for the virtual clinic and 12.3:1 for the in-person clinic.\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e \u003cp\u003ePharmacist-led virtual and in-person transplant pharmacotherapy clinics were associated with improved medication safety and substantial economic benefits. These findings support the integration of Telepharmacy services into transplant care, particularly in low- and middle-income healthcare systems.\u003c/p\u003e","manuscriptTitle":"Clinical and Economic Outcomes of Virtual vs. In-Person Transplant Pharmacotherapy Clinics: A Cross-Sectional Study in Iran","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-02-11 16:55:29","doi":"10.21203/rs.3.rs-8712266/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"03fac576-c031-49fd-8c0e-57089613314d","owner":[],"postedDate":"February 11th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2026-02-15T19:53:55+00:00","versionOfRecord":[],"versionCreatedAt":"2026-02-11 16:55:29","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8712266","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8712266","identity":"rs-8712266","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}